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Gemini surfactants are a class of lipid molecules that have been successfully used in vitro and in 
vivo as non-viral gene delivery vectors. However, the biological behavior of gemini surfactant 
nanoparticles has not been well understood and little is known about their cellular uptake, 
distribution, and metabolism after entering a biological system. Such knowledge is of great 
importance as it could explain their varying efficiencies and toxicities, and ultimately contribute to 
the development of novel gemini surfactants with enhanced efficiency and reduced toxicity. 
Therefore, my Ph.D. research investigated the biological behavior of gemini surfactant 
nanoparticles using mass spectrometry with a focus on their quantitative determination in the 
cellular matrix and identification of their potential metabolites. 
To determine the cellular uptake and distribution of gemini surfactants, a simple flow injection 
analysis-tandem mass spectrometry (FIA-MS/MS) method was developed and validated for the 
quantification of three model gemini surfactants, unsubstituted (16-3-16), with pyridinium head 
groups (16(Py)-S-2-S-16(Py)), and substituted with a glycyl-lysine di-peptide (16-7N(GK)-16), in 
the cellular matrix. To our knowledge, this is the first FIA-MS/MS method that was developed for 
the determination of three gemini surfactants belonging to different structural families. The method 
is superior to previous liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods, 
developed in our laboratory, with respect to sensitivity and time of analysis. The application of the 
method allowed for a time-course monitoring of the cellular uptake and subcellular distribution of 
gemini surfactants. 
Differential cellular uptake and distribution were observed among three gemini surfactants, which 
explained their varying efficiencies and toxicities. In general, high cellular uptake of gemini 
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surfactant corresponds to high transfection efficiency, while non-preferential accumulation in the 
nucleus may have contributed to the observed toxicity. The gemini surfactant 16-7N(GK)-16 
displayed the highest cellular uptake among three compounds, consistent with its high efficiency 
in gene transfection; whereas 16(Py)-S-2-S-16(Py) showed the highest distribution in the nucleus, 
corresponding to its high toxicity. In addition, the DNA binding capability and the shape of 
aggregates of the gemini surfactants explained their different behaviors in biological systems. The 
gemini surfactant 16-7N(GK)-16 has a balanced DNA binding property and tends to form 
aggregates with flexible bilayer structures, resulting in its high efficiency and low toxicity. At the 
same time, 16(Py)-S-2-S-16(Py) and 16-3-16 display relatively strong DNA binding properties and 
have cylindrical micelle aggregates, leading to their low efficiency and high toxicity. 
Different metabolic pathways for the three gemini surfactants were also determined for the first 
time. The gemini surfactant 16-3-16 was not metabolized in PAM 212 cells, which suggests it most 
likely remains intact during cellular detoxification and elimination. On the other hand, 16(Py)-S-
2-S-16(Py) was metabolized primarily via phase I biotransformations, including oxidation and 
dealkylation. Finally, the gemini surfactant 16-7N(GK)-16 was metabolized mainly via phase II 
biotransformations, such as methylation, acetylation, and conjugations (glucose, palmitoyl and 
stearyl conjugations). The metabolism studies of gemini surfactants provide insight for future 
directions in the design and development of novel compounds with low toxicity for gene delivery.  
Together, the work accomplished in this Ph.D. study lays the foundation for investigating the 
behavior of gemini surfactant nanoparticles in biological systems and feeds into the rationale for 
designing novel gene delivery systems. Ultimately, the results would contribute to the development 
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1 Chapter 1 - Literature Review and Proposed Research 
1.1 Introduction 
The first successful gene transfer in humans was performed in 1989 [1]. Since then, gene therapy 
has attracted a great interest over the past few decades [2-4]. To date, over 2,600 gene therapy 
clinical trials have been conducted worldwide, in which more than half are in the field of cancer 
gene therapy [5]. The tools used to achieve gene delivery are called vectors, which are key for an 
efficient and safe gene delivery. There are two types of gene delivery methods: viral and non-viral 
vectors [6]. Viral vectors use the viruses’ natural infection capability to introduce the target gene 
into cells [7, 8]. Viral vectors are known for high efficiency in transfection, but with potential 
genotoxicity and severe immune response; they also have limitations in the packing capacity for 
genetic materials that can be delivered [9, 10]. In contrast, non-viral vectors provide a non-
immunogenic and safer method for gene delivery, which are not limited to the size of genes that 
can be encapsulated and can be easily produced at low cost; however, they suffer from lower gene 
transfer abilities, especially in vivo, in comparison with viral vectors [11]. As such, numerous 
efforts have been focused on the development of novel non-viral vectors that provide high 
efficiency and low toxicity in gene transfection. 
Among numerous non-viral vectors, cationic lipids have been prominent gene delivery systems in 
recent years. In particular, cationic gemini surfactants are the most promising molecules as gene 
delivery agents due to their unique chemical structures that possess dual positively charged 
hydrophilic head groups, a spacer region, and two hydrophobic tail regions [12]. Such structures 
enable gemini surfactants to bind and compact DNA to form nano-sized particles, and subsequently 
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facilitate their cellular uptake for gene transfection [13, 14]. To date, a variety of gemini surfactants 
with different head groups, spacer regions, and tails have been used to successfully deliver nucleic 
acids into cells for efficient transfection [13, 15, 16]. For example, the gemini surfactant 14-2-14 
and serine-derived gemini surfactants (nSer)2N5 (n=14 and 16) showed the ability to efficiently 
deliver plasmid DNA into mitochondria in HeLa cells and promote gene expression [17]. To 
increase efficiency and reduce toxicity, numerous efforts have been made to design and develop 
novel gemini surfactants, such as varying the length of hydrophobic carbon tails, introduction of 
pyridinium head groups, and substitution with a di-peptide moiety in the spacer region [18-22]. In 
addition, the formulation methods of gemini surfactant-based lipoplexes and their cellular uptake 
mechanism have been well studied with the aim of enhancing efficiency while reducing toxicity 
[23-26]. Collectively, these researches have resulted in the development of numerous novel gemini 
surfactants with significantly improved efficiency and reduced toxicity. 
Despite the substantial improvement of efficiency and toxicity profiles, gemini surfactants are still 
not able to achieve the required efficiency in gene transfection in vivo so that they can fulfill clinical 
application for gene therapy. In addition, there are no unequivocal explanations for the varying 
toxicities among different gemini surfactant structures. Therefore, a better understanding of the 
mechanism of transfection and toxicity will aid in the development of more efficient and less toxic 
gemini surfactants for gene delivery. One factor that is possibly related to the efficiency and 
toxicity of gemini surfactant is their biological fate post transfection (i.e., their subcellular and 
tissue distribution, and metabolism). However, as of yet, the biological fate of gemini surfactants 
as gene delivery agents is still poorly understood and little is known about their cellular uptake, 
distribution, and metabolite formation within cells. Such knowledge may explain the reasons of 
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observed efficiencies and toxicities of various gemini surfactant structures, which will contribute 
to the design and development of more effective gemini surfactants.  
My Ph.D. research focused on the assessment of the behavior of gemini surfactant nanoparticles 
within biological systems using analytical mass spectrometry. In particular, I investigated the 
cellular uptake, distribution, and metabolism of three gemini surfactants, symmetrical m-s-m 
gemini surfactant 16-3-16, pyridinium gemini surfactant 16(Py)-S-2-S-16(Py), and di-peptide 
substituted gemini surfactant 16-7N(GK)-16, which have demonstrated great efficiency in the 
delivery of DNA into cells with low toxicities [13, 19, 27]. My research findings assisted in the 
understanding of the unknown behavior of gemini surfactant nanoparticles within biological 
systems and correlated their cellular uptake, distribution, and metabolite formation with their 
efficiencies and toxicities. The long-term goal is to develop novel gemini surfactants as gene 
delivery agents with high efficiency and low toxicity. 
1.2 Lipid-Based Gene Delivery Systems 
Cationic lipids have been widely used as non-viral gene delivery agents for decades. Cationic lipids 
are amphiphilic molecules that have a general structure with a cationic head group, a linker, and a 
hydrophobic tail [28]. The positively charged head groups can interact with the negatively charged 
phosphate groups in nucleic acids, allowing for the formation of compacted structures called 
lipoplexes [29], which are able to protect DNA from cellular nuclease degradation, interact with 
cell membrane for cellular uptake, and facilitate the release of DNA from intracellular vesicles for 
gene transfection. Typically, transfection efficiency of cationic lipids relies on a number of factors, 
such as the shape of the structure, the number of charges carried per molecule, the nature of the 
lipid tails, and the type of the linker [30]. To date, numerous cationic lipids with different structures 
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have been developed and synthesized as non-viral gene delivery agents, which were used for both 
in vitro and in vivo gene delivery. Due to the structural versatility, cationic lipids can often be 
categorized into different groups according to their specific characteristics of the structures. 
Typically, cationic lipids used for gene delivery can be classified into four main categories based 
on their different head groups, as outlined below.  
1.2.1 Quaternary ammonium lipids 
Quaternary ammonium lipids are a class of cationic compounds that have been well studied for 
gene delivery. Generally, quaternary ammonium lipid compounds contain positively charged 
quaternary ammonium groups that can interact with and compact negatively charged DNA to form 
nanosized particles and achieve gene delivery. Among numerous quaternary ammonium lipids, 
compound 2,3-dioleyloxypropyl-1-trimethylammonium bromide (DOTMA) (Figure 1.1) was the 
first one that displayed gene transfection capability. DOTMA has a structure with a quaternary 
amine connected to two unsaturated aliphatic hydrocarbon chains via ether groups, showing 
efficient DNA transfection in several cell lines [11].  
To improve transfection efficiency, a wide range of quaternary ammonium lipids were developed 
with various head groups, including 1,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide 
(DORIE) and 1,2-dioleoyloxypropyl-3-dimethyl-hydroxyethyl ammonium chloride (DORI) 
(Figure 1.1) [31, 32]. In general, these compounds showed great efficiency and toxicity profiles. 
Both DORIE and DORI are the quaternary ammonium compounds that have a hydroxyethyl group 
instead of a methyl group in their structures compared to DOTMA [32]. They showed a 2-3 fold 
increased transfection activity compared with their original structures [32]. The improved 
transfection efficiency was attributed to the hydroxyl moiety in the structure that may aid in the 
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interaction between DNA-lipid complexes and cell membranes, resulting in a greater transfection 
activity [32]. 
Furthermore, modifications to the tails of the structure were also conducted to increase transfection 
efficiency, which resulted in the development of a number of additional quaternary ammonium 
lipid compounds, such as 1,2-disteryloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide 
(DSRIE), 1,2-dipalmityloxy propyl-3-dimethyl-hydroxyethyl ammonium bromide (DPRIE), and 
1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE) (Figure 1.1) 
[32]. These compounds have the tails with varying lengths in the structure, displaying diverse 
transfection efficiencies. In particular, DSRIE and DPRIE are the quaternary ammonium lipids 
with saturated 18-carbon and 16-carbon tails, respectively, showing similar transfection activities 
compared with DORIE [32]. However, DMRIE is another quaternary ammonium lipid with 
saturated 14-carbon tails that displayed two times greater transfection activity than DORIE [32]. 
More importantly, DMRIE allowed DNA to be delivered in vivo at an increased concentration in 
the formulation, resulting in greater efficiency in gene transfection [33]. As such, different lengths 
of the tails showed a great influence on the transfection activity of quaternary ammonium lipids. 
Since DMRIE exhibited a significantly improved efficiency and toxicity profile compared with 
other quaternary ammonium lipid compounds, a number of gene therapy clinical trials have been 
conducted based on the DMRIE-mediated gene delivery systems and great therapeutic results were 
reported [34-36]. Collectively, these results demonstrated that quaternary ammonium lipids are 

















Figure 1.1. Chemical structures of quaternary ammonium lipids 
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In addition, various approaches have also been implemented to improve transfection efficiency of 
quaternary ammonium lipids. One strategy was to promote the internalization of the lipid/DNA 
complexes through receptor-mediated cellular uptake. For instance, Cheng et al. [37] attached 
transferrin to the DOTMA/DNA complexes in an attempt to target the cell surface transferrin 
receptors, a significantly enhanced transfection activity with transferrin-DOTMA/NDA complexes 
was achieved compared with the complexes alone. Another approach was to facilitate the 
cytoplasmic release of DNA from the endosomes using endosomal disrupting agents. For example, 
a fusogenic peptide, Glu-Ala-Leu-Ala, was used along with the complexes to destabilize the 
endosomal membrane that facilitated the release of DNA into the cytoplasm, thus resulting in a 
significant increase in transfection efficiency [38]. 
Physicochemical characterization indicated that quaternary ammonium lipids typically form 
lamellar bilayer vesicle complexes, which can facilitate the fusion of the DNA-containing 
complexes with cell membrane, resulting in their cellular uptake [11, 39]. A lamellar bilayer vesicle 
has a closed bilayer structure, which consists of two layers of lipid molecules with the hydrophobic 
tails pointing toward the center of the bilayer [39]. The DNA is typically encapsulated and 
protected in the center of the vesicle complexes. In general, large multilamellar vesicles (LMV) 
are more efficient in gene transfection than small unilamellar vesicles (SUV), this is because LMVs 
have the ability to interact with more DNA molecules due to their large molecular weight [32] and 
possibly have an enhanced sedimentation on the cells compared with SUVs, leading to more 
efficient cellular uptake [40]. Typically, quaternary ammonium lipids require additive lipids to 
achieve a high level of gene transfection activity. Such additive lipids generally can be 1,2-di-(9Z-
octadecenoyl)-sn-glycero-3-phosphoethanol amine (DOPE) or cholesterol, which increase the 
stability of formed lipoplexes and promote endosomal escape of DNA to enhance gene transfection 
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efficiency. In addition, the charge ratio of quaternary ammonium lipid/DNA is also of great 
importance to achieve a transfection activity, as it has a direct impact on the physicochemical 
properties of formed complexes, and an excess of positive surface charge of the complexes is 
imperative to obtain high transfection efficiency. 
However, quaternary ammonium lipids are still limited for their application in gene delivery due 
to relatively low transfection efficiency, especially in vivo, and high toxicity. As endogenous 
negatively charged substances interact and neutralize the positive charges of the lipids and the 
complexes, the electrostatic interaction between the complexes and cells is dramatically 
diminished, thereby resulting in reduced cellular uptake and subsequent low transfection activity. 
On the other hand, the toxicity of quaternary ammonium lipids is mainly determined by the 
structures of cationic groups and quaternary ammonium lipids are often more toxic than their 
tertiary amine counterparts. A 10-fold higher toxicity was observed in quaternary ammonium 
compounds compared with the corresponding ones with tertiary amines [41]. In addition, the 
toxicity is also dependent on the surface charge of the complexes and complexes with high charges 
are generally more toxic than those with low charges. Xu et al. [42] reported that the purified 
DOTAP/DNA complexes with low charges at 1:2.2 (lipid/DNA) were less toxic than the mixture 
with high charges at 3.5:1 (lipid/DNA), resulting in a 16-fold increase in transfection efficiency.  
1.2.2 Polyamine lipids 
Polyamine lipids are a class of compounds containing a large number of amine groups in the 
structure, which are protonated at physiological pH. They are efficient in compacting DNA to form 
nanosized particles with a typical size of 200 nm [43]. Polyamine lipid compounds have the ability 
to not only buffer the endosomal compartment to prevent DNA degradation but also drive nuclear 
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accumulation of the lipoplexes through the interaction with chromatin, resulting in enhanced gene 
transfection [43]. Due to this special property, polyamine lipids have been widely used as non-viral 
gene delivery agents. Dioctadecylamidoglycyl spermine (DOGS) (Figure 1.2) was the first 
polyamine lipid compound used for gene delivery, which contains a spermine attached to the 
hydrophobic tails via a glycyl spacer [44]. Spermine is a naturally nucleus-occurring polyamine 
that plays an important role in DNA compaction during cell division [45]. An in vitro transfection 
study indicated that DOGS was 2-fold more effective and 6-fold less toxic compared with 
quaternary ammonium lipid dimethyldioctadecylammonium chloride [44].  
In addition to DOGS, a wide range of polyamine lipids were also developed and synthesized to 
improve transfection efficiency by varying the shape of the structure, the type of the linker, and the 
length of the tails [46]. These compounds showed a variety of transfection efficiency and toxicity 
profiles. Although all these compounds demonstrated great transfection activities, compounds 
RPR-12650, RPR-126097 and RPR-120535 (Figure 1.2) displayed the highest transfection 
efficiency in multiple cell lines, equivalent to that of commercially available Transfectam and 
Lipofectamine [46]. Structurally, these three compounds have a linear geometry of polyamine 
group, which demonstrated a 4-fold higher transfection activity compared with those with a 
branched, T-shape, or globular geometry of polyamine group [46], indicating the linear polyamine 
shape is essential to achieve a high level of gene transfection. In addition, the substitution on the 
amino acid linker also significantly improved the transfection activity of these polyamine lipid 
compounds [46]. Such an increase in transfection efficiency was attributed to the substitution group 
that can facilitate the cellular entry of lipid/DNA complexes [46]. In addition, physicochemical 
characterization of the DNA/PPR-120535 complexes indicated that plasmid DNA was in 
compacted state in the complexes, which protects DNA against degradation [46]. 
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Aside from long alkyl chain, a cholesterol moiety has also been used as the lipid anchor in the 
structures of polyamine lipids [47]. As cholesterol is a naturally occurring molecule in cell 
membrane that can facilitate the cellular uptake of lipid/DNA complexes, these cholesterol 
derivative compounds typically display enhanced transfection activity. For example, the lipid #67 
(Figure 1.2) is a cholesterol derivative compound that has a spermine head group attached to 
cholesterol moiety via a spacer[48]. This compound was able to efficiently transfer a cystic fibrosis 
transmembrane conductance regulator (CFTR) cDNA to cells for the treatment of cystic fibrosis, 
which was significantly more active than other cationic lipids used previously for CFTR gene 
expression in BALB/c mice, exhibiting equivalent activity to virally-mediated transfection [48]. In 
addition, an aerosol formulation of lipid #67 with dimyristoyl phosphatidyl ethanolamine was 
developed with a significant increase in the concentration of DNA, which has the ability to protect 
DNA from degradation and thus maintained its biological activity [49, 50]. As a result, the lipid 
#67 formulation with plasmid DNA encoding for CFTR has been used in clinical trials for treating 
patients suffering from cystic fibrosis and promising results were reported with low toxicity [51].  
Similar to quaternary ammonium lipids, polyamine lipids are also able to form multilamellar 
bilayer complexes with DNA that favor efficient gene delivery, and typically large complexes are 
more potent in gene transfection than small ones [52, 53]. Daniel et al. [54] demonstrated that gene 
transfer was more efficient with large RPR120535 particles due to the formation of large 
intracellular vesicles that could be more easily disrupted to release DNA into the cytoplasm for 
gene transfection. However, there is limited information regarding the intracellular trafficking of 
lipid/DNA particles. One in vitro study using fluorescently labeled plasmid DNA indicated that 
lipid/DNA complexes were able to rapidly localize in the cellular cytoplasm of the transfected NIH 















Figure 1.2. Chemical structures of polyamine lipids 
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1.2.3 Amidinium, guanidinium and pyridinium lipids 
Amidinium and guanidinum lipids are versatile cationic compounds used for gene delivery. 
Generally, amidinium and guanidinum compounds have relatively high pKa, which allows them 
to be protonated in physiological conditions [55]. Once these compounds are positively charged, 
they can interact with the negatively charged DNA phosphate groups and compact the DNA. In 
addition, they also can interact with DNA through the formation of hydrogen bonds with the 
phosphate groups in DNA [56]. To date, a number of amidinium lipid compounds have been 
developed for non-viral gene delivery. Among them, N-t-butyl-N’-tetradecyl-3-tetradecylamino 
propionamidine (diC14-amidine) (Figure 1.3) is the first amidinium lipid used as a gene delivery 
agent [57, 58]. DiC14-amidine is a pH-sensitive cationic lipid with two titratable groups, an amine 
and an amidine, in the structure, which can possess two positive charges at low pH [59]. Its bilayer 
structure is highly sensitive to the pH of a medium. At high pH, diC14-amidine presents an 
organized bilayer structure, whereas it typically displays a rather non-organized bilayer phase at 
low pH due to the strong electrostatic repulsion of head groups [55]. An in vitro study demonstrated 
that diC14-amidine-containing liposomes were efficient in mediating transfection of both adherent 
and suspension cell lines [57]. In addition, low toxicity was observed with a 95% cell viability in 
treated cells compared with controls (non-treated cells) [57]. Other amidinium cationic lipids, such 
as ADPDE and ADODE (Figure 1.3), have also been developed. Their formulations with 
cholesterol and DNA were administered intravenously to mice, and great transgene activity was 
observed in lung, liver and heart, indicating a promise as gene delivery agents [60]. 
Similar to amidinium lipids, guanidinum cationic lipids are also used as effective gene delivery 
agents since they can be protonated in a wide range of pH. For example, compounds 3/3[N',N'-
diguanidinoethyl-aminoethane) carbamoyl] cholesterol (BGTC) and 3P3[4N-(QN,8N-diguanidino 
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spermidine)-carbamoyl] cholesterol (BGSC) (Figure 1.3) are the first two guanidinum lipids used 
as gene delivery agents, which were synthesized by attaching a bisguanidinium group to a 
cholesterol [56]. An in vitro study showed that both BGTC and BGSC have an up to two-fold 
higher gene transfection activity than Lipofectin in a number of mammalian cell lines [56]. The 
rationale of the development of such cationic lipids was to take advantage of the membrane-
compatible feature of a cholesterol moiety and the highly favorable DNA binding feature of a 
guanidinium to facilitate DNA delivery [56, 61]. Structural characterization of guanidinium-
cholesterol cationic lipid/DNA complex indicated that highly ordered multilamellar domains were 
formed with DNA condensation, and the DNA molecules were intercalated among the lipid 
bilayers [62]. It was proposed that the multilamellar complexes may have high endosomal 
membrane fusion/destabilization properties that contributed to their high transfection efficiency 
[62]. In addition, BGTC was sufficiently stable to permit effective gene delivery by the aerosol 
route to pulmonary sites, indicating a promise for clinical application of aerosol gene delivery [63]. 
Together, the results indicated that cationic lipids containing guanidinium head groups can be 


















Figure 1.3. Chemical structures of amidinium and guanidinum lipids 
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In addition to the polar head groups of amidine and guanidine, nitrogen-containing heterocycles 
have also been introduced in the structures of cationic lipids for gene delivery. Typically, 
heterocyclic cationic lipid compounds display relatively higher transfection efficiency and lower 
toxicity compared to the classical transfection systems, this is mainly due to the delocalization of 
the positive charge on the aromatic ring that might the ability to improve the interaction and 
compaction of DNA and facilitate their endosomal escape [19, 64]. Although a variety of  
heterocyclic compounds, such as pyridine, piperazine, and imidazoline, have been used as the head 
groups [20, 65, 66], pyridinium head groups are the most commonly used heterocyclic moieties in 
the design and development of novel cationic lipids used as gene delivery vectors. Their 
transfection efficiency has been reported to reach or surpass that of commercial transfection agents, 
while maintaining a low cytotoxicity profile [20, 67, 68]. 
Pyridinium cationic lipids were first introduced by Hoekstra et al. [20], who developed a series of 
double-chained pyridinium compounds named SAINT for transfection study. SAINT-1 (Figure 1.4) 
was the first pyridinium compound showing a transfection activity, which was comparable with 
the commercial agent lipofectin, but with less toxicity [20]. However, SAINT-2 (Figure 1.4) 
demonstrated 10 times more transfection efficiency than SAINT-1 in multiple cell lines [20], and 
most importantly without a concomitant increase in toxicity. In addition, SAINT-2 was able to not 
only transfect a relatively large number of cells per cell population (up to 45%) but also deliver a 
high number of DNA per cell (around 45%) compared with lipofectin (23% cell population and 
30% DNA), resulting in their high transfection efficiency [20]. 
To increase transfection efficiency of pyridinium cationic lipids, Balaban et al. [69] synthesized a 
series of pyridinium cationic lipids with different linkers and hydrophobic tails to determine the 
structural elements that produced high transfection efficiency. The results revealed that an aliphatic 
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linker is superior to an aromatic one, as the former provided better fluidity of the formed cationic 
liposomes than the latter [69]. In addition, pyridinium cationic lipids with myristoyl fatty acid 
chains have higher efficiency in transfection than compounds bearing other fatty acid tails [69], 
however, the reason for this was not articulated in this study. As a result, the highest transfection 
efficiency was obtained with 1-(1,3-dimyristoyloxyprop-2-yl)-2,4,6-trimethylpyridinium chloride 
(5DMyr) (Figure 1.4), which was able to transfect NCI-H23 lung carcinoma more effectively than 
DOTAP and with low cytotoxicity [69]. On the other hand, the structure-toxicity relationship of 
pyridinium cationic lipids was also studied. Recently, Singh et al. [70] developed a series of 
glycerol-based pyridinium cationic compounds and found that their toxicities have a direct 
relationship with the alky chain length of the compounds, with increasing the chain length resulting 
in an increase in toxicity. 
The other class of pyridinium cationic lipids are gemini pyridinium surfactants that contain two 
pyridines in the head group. Typically, gemini pyridinium surfactants provide strong binding and 
compaction of DNA due to double positive charges in the structure, resulting in enhanced 
efficiency in gene transfections. As such, gemini pyridinium surfactants have been a focus of 
pyridinium lipids used for gene delivery in recent years. Fisicaro et al. [15] developed a series of 
gemini pyridinium surfactants with different lengths of alkyl spacer (P16-n, n=3, 4, 8 and 12, 
Figure 1.4) for transfection study. The gene transfection capability of these compounds was found 
to be highly dependent on the spacer length [15]. Compound P16-4 (Figure 1.4) with a four-carbon 
atoms spacer showed the highest transfection activity on human rhabdomyosarcoma cell line RD-
4 comparable to that of the commercial agent [15]. The similar structure-activity relationship was 
also observed with highly fluorinated gemini pyridinium surfactants (FGPn, n=3, 4, 8 and 12, 
Figure 1.4) [16]. Compound FGP8 (Figure 1.4) that has a spacer formed by eight-carbon atoms 
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displayed the best gene delivery capability among tested compounds on RD-4 cells equivalent to 
that of commercial agent [16].  
Similar to amidinium and guanidinum compounds, pyridinium cationic lipids also tend to form 
lamellar bilayer structures in combination with DNA, facilitating its gene delivery [67]. Typically, 
the morphology of the DNA-containing complexes poses a significant influence on their 
transfection activity. The molecular shapes of pyridinium cationic compounds affect the stability 
of the structures of the complexes and thus impact the efficiency of gene delivery. For example, 
SIANT-2 has a low ratio of polar head group to hydrophobic tail, which forms unstable bilayers in 
the media and tends to be converted into the hexagonal structures to promote the endosomal release 
of DNA, improving transfection efficiency [71]. In addition, the overall charge of the complexes 
is important to achieve a high transfection efficiency, as a net positive charge is needed for the 
complexes to interact with the negatively charged cell membrane, facilitating their cellular uptake 
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Figure 1.4. Chemical structures of pyridinium lipids 
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1.2.4 Cationic gemini surfactants  
1.2.4.1 Gemini surfactants 
Gemini surfactants are a class of surfactant molecules that are comprised of two conventional 
monomeric surfactants covalently linked by a spacer (Figure 1.5A). Unlike conventional 
surfactants, gemini surfactants typically possess two hydrophilic head groups and two hydrophobic 
tail chains that are inter-connected through a spacer region [72]. Their structures are very versatile 
as the head groups can be positive, negative, or neutral moieties [73-76]; the spacer region can be 
a hydrocarbon chain at various lengths [77]; and the tails may consist of two hydrophobic alkyl 
chains with different degrees of unsaturation [78]. Typically, halide anions, such as chloride and 
bromide, are present as the counter ions to maintain the neutral charge of the molecules. 
Although gemini surfactants can have differential head groups or tails in their structures, the most 
common gemini surfactants have symmetrical structures with two identical head groups and tails. 
Typically, a gemini surfactant with two Cm (m is the number of carbon atoms) tails and a Cs (s is 
the number of carbon atoms) spacer is denoted as m-s-m (Figure 1.5B), which is the most 
conventional type of gemini surfactants. By varying the head group, the length of hydrophobic tails, 
and the type of the spacer group, a wide range of gemini surfactant compounds can be designed 
and developed for their intended applications. The physicochemical property of gemini surfactants 
can often be predicted based on their structures. In general, increasing hydrophilicity of the head 
group increases its solubility in water, whereas increasing hydrophobicity of the tail chain makes 
the molecule less soluble in aqueous media. In addition, the addition of hydrophilic functional 




                          
Figure 1.5. Structures of gemini surfactants, A) general structure of gemini surfactant, B) chemical structure 
of m-s-m gemini surfactant. 
Due to their unique structures, gemini surfactants possess a number of superior properties 
compared with conventional monomeric surfactants, such as: 1) lower critical micellar 
concentration (CMC), a concentration above which gemini surfactant molecules spontaneously 
aggregate to form micelles; 2) lower Krafft temperature, the minimum temperature at which ionic 
gemini surfactants form micelles; 3) three orders of magnitude or more surface activity; 4) greater 
solubilization power; and 5) a wide variety of aggregate arrangements depending on the surfactant 
structure, concentration, temperature, and type of solvent [72]. These properties have allowed 
gemini surfactants to be used in a variety of industrial applications, such as detergents, cosmetics, 
and solubilizing agents [80], as well as in the pharmaceutical sphere as gene and drug delivery 
agents [13, 23]. 
1.2.4.2 Cationic gemini surfactants as gene delivery agents 
Cationic gemini surfactants are promising non-viral gene delivery agents, which have been used 
for decades as they have the capability to compact and encapsulate large size of genetic materials 
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with low toxicity, and they are produced with relatively low cost [13, 81]. To date, a wide range of 
cationic gemini surfactants have been developed and successfully used for the delivery of DNA to 
cells [13, 82, 83]. 
In general, cationic gemini surfactants have several essential structural characteristics that make 
them suitable as gene delivery agents. Firstly, they have two positively charged head groups that 
can bind with the negatively charged phosphate groups of DNA, compacting and encapsulating 
DNA to form nanosized complexes, which allow for their cellular uptake via endocytosis [84]. 
Furthermore, cationic gemini surfactants have the capability of protecting DNA from enzymatic 
degradation during intracellular trafficking as DNA is condensed and encapsulated in lipoplexes 
[84]. Secondly, cationic gemini surfactants are able to fuse with cell membrane due to the fusogenic 
properties of their hydrophobic tails and thus facilitate the internalization of DNA into the cell [84]. 
Finally, cationic gemini surfactants are able to maintain an overall positive surface charge on the 
lipoplexes through appropriate formulation, which enables electrostatic interactions with the 
negative cell surface and subsequently enhances their cellular uptake [85]. For example, cationic 
gemini surfactants with C3-C12 alkyl spacers are able to compact DNA and form particles with 
sizes at 100-200 nm, which enable their interaction with the cell membrane allowing for 
endocytosis [86]. Typically, a helper lipid, such as 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
phosphoethanol amine (DOPE), is added to the gemini surfactant/DNA complexes to increase 
transfection efficiency as it has the ability to stabilize the lipoplexes and destabilize the endosomal 
membrane to facilitate intracellular release of DNA, leading to enhanced transgene expression [87, 
88]. 
To improve the transfection efficiency of cationic gemini surfactants, extensive research has been 
conducted to study their structure-activity relationship. Badea et al. [13] reported that the length of 
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the tails and type of spacer region played a significant role in determining transfection efficiency, 
with a 3-carbon spacer being the most efficient for the m-s-m gemini surfactant structural family. 
For instance, the gemini surfactants 12-3-12 and 16-3-16 (Figure 1.6) showed the highest 
transfection efficiency among the same category of gemini surfactants [86]. This is because the 
distance between the cationic head groups in their structures is similar to that between two 
phosphate groups in a DNA molecule, resulting in stronger interaction and complexation of DNA 
[86]. However, increasing the length of the spacer group up to 8 carbon atoms decreased the 
transfection efficiency, after which the efficiency began to increase [86]. It was proposed that as 
the length of the spacer increases, the spacer tends to bend into a U-shape conformation, especially 
for the spacer length greater than 12 carbons, which results in a decrease in the distance between 
the two cationic head groups, thus enhancing the compaction of DNA [86]. Therefore, the length 
of the spacer of gemini surfactants also plays an important role in their transfection activity. 
Furthermore, substitution of the alkyl spacer with pH-sensitive imino groups also increases the 
transfection efficiency of cationic gemini surfactants [8]. For example, the gemini surfactant 12-
7NH-12 (Figure 1.6) was able to transfect monkey kidney fibroblast cells (COS-7) at a 9-fold 
higher level than an unsubstituted alkyl spacer derivative (12-7-12) (Figure 1.6) and a 3-fold 
increase compared with the corresponding aza-substituted compound (12-7N-12) (Figure 1.6) [89]. 
Such results were attributed to the enhanced pH activity due to the incorporation of a protonable 
imino group in the structures, which contributed to the efficient escape of the complexes from the 
endosomes and subsequent intracellular release of DNA, thereby resulting in high gene transfection 
efficiency [89]. 
Recently, amino acid-substituted gemini surfactants have been introduced with the aim of making 
the delivery system more bio-compatible, thus enhancing transfection efficiency [26, 83, 90]. For 
23 
 
example, the amino acids-substituted gemini surfactants 12-7N(Gly)-12 and 12-7N(Gly-Lys)-12 
(Figure 1.6) exhibited significantly higher gene transfection efficiency compared with the imino 
substituted compound 12-7NH-12 in three different epithelial cell lines [83]. Such results indicated 
that the presence of amino acid group in the structure improved the interaction of the gemini 
surfactant/DNA complexes with the cell membrane via the formation of hydrogen bonds and, more 
importantly, aided in the endosomal escape of the complexes, thus facilitating the DNA release for 
transgene expression [83]. Collectively, structural modifications have greatly contributed to the 
development of novel gemini surfactants with enhanced efficiency and reduced toxicity.  
Physicochemical properties of gemini surfactant nanoparticles, such as size and zeta potential, have 
also been evaluated to explore their relations with transfection efficiency and toxicity. In general, 
the particle size decreases with the increase in the charge ratio of gemini surfactants/DNA, as 
increasing the charge ratio results in enhanced electrostatic interaction between gemini surfactants 
and DNA, thus resulting in a better DNA compaction [90]. In addition, the size of nanoparticles 
has a great impact on their cellular entry, cytotoxicity, and intracellular fate. Typically, small 
nanoparticles display a higher efficiency in gene transfection compared to large-sized nanoparticles. 
For example, the 16-7N(GK)-16/DNA nanoparticles with sizes of 81 ± 3 nm had a significantly 
higher transfection efficiency than the 18:1-7N(GK)-18:1/DNA nanoparticles in sizes of 206 ± 6 
nm [90]. Similarly, zeta potential is also a key parameter that influences the performance of the 
delivery systems both in vitro and in vivo. A high charge density can cause cell membrane to 
rupture, thus resulting in increased toxicity; whereas a low charge density is insufficient to enable 
nanoparticles to interact with the cell membrane, thereby leading to reduced transfection efficiency. 
As such, an optimal surface charge is generally needed to achieve high transfection efficiency of 
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nanoparticle-based gene delivery systems. Typically, gemini surfactant nanoparticles show a 
positive zeta potential of 10-30 mV at their optimal transfection efficiency [90].  
 
12-3-12                                              16-3-16                                                        12-7-12 
 
 








Figure 1.6. Chemical structures of cationic gemini surfactants 
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Despite the significant improvement in transfection efficiency and toxicity profiles, gemini 
surfactants are still limited in gene transfection efficacy for therapeutic applications. Furthermore, 
there are no clear explanations for the varying toxicities among different gemini surfactant 
structures. Therefore, a better understanding of the mechanism of transfection and toxicity will aid 
in the development of more efficient and less toxic gemini surfactants. One factor that could be 
investigated is their biological fate upon transfection, as gemini surfactant nanoparticles could 
deposit and be potentially metabolized in various cellular compartments during their intracellular 
trafficking that may affect their transfection efficiencies and toxicities. However, as of yet, little 
attention has been paid to study the biological fate of gemini surfactant nanoparticles. 
Understanding the behavior of these gemini surfactants nanoparticles within biological systems 
will gain insight on their cellular uptake, biodistribution, and metabolism, which will provide 
knowledge to comprehensively understand the role of gemini surfactants nanoparticles as non-viral 
gene delivery agents. 
The gemini surfactants being investigated in my research belong to three main categories: 1) m-s-
m gemini surfactant (16-3-16), 2) pyridinium gemini surfactant (16(Py)-S-2-S-16(Py)), and 3) 
peptide-substituted gemimi surfactant (16-7N(GK)-16) (Figure 1.7), which have been reported 
with high efficiencies and low toxicities in gene delivery [13, 90]. Structurally, 16-3-16 is a 
conventional gemini surfactant with two quaternary amines linked by a 3-carbon spacer region, 
16(Py)-S-2-S-(Py)16 contains two pyridinium head groups instead of quaternary amines, and 16-
7N(GK)-16 has a biocompatible glycyl-lysine di-peptide in the space region. However, these 
gemini surfactants vary amongst each other in terms of their gene transfection efficiency and 
toxicity profiles, this could theoretically be attributable to their different biological fate upon 
transfection, such as variable cellular uptake, subcellular biodistribution, and metabolism. Such 
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knowledge may provide a mechanistic explanation for the observed differences among these 
gemini surfactants in terms of efficiency and toxicity. In addition, the three gemini surfactants 
contain a variety of chemical structures, which allow them to be used for investigating the impact 
of different structures on their intracellular fate. Ultimately, these results will aid in the 
development of novel gemini surfactants with high efficiency and low toxicity in the long term. 
Although various analytical techniques are available for the detection, characterization, and 
analysis of gemini surfactant nanoparticles [91-93], mass spectrometry (MS) has the advantages of 
high sensitivity and selectivity, capability to provide accurate mass measurement, and a large 
dynamic range for detection, which allow for the identification and quantification of a variety of 
molecules in biological systems [94]. Since gemini surfactants lack chromophores or fluorophores 
in the structure, the fluorescent/UV-detection is not suitable for their analysis. However, they have 
two positively charged quaternary ammonium groups and thus MS is an ideal analytical technique 
for their detection and analysis [95, 96]. Therefore, I employed MS to study the behavior of gemini 














Figure 1.7. Chemical structures of gemini surfactants evaluated in this study 
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1.3 Mass Spectrometric Analysis of Gemini Surfactant Nanoparticles 
Mass spectrometry (MS) is a powerful analytical technique that has been used for both qualitative 
and quantitative applications in a variety of fields, such as food science, environmental science, 
forensic science, and life sciences [97-101]. Recently, MS has progressed rapidly in terms of 
sensitivity, accuracy, and high throughput capability, which allows it to be widely applied in 
pharmaceutical research and industry. For instance, MS has been used for the identification and 
quantification of a variety of drug molecules and their metabolites [102], for the determination of 
isotopic composition of elements [103], and for the structural elucidation of chemical compounds 
[104]. To date, MS has become an indispensable tool for the analysis of a wide range of analytes 
from small molecules to large biomolecules, such as peptides and proteins. 
1.3.1 Analytical mass spectrometry 
MS has dramatically evolved and improved in terms of function and performance over the past few 
decades, which allows it to be used for the detection, identification, and quantification of molecules 
in complex biological matrices [105]. Fundamentally, however, the principle concept of MS 
operation remains the same, which is to generate charged gas phase ions and then separate them 
based on their mass-to-charge ratios (m/z) under vacuum conditions, followed by the detection and 
recording of the relative abundance of each ion [94]. Typically, a MS instrument consists of three 
major components: 1) Ion source - for generating gaseous analyte ions, 2) Analyzer - for separating 
the ions based on their m/z values, and 3) Detector - for detecting the ions and recording their 
relative abundances [94] (Figure 1.8). Single-stage MS instruments contain one analyzer, whereas 
multiple-stage MS instruments have more than one analyzer in their configuration. Tandem MS, 
also known as MS/MS, involves two stages of MS selection, with fragmentation occurring in 
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between the stages. There are two types of tandem MS: tandem in space and tandem in time [94]. 
Tandem in space usually has two mass analyzers sequentially connected and one reaction region 
(i.e., collision cell) in between. On the other hand, tandem in time involves the use of an ion trap 
where the ion separation is accomplished in the same space over time [94]. In addition, a sample 
input system is necessary to introduce sample to the ion source and a data system is required to 
operate the instrument, acquire and generate mass spectra (Figure 1.8). 
 
 
Figure 1.8. Schematic representation of single-stage and tandem in space mass spectrometry 
As analyte molecules have to be ionized in order to be separated and detected in MS, various 
ionization techniques, such as electrospray ionization (ESI), atmospheric pressure chemical 
ionization (APCI), and matrix-assisted laser desorption ionization (MALDI), have been developed 
[94]. Each ionization technique has its own advantages and shortcomings and the use of a particular 
ionization method is mainly dependent on the physiochemical properties of the analytes and the 
type of the sample matrix [94]. For example, APCI is an ionization technique that uses the gas-
phase ion-molecule reactions at atmospheric pressure and is mainly applied to analyze relatively 
non-polar compounds with molecular weight below 1500 Da [106]. Conversely, ESI involves the 
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formation of highly charged droplets formed in a high electric field, which is ideal for the analysis 
of relatively polar compounds with a broad range of molecular weights, including large 
biomolecules, such as peptides, proteins, and polymers [107, 108]. In addition, as a soft ionization 
technique, ESI allows the formation of protonated or deprotonated ions with high abundance that 
can then be subjected to MS/MS analysis allowing for the identification and characterization of 
chemical compounds [108]. 
Similar to the wide variety of ionization sources, different types of mass analyzers and their 
combinations in hybrid instruments are available, such as triple quadrupole (QqQ), triple 
quadrupole-linear ion trap (QqQ-LIT), quadrupole-time of flight (Q-TOF), and hybrid quadrupole-
Orbitrap (Q-Exactive®) [94, 109]. Due to the difference in the structures and functions of various 
analyzers, each instrument has its own advantages and disadvantages that should be considered for 
a given application. In general, the use of a particular instrument is largely dependent on the type 
of the application. For example, QqQ and QqQ-LIT instruments are well known for high selectivity 
and sensitivity in the multiple reaction monitoring (MRM) mode and have been primarily used for 
the quantification of small molecules in complex biological matrices. On the other hand, Q-TOF 
and Q-Exactive instruments are often used for the characterization and identification of chemical 
compounds due to their capability of providing accurate mass measurements for parent molecules 
and their product ions [94, 109].  
In my study, I utilized the QqQ-LIT (4000 QTRAP®) to quantify gemini surfactants for the 
assessment of their subcellular uptake and biodistribution at various time points post transfection. 
Both free gemini surfactant compounds and any remaining gemini surfactant liposomes in treated 
cells are quantified as gemini surfactant molecules will be extracted in organic solvents from both 
forms and analyzed by MS. In addition, I used the Q-TOF (QSTAR XL®) and Q-Exactive 
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instruments to detect and identify the potential metabolites of these gemini surfactants within 
transfected cells. Positive ESI ionization was used for the analysis of these gemini surfactants, since 
they are amphiphilic compounds with two positively charged quaternary ammonium head groups, 
making them ideal for ESI in the positive ionization mode. Furthermore, the soft ionization of 
gemini surfactants in ESI allows for the formation of intact ions with limited in-source 
fragmentation, which can be used for identification and quantification of gemini surfactant 
compounds. 
1.3.2 Triple quadrupole-linear ion trap for quantitative analysis 
QqQ-LIT is a unit-resolution tandem mass spectrometer that has the ability to simultaneously 
measure and characterize target analytes [110]. QqQ-LIT is a hybrid system in which a quadrupole 
is sequentially connected with a linear ion trap (LIT) separated by a collision cell [94]. A 
quadrupole consists of four parallel rods, with opposite rod pairs being connected electrically. By 
applying an alternating radio-frequency (RF) potential and a positive direct current (DC) potential 
to one electrode pair while applying a negative potential to the other pair, accelerated ions entering 
the quadrupole will possess an oscillatory movement. As such, ions with particular m/z values will 
have a stable trajectory going through the quadrupole, whereas the rest of ions will have unstable 
trajectories and collide with the rods [94]. Functionally, the first quadrupole of a triple quadrupole 
system typically works as a mass filter that selects only ions with specific m/z values to enter the 
second quadrupole. The second quadrupole is a collision cell, in which the ions collide with a 
neutral gas (typically N2 or Ar) and fragment through a process known as collision activated 
dissociation (CAD) to generate product ions. The resulting product ions are transmitted to the LIT 
operating as a quadrupole, where only the product ions with specific m/z values are allowed to pass 
and reach the detector. In addition, the LIT can also be operated in the linear ion trapping mode 
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that can trap ions and subject them for further fragmentation (i.e., MS3) to generate more detailed 
structural information.  
QqQ-LIT combines the features of a triple quadrupole with that of a linear ion trap that allows the 
system to operate in various modes, such as product ion scan, precursor ion scan, neutral loss scan, 
MRM scan and MS3, for a wide range of applications. In particular, MRM scan is the most 
commonly used technique for the quantitative analysis of small molecules [94]. The MRM scan in 
QqQ-LIT combines the selectivity of the first quadrupole and that of the linear ion trap operated as 
a quadrupole, which, even without chromatographic separation, enables high selectivity and 
sensitivity for quantitative analysis [111-113]. Therefore, analytical methods based on MRM in 
QqQ-LIT have been predominately used for quantitative applications in the pharmaceutical 
industry and research, including measurement of dosed drugs and their metabolites [102, 114], as 
well as studying lipid metabolites in biological systems [110].  
In our group, we studied the mass spectrometric fragmentation behaviors of various families of 
gemini surfactants used as non-viral gene delivery agents and established the universal tandem 
mass spectrometric fragmentation patterns for each family [115-118]. Identification of these 
product ions allows for the development of tandem mass spectrometry MRM-based methods for 
the quantitative analysis of gemini surfactants. Initially, a high performance liquid chromatography 
(HPLC)-MS/MS method employing a cyano column for the quantification of m-s-m gemini 
surfactants in epidermal keratinocytes PAM 212 was developed and validated [95]. Subsequently, 
a quantitative hydrophilic interaction liquid chromatography (HILIC)-MS/MS method was 
established for the analysis of gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) within two 
different families. The latter method achieved a lower limit of quantification (LLOQ) at 50 ng/mL 
for compound 16-3-16, as compared with 300 ng/mL obtained in the former method [95, 96]. Both 
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compounds were observed to rapidly accumulate in PAM 212 cells during the course of treatment 
and subsequently depleted in a similar trend post transfection [96]. These results demonstrated the 
feasibility of LC-MS/MS method for the detection and quantification of gemini surfactants in a 
complex biological matrix.  
In addition, various high-throughput MS-based methods for the quantification of the gemimi 
surfactant 16-3-16 in cell lysates were also developed and compared [119]. These methods include 
fast chromatography (FC)-QTRAP-MS/MS, FC-ORBITRAP-MS, matrix-assisted laser desorption 
ionization (MALDI)-TOF/TOF-MS, and desorption electrospray ionization (DESI)-MS/MS [119]. 
FC-QTRAP-MS/MS and MALDI-TOF/TOF-MS were shown to be superior to the previous LC-
MS/MS method in terms of the linearity range and sample analysis time for the quantification of 
gemini surfactant 16-3-16 [119]. Furthermore, the LLOQ was 10-fold lower in the FC-QTRAP-
MS/MS method compared with the LC-MS/MS method [95, 119]. As such, high-throughput MS 
methods based on direct analysis, such as flow injection analysis, could be also utilized for the 
quantitative analysis of gemini surfactants in biological matrices. 
Flow injection analysis-tandem mass spectrometry (FIA-MS/MS) is an analytical technique that 
can be used for rapid quantitative analysis of a variety of compounds. In this approach, both 
separation and detection of the analyte occur within the MS instrument as no column is used [112]. 
Without prior column separation, the FIA-MS/MS method mainly relies on the mass 
spectrometer’s separation capability in multiple reaction monitoring (MRM) mode, as the MRM 
in the QqQ-LIT system has the capability of selectively monitoring and accurately quantifying the 
analytes of interest in complex matrices [120]. In addition, the removal of the analytical column 
can significantly reduce the complexity of the method, shorten the time of method development, 
and decrease the time of sample analysis. Although matrix effect and interference could be a 
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potential challenge in the FIA-MS/MS analysis, finding suitable sample extraction techniques can 
be used to avoid this issue. In fact, a wide range of molecules have been detected and quantified in 
biological samples using FIA-MS/MS methods [121-123].  
In my research, I developed a FIA-MS/MS method using a QqQ-LIT (4000 QTRAP®) instrument 
to quantify the three gemini surfactants belonging to different families for the assessment of their 
subcellular uptake and distribution in treated cells at various time points after treatment. The 
rationale for the use of FIA-MS/MS is to achieve a simple and reliable analysis that can accurately 
determine the tested compounds while reducing sample analysis time. 
1.3.3 Quadrupole-time of flight for qualitative analysis 
Q-TOF is a high-resolution tandem mass spectrometer that offers simultaneously high speed data 
acquisition, accurate mass measurement, and full scan spectral sensitivity [101]. In this hybrid 
system, the first quadrupole (Q) and second quadrupole (collision cell) are coupled with time of 
flight (TOF) in such a way that acceleration of the ions in the TOF occurs perpendicular to the 
initial trajectory of the ions [124]. Structurally, a Q-TOF instrument is similar to a QqQ-LIT, 
whereas the LIT is replaced by a TOF analyzer, which contains an ion acceleration region and a 
field free region (flight tube). The TOF analyzer measures the time for ions to travel through the 
flight tube; ions with small m/z values need a shorter time to reach the detector than those with 
large m/z values. The mass can be determined based on the time taken to travel the distance [124]. 
Thus, the resolution of a TOF analyzer is highly dependent on the length of the field-free region. 
Given the specific structure, a Q-TOF  instrument typically can provide a high detection sensitivity 
in the atto-mole range, a high resolution of 20,000 or more, and a high mass accuracy of less than 
5 ppm [124, 125], which has enabled it to be used in a wide scope of applications. 
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Depending on the type of application, a Q-TOF is typically operated in two modes: TOF-MS and 
TOF-MS/MS. In TOF-MS mode, the first and second quadrupoles are used as ion guides operated 
in RF-only mode that allow all ions to enter the fight tube travelling to the detector. Therefore, 
accurate mass measurement can be achieved, providing the confirmation and possible elemental 
composition of target analytes [126]. In TOF-MS/MS mode, the first quadrupole is used as an ion 
filter that selects specific ions for fragmentation via CAD in the collision cell. The product ions are 
then transmitted into the flight tube for differentiation and subsequent detection. Thus, both 
precursor and product ions can be detected with accurate mass information that can be used to 
characterize and identify unknown compounds. Based on these advantages, Q-TOF has been 
extensively used for the characterization and identification of drug molecules and their metabolites 
[94, 127].  
Similarly, Q-TOF can also be used to study the metabolism of gemini surfactants in biological 
systems. Upon transfection, gemini surfactant nanoparticles enter cells and travel through different 
cellular compartments prior to releasing the genetic materials for gene expression. During this 
process, nanoparticles will potentially be metabolized by various cytoplasmic enzymes. The 
metabolites can possibly be related to the toxicity and efficiency of nanoparticles. Thus, 
understanding the metabolism of gemini surfactants can contribute to the design and development 
of more effective gemini surfactants for gene delivery. Therefore, it is of great importance to 
understand the metabolism and metabolite formation of gemini surfactants in cells. To achieve this 
goal, a Q-TOF instrument would be suitable as it can detect and characterize the metabolites of 
gemini surfactant nanoparticles in biological systems. Characterization and structural elucidation 
of gemini surfactants using Q-TOF has been extensively conducted in our group. For example, the 
MS/MS fingerprints of 10 novel di-quaternary ammonium gemini surfactants were illustrated using 
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an ESI-Q-TOF-MS/MS [117]. Similarly, 29 novel di-quaternary ammonium gemini surfactants 
were analyzed using a Q-TOF-MS and a quadrupole-hexapole-quadrupole mass spectrometer 
(QhQ-MS) for their structural elucidation and characterization [116]. Most recently, the analysis 
of a series of novel amino acid/dipeptide-modified gemini surfactants were accomplished by an 
ESI-Q-TOF-MS to obtain accurate mass measurements for the confirmation of their structures 
[118].  
In my work, I used a non-targeted metabolic profiling approach to study the metabolites of the 
three gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 in PAM 212 cells. 
Despite the potential change with matrix effects and interferences, flow injection analysis-high 
resolution MS methods were used for establishing the metabolic profiles of treated cells as they 
offer simple and fast analysis along with accurate mass measurements suitable for the putative 
identification and characterization of metabolites. Specifically, FIA-TOF-MS methods in both 
positive and negative ESI modes were initially developed on a Q-TOF (QSTAR XL®) instrument. 
The extracts of treated and untreated (control) cells were then analyzed by the FIA-TOF-MS 
methods to establish their metabolic profiles in each mode, in which accurate mass measurements 
for potential metabolites were achieved to assist in their identification. Furthermore, potential 
metabolites were analyzed in FIA-TOF-MS/MS mode to obtain its product ions that offers 
additional confirmation for structural elucidation. However, after a preliminary evaluation of the 
potential metabolites of these gemini surfactants on a Q-TOF instrument, their metabolisms were 
further investigated using a hybrid quadruple-Qrbitrap (Q-Exactive) mass spectrometer due to its 
higher sensitivity and superior resolution, providing high confidence for the putative identification 
and characterization of the metabolites. 
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1.3.4 Hybrid quadrupole-Orbitrap for qualitative analysis 
A Q-Exactive is also a high-resolution tandem mass spectrometer that provides high sensitivity, 
accurate mass measurement, and a wide dynamic range [128]. In this system, a quadrupole mass 
filter is connected to a high energy collisional dissociation (HCD) cell via an intermediate curved 
linear trap (C-trap) that is coupled with an Orbitrap mass analyzer [109]. Samples are introduced 
into the ion source and the ions are transmitted to the quadrupole which works as an ion guide and 
can filter the ions based on their m/z values. The ions are then transferred into the C-Trap and 
injected into the Orbitrap for analysis. In the Orbitrap analyzer, ions are trapped by rotating around 
a central spindle electrode with harmonic oscillations [129]. As the frequency of harmonic 
oscillation depends on the ion’s m/z value, a time-domain image current transient is generated 
based on the frequency of harmonic ion oscillation, which is used to produce the high-resolution 
mass spectra via Fourier transformation [129]. In addition, ions can be passed through the C-Trap 
into the HCD cell to conduct fragmentation experiments and then the fragment ions can be moved 
back into the C-Trap and ejected into the Orbitrap for detection. Given the specific structure, Q-
Exactive can achieve a resolution of 140,000 at m/z 200 and a mass accuracy of less than 2 ppm 
[128, 130]. Such an advantage enables the Q-Exactive to be used for a wide range of applications, 
including characterization, identification, and quantification of small molecules, peptides, and 
intact proteins [131-133]. 
Typically, a Q-Exactive instrument can be operated in two modes: MS scan and MS/MS scan. In 
MS mode, the quadrupole is used as an ion guide that allows all ions to pass into the C-trap for 
injection and analysis in the Orbitrap analyzer at high resolution. As such, accurate mass 
measurements can be achieved to provide possible elemental compositions of molecules. In 
MS/MS mode, the quadrupole is operated as an ion filter to select desired ions with specific m/z 
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values to pass through the C trap and enter the HCD cell for fragmentation. The product ions are 
then transmitted back into the C trap and ejected into the Orbitrap analyzer for high resolution mass 
detection. In this mode, both precursor and product ions are measured with accurate masses that 
contribute to the identification and characterization of unknown molecules. Therefore, Q-Exactive 
can be used to identify and characterize the metabolites of gemini surfactants in biological systems. 
In my project, the metabolism of the three gemini surfactants in PAM 212 cells were mainly 
investigated on a Q-Exactive instrument. All metabolites were structurally proposed and 
characterized based on accurate mass measurements and characteristic product ions. As such, the 
metabolic pathways of gemini surfactants were elaborated. 
1.4 Biological Fate of Gemini Surfactant Nanoparticles 
In biomedicine, drug molecules must reach their target sites to exert therapeutic effects. However, 
the target sites can be in various locations, such as the organs, issues, and cells, in the body 
depending on the type of drug molecules. For nucleic acids used in gene therapy, the target sites 
are either in the cytoplasm or in the nucleus of a cell. Thus, it is imperative that these molecules 
travel through the plasma membrane to reach their target sites in cells for transgene expression. 
However, due to the unique structure of cell membrane that is dynamic and relatively lipophilic in 
nature, it restricts the entry of large and hydrophilic molecules, such as DNA and RNA. Therefore, 
an appropriate delivery system is required for nucleic acids to enter the cells and achieve gene 
transfection. 
Nanoparticle-based medicine has the ability to deliver drugs and genetic materials to specific 
locations, such as specific regions in the body, specific cells, and even specific sites within cells, 
to achieve therapeutic effect [134]. In general, the behavior of nanoparticles can be summarized as 
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follows: 1) nanoparticles can be administrated via various routes, such as intravenous, 
subcutaneous, intraperitoneal, dermal, inhalation, and oral [135]; 2) they are absorbed once they 
begin to interact with biological components; 3) they circulate and distribute to various organs in 
the body and may remain structurally intact or be metabolized during this process [136]; 4) they 
enter the cells of target organ to release therapeutic contents; and 5) finally they are excreted or 
metabolized by various cellular enzymes. As such, the biological fate of nanoparticles varies 
largely depending on the characteristics of nanoparticles, the route of entry, and the biological 
conditions. Specifically, a series of events, including cellular uptake, trafficking, biodistribution, 
and metabolism, as well as systemic absorption, distribution, and clearance, can take place after 
administration that could dictate the biological fate of gemini surfactant nanoparticles. 
1.4.1 Cellular uptake 
Cellular uptake is one of the most important processes for gene delivery, as it determines the 
cellular internalization of therapeutic genes available for gene expression. The mechanism of 
internalization of gene-encapsulated nanoparticles in cells has been widely studied [26, 137]. 
Endocytosis has been established to be the main approach for the internalization of 
polycation/DNA complex into the cells, as the use of endocytosis inhibitors significantly reduced 
gene expression and the interference of endocytic pathway with lysosomotropic reagents 
substantially enhanced gene expression [138-140]. Endocytosis is a cellular uptake process that 
involves a controlled invagination of the cell membrane, allowing macromolecules, such as 
liposome/DNA complexes, to be enveloped by cell membrane; and subsequently the membrane 
buds off to form new vesicles inside the cell, which eventually fuses with the lysosome where the 
liposome/DNA complexes are degraded [84]. 
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To date, a variety of mechanisms for endocytosis have been identified (Figure 1.9) [141, 142]. 
Among them, clathrin-mediated endocytosis, caveolae-mediated endocytosis, and 
macropinocytosis are the most common uptake pathways used by mammalian cells to internalize 
macromolecules [143]. However, these endocytic pathways differ in the composition of coat, the 
size of detached vesicles, and the fate of internalized particles. Clathrin-mediated endocytosis is a 
process that involves the formation of ligand-receptor complexes in coated pit on the cell 
membrane and subsequent generation of clathrin-coated vesicles in the cytoplasm; the intracellular 
vesicles then form endosomes and fuse with lysosomes where the particles are degraded in low pH 
environment [144]. It is the major endocytic pathway for the uptake of essential nutrients, antigens, 
and pathogens [144]. Caveolae-mediated endocytosis is another important uptake pathway that 
typically involves the use of small hydrophobic membrane microdomains (caveolae) to achieve an 
entry to cells [145]. Compared with clathrin-mediated uptake, caveolar-mediated uptake is a non-
acidic and nondigestive route for internalization of particles, which avoids normal lysosomal 
degradation due to the drop in pH [146]. Macropinocytosis is an actin-driven invagination of the 
plasma membrane that generates the large endocytic vesicles with irregular sizes and shapes [147]. 
It is an efficient route for the non-selective endocytosis of macromolecules and large volumes of 
extracellular medium, which has no formation of the coat and is also not receptor-dependent. For 
a given delivery agent, the specific mechanism of endocytosis is typically dependent on many 
factors, such as the properties of the carriers, the ligands attached to the complexes, and the surface 
characteristics of the cells. 
Numerous studies have indicated that gene-encapsulated nanoparticles interact with cells to 
achieve cellular uptake via the above endocytic processes. For example, the cellular uptake of 
lipoplexes formed with the cationic lipid DOTAP and DNA has been observed to occur solely by 
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clathrin-mediated endocytosis and internalized particles were eventually degraded in the lysosomes 
[148]. Similarly, it was observed that SAINT-2/DNA lipoplexes-mediated transfection occurred 
through the cholesterol-dependent clathrin-mediated endocytosis and cholesterol depletion 
decreased the transfection activity [140]. Recently, an in vitro study showed that the internalization 
of gemini surfactant nanoparticles of P/L/12-7NH-12 and amino acid-substituted gemini surfactant 
nanoparticles of P/L/12-7N(GK)-12 was via  both clathrin-mediated and caveolae-mediated uptake 
pathways [26]. Collectively, these results suggested that receptor-mediated endocytosis is an 
essential uptake pathway for gene-encapsulated nanoparticles.  
In addition to the endocytic uptake pathway, non-endocytic pathways are also able to achieve the 
intracellular delivery of genes using various techniques, such as, microinjection, permeablization, 
and electroporation [149]. Microinjection is a technique that uses a glass capillary pipette to inject 
genes into the cytosol or the nucleus to achieve rapid delivery of genes [149]. Permeabilization is 
another technique for non-endocytic delivery, in which a pore-forming agent is used to induce 
transmembrane channels in  cell membrane, allowing for the entry of large molecules [150]. 
Similarly, electroporation involves the use of an electric field to open pores in cell membrane to 
facilitate the entry of DNA [151]. Although these techniques have the ability to rapidly deliver 
genes to target sites in cell, they are not typically used for in vivo gene delivery due to their highly 
invasive nature [152]. In addition, the gene delivery efficiency of non-endocytic pathway is still 
limited, preventing their clinical applications. Therefore, the use of non-invasive endocytic cellular 





Figure 1.9. Different cellular uptake pathways in non-viral gene delivery [137] 
As the quantity of nanoparticles internalized in cells can directly correlate with transfection 
efficiency and/or toxicity, it is of great importance to measure the level of cellular uptake of 
nanoparticles. This can be achieved by the quantitative determination of nanoparticles in cells using 
MS-based methods. In our lab, the cellular uptake of the gemini surfactants 16-3-16 and 16(Py)-S-
2-S-(Py)16 was previously determined in PAM 212 cells using a quantitative LC-MS/MS method 
[96]. The results showed a rapid increase in the cellular concentration of both gemini surfactants 
during the course of 5 h treatment, followed by a gradual depletion post transfection [96]. However, 
the similar trend was not able to explain the difference in the efficiency and toxicity of the two 
compounds as gene delivery agents. Thus, we anticipate there is a difference within the cellular 
uptake and biodistribution of the two gemini surfactants nanoparticles, which could provide an 
insight on their different efficiency and toxicity profiles. The subcellular level of each gemini 
surfactant nanoparticle upon transfection can be determined by an FIA-MS/MS method. 
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1.4.2 Cellular trafficking and biodistribution 
After internalization, the nanoparticles reside in the endosomes, which further develop and fuse 
with lysosomes where the nanoparticles can be degraded in the reduced pH condition. To achieve 
a successful gene transfection, a fraction of nanoparticles has to escape from the endosomes into 
the cytoplasm prior to their fusion with the lysosomes, which then goes through the intracellular 
trafficking and translocation process to reach various subcellular compartments. During this 
process, DNA within the complexes is protected from nuclease actions, but will inevitably be 
degraded unless it enters the nucleus. Currently, the most established mechanism for 
internalization, cellular trafficking and translocation, and gene release and expression of lipid-
based nanoparticles is described below (Figure 1.10). 
a) Binding of the lipoplex to cell membrane - The first step for internalization of DNA-
encapsulated gemini surfactant nanoparticles is to bind with the cell membrane [153]. Both 
non-specific and specific bindings can trigger the internalization of the lipoplex into the cell 
[154]. Non-specific binding is primarily driven by electrostatic interaction between positive 
charge of the complexes and negative charge of the cell membrane surface, whereas specific 
binding is typically initiated by a specific targeting ligand that is specifically recognized by a 
cell surface receptor. 
b) Internalization into the endosome - It is an internalization process primarily via endocytosis 
[84, 140], in which  the complexes are surrounded by an area of plasma membrane and then 
buds off inside the cell to form a vesicle containing the ingested materials in the cytoplasm. 
Such vesicles can combine to form the endosomes, which develop powerful hydrolytic 
capabilities as the internal pH falls sharply. Eventually, the endosomes merge with the 
lysosomes where the lipoplexes are degraded [84]. 
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c) Endosomal escape of the lipoplexes - The escape of lipoplexes from the endosome into 
cytoplasm is to prevent from degradation in the late endosome and lysosome due to the 
decreased pH. The pH decrease in the late endosome can induce the formation of an inverted 
hexagonal phase of the lipid/DNA complex, resulting in the fusion with endosomal membrane. 
Such an integration destabilizes the membrane and allows the escape of lipoplex from the 
endosome, facilitating the subsequent cellular trafficking and release of DNA into cytoplasm 
[84, 155]. In addition, DNA escape from the endosome can be facilitated by pH-sensitive 
cationic lipids, which possess a buffering capacity to promote the influx of protons in the late 
endosome/lysosome, resulting in an osmotic effect. This is called “proton sponge” effect that 
can aid in the disruption of endosomal membrane, enhancing the availability of  DNA  for 
nuclear transport and gene expression [156].  
d) Translocation into the nucleus - In the cytoplasm, free DNAs or DNA-encapsulated 
nanoparticles can translocate to the nucleus through intracellular trafficking, which represents 
a significant barrier for gene expression [155, 157]. In the translocation process, the passage 
through the nuclear membrane competes with the rapid degradation of DNA by cytoplasmic 
nucleases [84]. Only a fraction of DNAs is able to enter the nucleus and the rest are destroyed 
in the cytoplasm. To increase the nuclear localization of DNA, nuclear localization ligands 
have been used to promote an efficient nuclear import of DNA, thus resulting in higher gene 
expression [158]. 
e) Transcription of the therapeutic gene in the nucleus - Once inside the nucleus, the 
therapeutic gene is transcribed to mRNA, followed by its translation in the cytoplasm and 




Figure 1.10. Cellular uptake, trafficking, and distribution of lipid/DNA nanoparticle. The process starts 
with a binding of the lipoplex to the cell membrane (A), followed by internalization into the endosome (B). 
Endosomal escape of the lipoplex (C) occurs for the subsequent intracellular trafficking and translocation 
into the nucleus (D). Transcription of the therapeutic gene takes place in the nucleus (E), followed by its 
translation in the cytoplasm and expression of therapeutic protein [155]. 
As shown in Figure 1.10, the internalization, cellular trafficking, and biodistribution of gemini 
surfactant nanoparticles involves a series of events taking place in various intracellular 
compartments. During this process, the nanoparticles travel through different cellular 
compartments and remain for a certain period of time at each compartment. Furthermore, the 
biodistribution of gemini surfactant nanoparticles within subcellular compartments also changes as 
the nanoparticles might migrate from one compartment to another and also undergo degradation 
by cytoplasmic nucleases [159]. As such, a time-course determination of the concentration of 
gemini surfactant nanoparticles in subcellular compartment is essential to assess their 
biodistribution. This can be achieved by a quantitative measurement of gemini surfactant 
nanoparticles in the isolated intact subcellular compartments of treated cells. 
By using differential centrifugation, the subcellular compartments, such as the nucleus, 
mitochondria, plasma membrane, and cytosol, can be isolated intact from treated cells [160, 161]. 
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These are the major compartments that gemini surfactant nanoparticles most likely accumulate 
during their intracellular trafficking process. Differential centrifugation is an isolation and 
purification technique that uses different centrifugal forces to pull on the subcellular components 
for precipitation based on their distinct densities, sizes, and shapes [161]. Once the subcellular 
compartments containing gemini surfactant nanoparticles are obtained, the gemini surfactant 
nanoparticles can be extracted from biological matrix using various extraction methods [95, 162]. 
In this process, free gemini surfactant molecules will also be extracted along with gemini surfactant 
nanoparticles from cellular compartments. Together, the quantity of gemini surfactants in each 
compartment can then be determined by a FIA-MS/MS method to assess their subcellular 
distributions. 
1.4.3 Metabolite formation  
Understanding the metabolism of gemini surfactants nanoparticles in biological systems provides 
information on how gemini surfactants interact with biological components and how the 
metabolites can possibly affect biological systems. Such information will aid in the design and 
optimization of gemini surfactant structures to improve efficiency and decrease toxicity. Currently, 
extensive research have been conducted to achieve the most efficient delivery systems by means 
of optimization of formulation strategy, facilitation of cellular uptake, and promoting efficient 
endosomal escape [163, 164]. For instance, various formulation conditions have been investigated 
with a number of gemini surfactant compounds to obtain the delivery system with high efficiency 
and low toxicity [164]. Although such investigations obtained the knowledge pertaining to the 
formulation methods of lipoplexes, other important factors, such as metabolite formation, were not 
explored, which might have great impact on their efficiency and toxicity. In addition, the 
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metabolites of the nanoparticles might also play important biological roles in host body, which 
need to be further investigated. 
To obtain optimal transfection and minimal toxicity, drug-loaded nanoparticles should deliver and 
release their therapeutic contents at the target sites, followed by their biodegradation and excretion. 
However, the therapeutic agents might be practically released at any time during the delivery 
process depending on the characteristics of nanoparticles and their interactions with biological 
components, leading to reduced efficiency and increased toxicity. Furthermore, nanoparticles 
typically possess high toxicity when genetic materials are not incorporated as a result of the carried 
excessive positive charges [21]. Also, the metabolites of nanoparticles might pose potential harm 
to host cells, contributing to the overall toxicity of the delivery system. To date, the detailed 
mechanism of degradation and excretion processes for nanoparticles has not been well understood, 
and there is no report describing the metabolite formation of nanoparticles, including gemini 
surfactant nanoparticles, as gene delivery agents. 
Generally, the internalized nanoparticles in the endosomes will be either degraded in the lysosomes 
or recycled back to the cell surface via exocytosis if they are not able to escape from the endosomes 
[84]. Therefore, an efficient escape of the nanoparticles from the endosomes into cytoplasm is 
essential to achieve effective transfection as it dictates the amount of genetic materials that can 
reach the nucleus for gene expression. After escape from the endosome, the nanoparticles can either 
release DNA in the cytoplasm, which further migrates to the nucleus for expression [165, 166]; or 
as a whole enters the nucleus, followed by the release of therapeutic materials [167]. During this 
process, the nanoparticles can possibly be metabolized by various cytoplasmic enzymes depending 
on their structures and characteristics.  
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Phase I and II biotransformations are common pathways for drugs and other foreign substances to 
be detoxified and eliminated [168-170]. Typically, phase I biotransformations contain oxidation, 
hydroxylation, reduction, and hydrolysis, which involve the modification of a substrate molecule 
with polar functional groups, such as hydroxyl (-OH), carboxyl (-COOH), sulfhydryl (-SH), and 
amino (-NH2) group [169]. Such reactions often result in a modest increase in the parent drug’s 
water solubility, which usually makes the drug ready to undergo subsequent phase II conjugation 
reactions. On the other hand, phase II biotransformations generally involve the addition of 
endogenous polar functional moieties, such as glucuronic acid, glycine, and amino acids, to make 
the drugs more hydrophilic so that they can be easily excreted [169]. These reactions often include 
a variety of conjugation reactions, such as glucuronic acid, sulfate, amino acids, and glutathione 
conjugations [171]. 
A variety of xenobiotics, including drugs and delivery agents, have been reported to undergo phase 
I and phase II biotransformations to achieve cellular detoxification and elimination [172]. It is well 
known that liver is the principal organ of drug metabolism with a large number of enzymes, 
however, other tissues, such as the lungs, the skin, and the kidneys, also exhibit substantial 
enzymatic activities [173-175]. Therefore, the metabolism of the gemini surfactants nanoparticles 
in the keratinocyte PAM 212 cells was also investigated in my research to understand their 
metabolite formation as the main therapeutic use of these gemini surfactants are for topical 
applications. Since the potential metabolites of these gemini surfactants might have close structural 
relationship with their original compounds, their masses can be accurately determined by high-
resolution MS to assist in structural identification. Thus, by using high-resolution mass 
spectrometry, the metabolites of the gemini surfactant nanoparticles in cells can possibly be 
identified and characterized. 
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1.4.4 In vivo fate 
The in vivo biological fate of lipid-based nanoparticles is closely related to the absorption, 
distribution, and excretion in host body, which might also have a profound impact on their 
efficiency and toxicity. Typically, nanoparticle-based medicines are introduced into the body via a 
variety of routes, including oral administration, injection, inhalation, and topical application, 
depending on their physiochemical properties [135]. Once the nanoparticles are in the host body, 
they enter blood circulation by two main approaches, active diffusion and passive diffusion, 
followed by systemic circulation and distribution in various organs, such as the liver, the heart, the 
spleen, the lungs, the brain, and the lymphatics [176, 177]. During the distribution process, the 
nanoparticles will interact with the blood components and travel through the blood stream to reach 
the organs, followed by absorption and distribution in the tissues and cells. The net positive charge 
of the particles is a crucial factor that determines the circulation time and tissue distribution, as it 
can interact with the negative charge of blood constituents, such as erythrocytes and proteins. Such 
an interaction will reduce the net positive charge of the nanoparticles that changes their 
physicochemical property. As a result, the circulation time and distribution preference will be 
changed, resulting in reduced efficiency of the nanoparticles. In addition, particle size is another 
critical factor that affects the circulation and distribution in the body. Typically, small particles 
with sizes less than 40 nm diffuse fast in the inner layers of tissues and extracellular matrix, whereas 
large particles in sizes greater than 100 nm circulate and diffuse relatively slow due to the steric 
hindrance [178]. 
The clearance of nanoparticles from systemic circulation is inevitable after distribution, primarily 
conducted by macrophages in the liver and spleen [179]. Clearance and opsonization are the natural 
processes in biological systems to remove foreign particles by innate immune systems [180]. This 
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process can also occur under certain conditions for nanoparticles depending upon their sizes and 
surface characteristics [179, 181]. However, several strategies can be taken to reduce the rapid 
clearance of lipid-based nanoparticles, For example, the attachment of hydrophilic polymers 
polyethylene glycol (PEG) to the surface of nanoparticles can sterically enhance its stability and 
avoid rapid clearance by the phagocyte systems, which significantly increases its circulation time 
[182]. Similarly, coating hydrophilic polymers to hydrophobic particles can prevent their 
adsorption of opsonins, thereby reducing the uptake by the phagocyte systems and prolonging the 
circulation half-life of encapsulated genetic materials [182]. In addition, the route of administration 
has a great impact on the elimination process of nanoparticles in the host body. Typically, inhaled 
nanoparticles are cleared in the alveolar region via phagocytosis, which was facilitated by 
chemotactic attraction of alveolar macrophages to the deposition sites [182]. On the other hand, 
orally administrated nanoparticles are often removed from the host body by urinary excretion and 
they can also be eliminated by passing through the gastrointestinal tract in feces [183]. 
Intravenously injected nanoparticles are normally eliminated from circulation by the 
reticuloendothelial system in a process that is facilitated by the surface deposition of opsonic 
factors and complement proteins on the nanoparticles [184, 185]. In general, large particles are 
eliminated more rapidly than small nanoparticles as they can activate the complement systems 




1.5 Proposed Research 
1.5.1 Research hypotheses 
1) Gemini surfactant nanoparticles 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 will 
show different cellular uptake and distribution profiles that can explain their varying 
transfection efficiencies and toxicities. 
2) Upon transfection, the gemini surfactant nanoparticles 16-3-16, 16(Py)-S-2-S-16(Py), and 
16-7N(GK)-16 will be degraded/metabolized by enzymes in cells. The metabolites can be 
detected and possbily identified using high-resolution mass spectrometry, which will help 
explain their various transfection efficiencies and toxicities. 
1.5.2 Research objectives 
1) Assessment of the cellular uptake and distribution of the three gemini surfactants 
nanoparticles 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 using mass spectrometry 
to explore their relationship with the varying efficiencies and toxicities in gene transfection. 
a. In vitro evaluation of gene transfection efficiencies and toxicities of the gemini 
surfactants nanoparticles 16-3-16 and 16(Py)-S-2-S-16(Py) within PAM 212 cells. 
b. Development and validation of a flow injection analysis-tandem mass spectrometric 
(FIA-MS/MS) method for the quantification of the three gemini surfactant 
nanoparticles in cellular matrix. 
c. Determination of the three gemini surfactant nanoparticles in the subcellular 




2) Evaluation of DNA binding capabilities and molecular packing parameters of the three 
gemini surfactants to understand their behaviors in subcellular compartments. 
a. Evaluation of DNA binding capabilities of the three gemini surfactants using ethidium 
bromide dye exclusion assay. 
b. Determination of molecular packing parameters of the three gemini surfactants using 
Langmuir studies. 
3) Investigation of the metabolite formation of the gemini surfactants nanoparticles 16-3-16, 
16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 using high-resolution mass spectrometry. 
a. Development of FIA-MS and FIA-MS/MS methods on high-resolution mass 
spectrometry instruments for the analysis of gemini surfactant metabolites. 
b. Establishment of the metabolic profiles of cells treated with gemini surfactant 
nanoparticles using a non-targeted metabolic profiling approach. 
c. Putative identification and characterization of the metabolites of the three gemini 
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To determine cellular uptake and subcellular distribution, a flow injection analysis-tandem mass 
spectrometry (FIA-MS/MS) method was developed and validated for the quantification of three 
gemini surfactants 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16 in the cellular matrix. In 
additon, an application of this method was demonstrated to quantitatively determine the gemini 




A simple, reliable flow injection analysis-tandem mass spectrometric (FIA-MS/MS) method was 
developed for the determination of gemini surfactants, designated as 16-3-16, 16(Py)-S-2-S-(Py)16, 
and 16-7N(GK)-16, as gene delivery agents in the cellular matrix. Compound 16-3-16 is a 
conventional gemini surfactant bearing two quaternary amines, linked by a 3-carbon spacer region, 
compound 16(Py)-S-2-S-(Py)16 contains two pyridinium head groups, while 16-7N(GK)-16 bears 
a glycyl-lysine di-peptide in the space region. The method was fully validated according to the 
USFDA guidelines. It is the first FIA-MS/MS method that was developed for the quantification of 
three gemini surfactants belonging to different structural families. The method was superior to the 
existing liquid chromatographic (LC)-MS/MS methods in terms of sensitivity and time of analysis. 
Positive electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode was used on 
a triple quadrupole-linear ion trap (4000 QTRAP®) instrument. Deuterated internal standards were 
used to correct for matrix effects and variations in ionization within the ESI source. Isotope dilution 
standard curves were established in the cellular matrix, with a linear range of 10 nM-1000 nM for 
16-3-16 and 16(Py)-S-2-S-(Py)16, and 20 nM-2000 nM for 16-7N(GK)-16. The precision, 
accuracy, recovery, and stability were all within the acceptable ranges as per the USFDA guidelines. 
The method was successfully applied for the quantification of target gemini surfactants in the 
nuclear fraction of PAM 212 cells treated with nanoparticles, which varied significantly and may 
explain differences in the observed efficiency and toxicity of these gemini surfactants in gene 
delivery. 





Gene therapy is a promising approach to treat or improve the health condition of patients by 
introducing therapeutic genetic materials into the patient’s cells [1-4]. To date, almost 2,600 gene 
therapy clinical trials have been conducted worldwide, with more than half of them being in the 
field of cancer gene therapy [5]. The most difficult challenge in gene therapy is the issue of gene 
delivery. Typically, there are two main types of gene delivery methods; viral and non-viral vectors 
[6]. Viral vectors utilize the viruses’ natural infection capability to introduce a target gene into cells 
[7, 8]. While viruses are efficient vectors for transfection, a limited capacity of genetic material 
can be delivered and they present challenges with respect to potential genotoxicity and induction 
of a severe immune response [9, 10]. On the other hand, non-viral vectors have relatively low 
toxicity profiles, are not limited to the size of genes they can encapsulate, and can be easily 
produced at low cost [4, 11, 12]. However, the major disadvantage of non-viral vectors is their low 
gene delivery efficiency compared to viral vectors [13]. Thus, major efforts have been made to 
discover and develop novel non-viral vectors that offer both high transfection efficiency and low 
toxicity. 
A family of lipid cationic molecules, called gemini surfactants, has been investigated as gene 
delivery vehicles [14, 15]. They are comprised of two surfactant monomers that are chemically 
linked by a rigid spacer group [16]. Gemini surfactants possess dual positively charged hydrophilic 
head groups and hydrophobic tail regions [17] (Figure 2.1A). This structure enables gemini 
surfactants to bind and compact DNA, and subsequently facilitate its cellular entry [18, 19]. For 
example, the conventional bis-quaternary gemini surfactant 14-2-14 and the serine-derived bis-
quaternary gemini surfactants (nSer)2N5 (n=12 and 14) were shown to efficiently deliver plasmid 
DNA into mitochondria in HeLa cells in combination with the helper lipids 1,2-di-(9Z-
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octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol [20]. A transfection of 
up to 40% of the cells was achieved, which is almost twice of that obtained with the commercial 










Figure 2.1. (A) Schematic representation of the general structure of gemini surfactant, (B) structures of 16-
3-16 and the monitored product ions, (C) structures of 16(Py)-S-2-S-16(Py), and the monitored product ions, 
and (D) structures of 16-7N(GK)-16 and the monitored product ions.  
By varying the head group, the length of hydrophobic tails and the spacer region, a wide range of 
gemini surfactant compounds can be designed and synthesized. The aim is to increase efficacy 
while reducing toxicity. N, N-bis(dimethylhexadecyl)-1,3-propanediammonium (denoted 16-3-16, 
Figure 2.1B) is a representative of the traditional non-substituted m-s-m gemini surfactants, where 
m is the number of carbon atoms in the tail chain and s is the number of carbon atoms in the spacer 
region [17]. Other classes of gemini surfactants with variations in the head group have also been 
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studied, such as 1,1’-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium bromide 
(denoted 16(Py)-S-2-S-16(Py), Figure 2.1C) [21], which displayed effective DNA binding 
capability and low cytotoxicity [21]. Most recently, bio-compatible moieties, such as amino acids, 
have been incorporated within gemini surfactant structure to enhance the biocompatibility of the 
delivery agent [22]. One compound, in particular, substituted with a di-peptide glycyl-lysine 
(denoted 16-7N(GK)-16, Figure 2.1D) showed higher transfection efficiency with lower toxicity 
in gene delivery compared with earlier generations of gemini surfactants [23].  
However, these gemini surfactants nonetheless vary amongst each other in terms of their gene 
transfection efficiency and toxicity profiles. This could theoretically be attributable to their 
different biological fate upon transfection, such as variable cellular uptake, subcellular 
biodistribution and metabolism. Garnering such knowledge is important and may provide a 
mechanistic explanation for the observed differences among these gemini surfactants in their 
efficiency and toxicity. However, there is a need for sensitive analytical methods that can detect, 
differentiate, and quantify these gemini surfactants in biological matrices to determine their post-
transfection fate. 
Since gemini surfactants lack a chromophore or fluorophore and contain permanent positive 
charges, mass spectrometry (MS) is ideal for their qualitative and quantitative analysis [24-26]. 
Tandem mass spectrometry (MS/MS) using multiple reaction monitoring (MRM) allows for the 
detection and quantification of gemini surfactants using specific precursor ion-to-product ion 
transitions, which provides high specificity to target gemini surfactants in complex biological 
matrices. Our group has established the collision-induced dissociation (CID)-MS/MS 
fragmentation patterns of over 50 gemini surfactant structures belonging to various structural 
families and identified their characteristic product ions [27-31]. In addition, we developed liquid 
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chromatography electrospray ionization (LC-ESI)-MS/MS methods employing cyano and 
hydrophilic interaction liquid chromatography (HILIC) columns for the quantification of gemini 
surfactants within cells [25, 26]. However, these methods suffered from some drawbacks, such as 
ion suppression due to the addition of an ion pairing reagent, relatively long run time, and the use 
of an analytical column and gradient elution. Therefore, we aim herein to develop a simple and 
reliable method that can quantify the gemini surfactants in the cellular matrix. 
Flow injection analysis (FIA)-MS/MS is an analytical approach for rapid quantitative analysis, in 
which no analytical column is used and both separation and detection occur within the MS 
instrument [32]. The removal of the analytical column can dramatically reduce the time for method 
development and sample analysis. Furthermore, the FIA-MS/MS can offer high-throughput 
quantitative analysis without compromising the sensitivity, precision, and accuracy [33]. Many 
studies have demonstrated the feasibility of FIA-MS/MS for the quantification of small molecules 
in biological samples [34-36]. For example, FIA-MS/MS has been used to quantify nifedipine in 
human plasma samples, with high sensitivity, selectivity, and a short run time [37]. Similarly, the 
drug metformin was quantified in dog plasma using a validated FIA-MS/MS method that was 
superior to all existing methods in terms of speed of analysis without compromising sensitivity 
[38]. Most recently, a simple FIA-MS/MS method has been developed for the cutaneous 
determination of peptide-modified cationic gemini surfactants used as gene delivery vectors [39]. 
In this work, we report for the first time the development and validation of a fast and simple FIA-
MS/MS quantification method that was applied for the quantification of structurally different 
gemini surfactants at the subcellular level. 
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2.3 Materials and Methods 
2.3.1 Materials 
All gemini surfactants and the deuterated internal standards were previously synthesized using 
established protocols [21, 23]. Their structures are listed in Figures 2.1 and 2.S1 in supporting 
information. For analyte 16-3-16, the internal standard (16-3-16-D66) contains 66 deuterium atoms 
in the alkyl tails. Analyte 16(Py)-S-2-S-16(Py) has an internal standard (16(Py)-S-2-S-16(Py)-D10) 
with deuterated pyridinium head groups (10 deuterium atoms), whereas the internal standard (16-
7N(GK)-16-D4) for analyte 16-7N(GK)-16 possesses 4 deuterium atoms on the peptide group 
(Figure 2.S1 in supporting information).  
PAM 212 keratinocyte cells were kindly provided by Dr. S. Yuspa, National Cancer Institute, 
Bethesda, MD, USA. The neutral lipid, 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Formic acid, chloroform, 
methanol, and acetonitrile were purchased from Fisher Scientific (Ottawa, ON, Canada). Minimum 
essential media (MEM), fetal bovine serum albumin (FBS), and antibiotic-antimycotic solution 
were obtained from Sigma-Aldrich (Oakville, ON, Canada). Tissue culture flasks (150 cm2) and 
petri dishes (150 cm2) were purchased from Fisher Scientific (Ottawa, ON, Canada). The motorized 
tissue-grinder/pellet homogenizer (#12-141-361, 12-141-368) was purchased from Fisher 
Scientific (Toronto, ON, Canada). 
2.3.2 Instrumentation 
A quadrupole-linear ion trap (4000 QTRAP®) mass spectrometer (AB Sciex, Concord, ON, Canada) 
was coupled with an Agilent 1200 series HPLC, comprised of a quaternary pump, degasser and 
auto sampler (Agilent Technologies, Mississauga, ON, Canada), to perform the FIA-MS/MS 
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analysis. 3 µL of sample at 6 ℃ was loop-injected into the turbo ion source with an isocratic mobile 
phase consisting of acetonitrile-water (98:2, v/v) with 0.1% formic acid at a flow rate of 0.5 mL/min. 
The data acquisition time was 2 min. No sample carryover was observed and to eliminate any 
chance of carryover, the injection of the highest calibration curve sample was followed by one 
blank sample injection during sample analysis. 
The source was set at 600 ℃ at the interface, with ion spray voltage (ISV) at 5500 V, curtain gas 
(CUR) at 30, nebulizer gas (GS1) at 55, and heater gas (GS2) at 50. Nitrogen was used for all gas 
consumption. Multiple reaction monitoring (MRM) in positive electrospray ionization (ESI) mode 
with unit resolution was employed to monitor all analytes and internal standards. Two MRM 
transitions were monitored for each analyte, with one as a quantifier ion and the other as a qualifier 
ion (Figure 2.1); one MRM transition was used for each internal standard (Figure 2.S1 in 
supporting information). Dwell times for all transitions were set at 150 ms. The monitored MRM 
transitions and compound-dependent parameters for analytes and internal standards are listed in 
Table 2.1. Data acquisition and analysis was performed with Applied Biosystems/MDS Sciex 




Table 2.1. MRM transitions and compound-dependent parameters for analytes and internal standards 
Gemini surfactants Molecular Formula MRM Transition (m/z) DP EP CE CX
P 
16-3-16 C39H84N22+ 290.3/355.4 (quantifier) 70 10 22 10 
290.3/86.1 (qualifier) 70 10 35 10 
16-3-16-D66 C39H18D66N22+ 323.5/388.6  70 10 22 10 
       
16(Py)-S-2-S-16(Py) C44H78N2S22+ 349.3/396.3 (quantifier) 50 10 22 10 
349.3/203.1 (qualifier) 50 10 22 10 
16(Py)-S-2-S-16(Py)-D10 C44H68 D10N2S22+ 354.3/401.3  50 10 22 10 
       
16-7N(GK)-16 C50H106N6O22+ 411.4/276.8 (quantifier) 100 12 28 10 
411.4/268.3 (qualifier) 100 12 31 10 
16-7N(GK)-16-D4 C50H102 D4N6O22+ 413.4/278.8  100 12 28 10 
  DP- declustering potential, EP-entrance potential, CE-collision energy, and CXP-collision exit potential. 
2.3.3 Standard preparation 
All gemini surfactants and internal standards were prepared as aqueous stock solutions at a 
concentration of 3 mM and stored at -80 ℃ under darkness. Working solutions for each analyte 
were prepared by a serial dilution of the stock solution to achieve a concentration range of 50 nM-
5,000 nM for 16-3-16 and 16(Py)-S-2-S-16(Py), and 100 nM-1,0000 nM for 16-7N(GK)-16. 
Working solutions for each internal standard were prepared at a concentration of 1,000 nM. For 
the preparation of standard curves and quality control samples, 50 µL of analyte and internal 
standard working solutions were added to 900 µL of blank cell lysate (untreated cell lysate), the 
mixture then was processed in the same sample extraction process as described below. After 
extraction, 150 µL of organic solution was transferred into an HPLC vial for FIA-MS/MS analysis. 
DOPE vesicles were prepared freshly at 1 mM in isotonic sucrose solution (9.25% w/v, pH=9) as 
per established protocol [14]. Plasmid DNA (pGT·IFN-GFP) solution at 200 µg/mL was prepared 
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in ultra-pure water and stored at -80 ℃. The DOPE vesicles and plasmid DNA solutions were used 
without further dilutions. 
2.3.4 Cell treatment and sample collection 
The plasmid DNA, gemini surfactant, and lipid DOPE (P/G/L) nano-lipoplex was formulated as 
previously described [14]. Briefly, a gemini surfactant solution (190 µL) was added to the plasmid 
DNA (190 µL) and mixed, followed by a 15 min incubation at room temperature; the DOPE 
solution (4620 µL) was then added to the binary mixture, which was incubated at room temperature 
for 15 min to yield 5,000 µL of the ternary P/G/L system (nanoparticles).  
PAM 212 cells were cultured inside a humidified incubator at 37 ℃ in an atmosphere of 5% CO2. 
The MEM cell culture medium was supplemented with 10% (v/v) FBS and 1 % (v/v) antibiotic-
antimycotic solution. Upon reaching 80% confluence in the 150 cm2 flasks, cells were washed with 
phosphate buffered saline (PBS, 25 ml), dissociated with a 5 min incubation in a versene (5ml) and 
trypsin (0.5 mL) mixture, and collected by centrifugation (250 x g, 5 min, 4 ℃). The cells were 
then seeded at 8×106 cells per dish (150 cm2) 24 h prior to treatments. At 1 h prior to transfection, 
cells were switched to a serum-free media. Nanoparticle formulations (500 µL) were added to each 
dish in a dropwise manner and incubated for 5 h, after which the cells were returned to the 
supplemented media for all subsequent incubation steps. During the incubation period, triplicates 
of treated cell samples were trypsinized and collected along with one control (untreated cells) at 2 
h, 5 h, and 8 h. The collected cells were pelleted (250 x g, 5 min, 4 ℃), rinsed with PBS, 
reconstituted in 500 µL ice-cold hypotonic homogenization buffer (10 mM NaCl, 1.5 mM MgCl2, 




The ice-cooled 500 µL treated cell samples were gently homogenized using a motorized tissue-
grinder/pellet homogenizer to release the subcellular components and diluted in ice-cold hypertonic 
homogenization buffer (420 mM mannitol, 140 mM sucrose, 10 mM Tris-HCL (pH=7.5), and 2 
mM EDTA (pH=7.5)) to a total volume of 1,000 µL. Cell homogenates were then fractionated by 
differential centrifugation as described [40] to obtain the nuclear, mitochondrial, plasma membrane, 
and cytosolic fractions. It should be mentioned that the reported differential centrifugation 
procedure was slightly modified using 100,000 x g, instead of 80,000 x g, to separate the plasma 
membrane and cytosolic fractions. Finally, all fractions were suspended in an equal volume of 950 
µL PBS and stored at -80 ℃ prior to sample preparation.  
2.3.5 Sample preparation 
The 950 µL subcellular fractions were thawed and lysed by undergoing six freeze/thaw cycles plus 
1 h sonication at 25 kHz on a water bath at room temperature. After that, each sample was spiked 
with 50 µL of internal standard bringing the volume for subsequent extraction to 1 mL. Liquid-
liquid extraction of the analytes and internal standards from cellular matrix was carried out using 
the Bligh/Dyer method [41]. Briefly, each 1mL of sample was mixed with 3.75 mL of methanol-
chloroform (2:1, v/v), followed by mixing with 1.25 mL of chloroform and finally 1.25 mL of 
water. At each step, samples were vortexed for at least 10 s to ensure that a thorough mixing was 
achieved. The final combined mixture was centrifuged at 2,800 x g for 10 min at room temperature 
to separate the aqueous and organic phases. The bottom organic phase (80% portion) was retrieved 
and dried under a nitrogen gas stream, followed by reconstitution in 200 µL of methanol. Methanol 
solution (150 µL) was transferred into an HPLC vial for FIA-MS/MS analysis. 
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2.3.6 Method validation 
Method validation for all gemini surfactants was conducted in accordance with the USFDA 
guidelines [42], which include matrix effects, selectivity, linearity, precision, accuracy, recovery, 
and stability. 
 Matrix effects were assessed by comparing the instrument response of analytes added to the 
extracted cell samples to that of analytes in a methanol solution at low, mid, and high concentration. 
Selectivity was evaluated to ensure no interference from other components of the sample matrix 
through the analysis of six different blank cell samples.  
Linearity was explored over a wide range of analyte concentrations in the sample extract, from 10 
nM to 1,000 nM for both 16-3-16 and 16(Py)-2-S-2-16(Py), and from 20 nM to 2,000 nM for 16-
7N(GK)-16. Standard curves were constructed by plotting the ratio of peak areas of analytes to 
peak areas of internal standards versus the analyte concentrations using the least-square regression 
with a weighting factor of 1/x. Each standard curve was established with the slope, intercept and 
coefficient of determination (r2). The curve was accepted if the ± 15% deviation of the nominal 
value for each standard point other than LLOQ, which can be ± 20%, is achieved. The limit of 
detection (LOD) was set as the lowest detectable concentration with a signal-to-noise ratio (S/N) 
≥3, while the lower limit of quantification (LLOQ) was set as the lowest concentration with S/N 
≥5, with a precision of ± 20% coefficient of variation (CV) and a accuracy of ± 20% deviation from 
the nominal value as per the USFDA guidelines [42].  
Precision and accuracy of the method were determined by the analysis of six replicates of quality 
control samples at four different concentrations (LLOQ, low quality control (LQC), middle quality 
control (MQC), and high quality control (HQC)). The LQC was within 3-fold of the LLOQ, the 
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MQC was at the middle part of the standard curve range, and the HQC was within 80% of the upper 
limit of quantitation (ULOQ). One run per day was conducted across three consecutive days to 
assess the intra- and inter-day precision and accuracy. Precision was accepted if the CV is ± 15% 
for concentrations other than the LLOQ, which can be ± 20%; while accuracy was accepted if they 
were ± 20% deviation of the nominal value for the LLOQ and ± 15% deviation of nominal values 
for other concentrations. 
Recovery experiments were conducted by preparing one set of samples with analyte pre-spiked 
prior to extraction and the other set with analyte post-spiked after extraction and comparing the 
peak areas of analytes obtained from each set. For each analyte, three different concentrations at 
LQC, MQC, and HQC levels in each set were used to determine the recovery.  
Freeze-thaw stability, bench-top stability, auto-sampler stability, and long-term stability were 
carried out using samples with the concentrations at LQC, MQC, and HQC levels. Six replicates 
of samples at each concentration were prepared for the stability evaluation. Freeze/thaw stability 
was tested after all samples had gone through six freeze-thaw cycles, with one cycle involving 
taking out samples stored at -80 ℃ for at least 24 h and allowing them to thaw completely at room 
temperature prior to refreezing. Bench top stability was evaluated after the samples were placed on 
the bench at room temperature for 8h and then extracted and analyzed. For the auto-sampler 
stability, a set of samples was prepared and placed in the auto-sampler at 6 ℃ for 20 h prior to 
injection for analysis. Long-term stability was tested for samples that were stored at -80 ℃ for 90 
days. All samples were analyzed along with freshly prepared standard curves. Samples were 
considered stable when the USFDA criteria for precision and accuracy were met [42]. 
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2.4 Results and Discussion 
2.4.1 Method development 
In this work, we aimed at developing a simple and reliable method that can quantify the three target 
gemini surfactants in biological matrix for the assessment of their cellular uptake and 
biodistribution. Although gemini surfactants have been previously separated and determined using 
LC-MS/MS methods with various analytical columns, such as cyano [25] and HILIC columns [26], 
all of these methods require relatively long run time for the separation and the prior optimization 
of LC method for the analysis. Therefore, we chose to develop an FIA-MS/MS method that relies 
on the mass spectrometer’s separation capability, as the MRM mode in the quadrupole-linear ion 
trap system has the capability of selectively monitoring and accurately quantifying the analytes of 
interest in complex matrices. 
Optimization of the FIA-MS/MS condition was the main focus in the process of method 
development. All source-dependent parameters, such as nebulizer gas and heater gas, and 
compound-dependent parameters (i.e., DP, EP, and CE) were properly optimized so that a high 
sensitivity of the MRM transitions for each analyte and internal standard can be achieved. Two 
MRM transitions were selected for each analyte in this method; the qualifier transition was used to 
confirm the presence of the analyte peak, whereas the quantifier transition was used for the 
calculation of the concentration of analyte. Matrix effects have been identified as a challenge in 
the ESI-MS/MS analysis as it can result in the inconsistency in ion current response [43]. To correct 
for such variations, we used deuterium-labeled gemini surfactants as internal standards that have 
similar physicochemical properties and MS behavior to the analytes. The deuterated gemini 
surfactants possess various numbers (n=4, 10, and 66) of deuterium atoms (Figure 2.S1 in 
supporting information), which resulted in large mass differences between the analytes and their 
85 
 
respective internal standards and thus eliminated the potential for cross-talk. In addition, we did 
not observe any interference from the endogenous compounds in the biological matrix for all 
standards.  
For the optimization of FIA, different compositions of solvent mobile phases, including acetonitrile, 
methanol and water mixed with varying concentrations of formic acid, were tested. Acetonitrile 
was found to be superior to methanol in terms of obtaining better peak shape and reducing carry 
over, as gemini surfactants are amphiphilic compounds that tend to stick to the injection loop and 
tubing (Figure 2.2). In addition, aqueous solvent and acid condition are required to achieve high 
ionization efficiency of gemini surfactant compounds for better detection sensitivity. As a result, 
acetonitrile-water (98:2, v/v) with 0.1% formic acid was the best mobile phase system that can 
result in high ionization efficiency, minimize peak tailing for all analytes and internal standards, 




Figure 2.2. FIA-MS/MS chromatogram of 16(Py)-S-2-S-16(Py) using various mobile phases: (a) 
acetonitrile with 0.1% formic acid, (b) acetonitrile-water (98:2, v/v) with 0.1% formic acid, and (c) 
methanol-water (98:2, v/v) with 0.1% formic acid. 
 
The Bligh/Dyer extraction method was adapted in this study as it was reported previously to be 
highly efficient at extracting lipids, including gemini surfactants, from biological matrices [26, 41]. 
In this method, methanol-chloroform (2:1, v/v) was used as the binary extraction solvent, because 
XIC of +MRM (9 pairs): 290.330/355.400 Da  from Sample 2 (16-Py-s-2-s-Py-16) of 001.wiff (Turbo Spray) Max. 73.3 cps.




























XIC of +MRM (9 pairs): 290.330/355.400 Da  from Sample 1 (16-Py-s-2-s-Py-16) of 001.wiff (Turbo Spray) Max. 1.1e4 cps.






















0.09 1.911.631.491.311.00 1.441.401.16 1.220.810.720.25
XIC of +MRM (9 pairs): 290.330/355.400 Da  from Sample 5 (16-Py-s-2-s-Py-16) of 001.wiff (Turbo Spray) Max. 3266.7 cps.
































0.11 0.33 1.070.47 0.60 0.69 1.00 1.600.78 1.52 1.701.28 1.41
A. Mobile phase: acetonitrile with 0.1% formic acid 
B. Mobile phase: acetonitrile-water (98:2, v/v) with 0.1% formic acid 
C. Mobile phase: methanol-water (98:2, v/v) with 0.1% formic acid 
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it is highly compatible with the amphiphilic nature of gemini surfactants and thus results in high 
extraction efficiency. To minimize variation in extraction efficiency across samples, internal 
standards were spiked into samples at appropriate concentrations prior to extraction. 
2.4.2 Selectivity and matrix effects 
Selectivity was assessed with the analysis of six different blank cell matrices. These blank cell 
samples did not contain either the analytes or the internal standards, and a typical chromatogram 
for the blank cell sample is shown in Figure 2.S3 in supporting information. No interference peak 
from endogenous compound was observed in the analyte and the internal standard channels from 
the cell matrix. Furthermore, no cross-talk was observed between the analytes and the internal 
standards as they have large mass differences due to the presence of multiple (n=4, 10, and 66) 
deuterated atoms in the structures of internal standards. The peaks of analytes and internal 




Figure 2.3. FIA-MS/MS chromatograms in the cellular extract. (a) 16-3-16 (0.25 uM) and internal standard 
(0.2 uM), (b) 16(Py)-S-2-S-16(Py) (0.5 uM) and internal standard (0.2 uM), and (c) 16-7N(GK)-16 (0.5 uM) 
and internal standard (0.2 uM). 
 
Matrix effects were evaluated by comparing the analyte response in the post-extracted spiked 
sample with non-extracted neat sample. Three different concentrations for each analyte in three 
replicates were used for the evaluation. The matrix effects across all concentration levels were 
calculated, on average, to be 41.5% ± 7.2% for 16-3-16, 40.2% ± 7.8% for 16(Py)-S-2-S-16(Py), 
and 35.7% ± 4.4% for 16-7N(GK)-16 (Table 2.S1 in supporting information), which were most 
likely caused by ion suppression. Although a column or additional preparative steps may help 
XIC of +MRM (4 pairs): 290.330/355.410 Da  from Sample 1 (16-3-16_C-5) of 16-3-16_C-5.wiff (Turbo Spray) Max. 9.2e4 cps.
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XIC of +MRM (4 pairs): 349.280/203.090 Da  from Sample 1 (16(Py)-s-2-s-16(Py)_C-6) of 16(Py)-s-2-s-16(Py)_C-6.wiff (Turbo Spray) Max. 3.3e4 cps.

























XIC of +MRM (4 pairs): 411.480/276.900 Da  from Sample 1 (NK-00) of NK-CC-07-2.wiff (Turbo Spray) Max. 9.6e4 cps.
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reduce the matrix effect, the observed ion suppression does not undermine the quantification of 
gemini surfactants as the sensitivity of the method was sufficient for the detection and 
quantification of target gemini surfactants. In addition, internal standards are used, which are 
considered to be the gold standard approach for correcting any matrix effects. 
2.4.3 Linearity and Sensitivity 
Each standard curve was established with a wide range sufficient to cover the expected 
concentrations of analytes. The standard curves were linear at a concentration range of 10 nM-
1,000 nM for 16-3-16 and 16(Py)-S-2-S-(Py)16, and 20 nM-2,000 nM for 16-7N(GK)-16, with r2 
≥0.998. The LLOD was 4 nM for both 16-3-16 and 16(Py)-S-2-S-16(Py) and 8 nM for 16-7N(GK)-
16, whereas the LLOQ was 10 nM for 16-3-16 and 16(Py)-S-2-S-(Py)16, and 20 nM for 16-
7N(GK)-16. Compared with the recent HILIC-MS/MS method [26], which reported an LLOQ of 
67.5 nM and 58.2 nM for the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py), respectively 
[26], the current FIA-MS/MS method has a lower LLOQ and thus higher sensitivity. The increase 
in sensitivity could be attributable to the optimized mobile phase containing appropriate 
composition of organic and aqueous solvents, which resulted in narrower and more symmetrical 
analyte peaks compared to those obtained with the HILIC-MS/MS method [26]. In addition, the 
sample loss during chromatographic separation could also be a contributing factor to the reduced 
sensitivity of the HILIC-MS/MS method, as gemini surfactants are amphiphilic compounds, prone 
to sticking to a guard-column and a column. In fact, Buse et al. [24] observed a 10 fold higher 
sensitivity for the quantification of 16-3-16 using an FC-MS/MS method (LLOQ=37 nM) 
compared with an LC-MS/MS method (LLOQ =406 nM). Such sensitivity is needed to detect the 
target analytes in the subcellular matrix. 
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2.4.4 Intra- and inter-day precision and accuracy 
Intra- and inter-day precision and accuracy were evaluated by analyzing samples at four different 
concentrations LLOQ, LQC, MQC, and HQC as per the USFDA guidelines [42]. Tables 2.2 and 
2.3 show the precision and accuracy obtained for gemini surfactants 16-3-16 and 16(Py)-S-2-S-
16(Py) at various concentrations. The precision and accuracy of 16-7N(GK)-16 are listed in Tables 
2.4 and 2.5. The precision is reported as CV% among all measurements and accuracy is expressed 
as a percentage of the mean of all measurements relative to their theoretical values. The intra-day 
precision did not exceed 7.7% for any of the gemini surfactants at the four concentration levels, 
while accuracy ranged between 94.4% and 108.8%. The inter-day assessment yielded a precision 
less than 3.3% and accuracy between from 97.2% to 108.4%. 
Table 2.2.  Intra-day precision and accuracy of the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) 
Samples Day 
Measured concentration 








LLOQ   
(10 nM) 
1 10.6±0.4 10.3±0.6 3.7% 5.5% 105.8% 102.7% 
2 10.2±0.3 10.8±0.8 3.1% 7.7% 101.9% 108.3% 
3 10.1±0.2 10.2±0.5 2.0% 5.1% 100.6% 102.0% 
        
LQC      
(30 nM) 
1 29.7±0.5 29.0±1.8 1.6% 6.0% 98.9% 96.5% 
2 29.2±0.4 30.2±1.2 1.5% 3.9% 97.4% 100.7% 
3 28.9±0.6 28.3±1.5 1.9% 5.4% 96.3% 94.4% 
        
MQC   
(150 nM) 
1 150.7±1.2 143.3±7.3 0.8% 5.1% 100.4% 95.6% 
2 150.2±1.5 149.8±7.2 1.0% 4.8% 100.1% 99.9% 
3 150.7±1.8 149.0±3.9 1.2% 2.6% 100.4% 99.3% 
        
HQC     
(800 nM) 
1 805.8±8.6 761.7±17.0 1.1% 2.2% 100.7% 95.2% 
2 814.0±6.6 804.0±24.7 0.8% 3.1% 101.8% 100.5% 
3 809.5±7.9 775.7±20.2 1.0% 2.6% 101.2% 97.0% 
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Table 2.3. Inter-day precision and accuracy of the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) 
Samples Replicates  
Measured concentration 
(Mean± SD, nM) 









18 10.3±0.3 10.4±0.4 2.6% 3.3% 102.8% 104.3% 
LQC  
(30 nM) 
18 29.3±0.4 29.2±1.0 1.3% 3.3% 97.6% 97.2% 
MQC     
(150 nM) 
18 150.5±0.3 147.4±3.5 0.2% 2.4% 100.3% 98.3% 
HQC     
(800 nM) 




Table 2.4. Intra-day precision and accuracy of the gemini surfactant 16-7N(GK)-16 
Samples Day Measured concentration (Mean± SD, nM) Precision  Accuracy  
LLOQ    
(20 nM) 
1 21.7±0.8 3.5% 108.7% 
2 21.5±1.1 5.3% 107.7% 
3 21.8±1.0 4.5% 108.8% 
     
LQC       
(60 nM) 
1 60.3±1.4 2.4% 100.5% 
2 60.1±0.8 1.4% 100.1% 
3 62.8±1.8 2.9% 104.6% 
     
MQC     
(400 nM) 
1 401.2±8.4 2.1% 100.3% 
2 397.0±15.2 3.8% 99.3% 
3 389.0±10.8 2.8% 97.3% 
     
HQC     
(1600 nM) 
1 1613.3±35.6 2.2% 100.8% 
2 1575.0±50.9 3.2% 98.4% 




Table 2.5. Inter-day precision and accuracy of the gemini surfactant 16-7N(GK)-16 
Samples Replicates Measured concentration (Mean± SD, nM) Precision Accuracy 
LLOQ  
(20 nM) 
18 21.7±0.1 0.6% 108.4% 
LQC  
(60 nM) 
18 61.0±1.5 2.5% 101.7% 
MQC     
(400 nM) 
18 395.7±6.2 1.6% 98.9% 
HQC     
(1600 nM) 
18 1575.0±38.3 2.4% 98.4% 
 
2.4.5 Recovery 
Recovery was determined as the ratio of analyte peak area of the pre-spiked sample before 
extraction versus that of the post-spiked sample after extraction, expressed as a percentage. Three 
concentrations for each analyte were evaluated in this study. On average, the recovery was 104.9 
± 10.5% at 30 nM, 111.3 ± 9.7% at 150 nM, and 94.3 ± 6.2% at 800 nM for 16-3-16, 104.0 ± 9.9% 
at 30 nM, 95.7 ± 8.6% at 150 nM, and 102.9 ± 11.2% at 800 nM for 16(Py)-S-2-S-(Py)16; and 42.9 
± 7.5% at 60 nM, 33.1 ± 3.8% at 400 nM, and 34.4 ± 5.8% at 1,600 nM for 16-7N(GK)-16. Similar 
to previously published results [26], the Bligh/Dyer method efficiently extracted the gemini 
surfactants 16-3-16 and 16(Py)-S-2-S-(Py)16 from the cellular matrix. In contrast, the extraction 
efficiency for the gemini surfactant 16-7N(GK)-16 was significantly reduced. This finding was 
expected as 16-7N(GK)-16 is a more hydrophilic compound due to the presence of a di-peptide in 
the spacer region compared with the other two compounds, which decreases its partition to the 
organic solvent (methanol-chloroform), thereby reducing the extraction efficiency. However, with 
the use of deuterated internal standards spiked prior to sample extraction, the recovery of analyte 
was corrected with internal standard. Therefore, the determination of 16-7N(GK)-16 is not 
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compromised. Such low recovery explains the slightly higher LLOQ for 16-7N(GK)-16 in 
comparison with the other two analytes (Tables 2.2 and 2.4). 
2.4.6 Stability 
Freeze-thaw stability, bench top stability, auto-sampler stability, and long-term stability were 
assessed with the analysis of samples at three different concentrations as shown in Tables 2.S2 and 
2.S3 in supporting information. Freeze-thaw stability was determined to be with a precision of less 
than 6.7% and a accuracy between 94.7% and 104.4%. For the bench top stability, the precision 
and accuracy varied from 2.6% to 7.3% and from 96.7% to 100.3%, respectively. The stability of 
these samples in the auto-sampler resulted in a precision range of 2.8% - 5.7% and accuracy range 
of 96.9% - 102.5%. These results confirmed that the samples were stable during sample preparation 
and data acquisition. Also, the stability of these samples was not compromised by long-term storage 
at -80 oC, with the values of precision ranging from 2.0% to 7.0% and accuracy ranging from 89.1% 
to 101.1%.  
2.5 Application 
The uptake and subcellular distribution profiles of the gemini surfactants 16-3-16, 16(Py)-S-2-S-
(Py)16, and 16-7N(GK)-16 in PAM 212 cells were studied using the validated FIA-MS/MS method. 
In this work, we show proof-of-principle application of the method to analyze these compounds in 
the nuclear fraction. The complete analysis of various subcellular fractions including the nucleus, 
mitochondria, plasma membrane and cytosol, along with other biological assessments, will be 
reported upon completion of the analyses. Although the standard curves and QC samples were 
prepared in the blank cell lysate matrix, no matrix difference was observed among the various 
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subcellular fractions and the whole cell lysate, which ensured the accurate quantification of the 
gemini surfactants in each cellular fraction. 
The uptake rate of the gemini surfactants in the nuclear fraction increased rapidly over the course 
of 5 h treatment, reaching a peak concentration of approximately 800 nM for 16(Py)-S-2-S-(Py)16 
and 16-7N(GK)-16 and 300 nM for 16-3-16, followed by a gradual decrease after the removal of 
the dosed culture media (Figure 2.4). The observations are consistent with the reported progressive 
nanoparticle uptake, which reaches a maximum before a depletion of the intracellular analytes [26]. 
As expected, the rate of uptake and the biodistribution in the nuclear fraction is different among 
the three gemini surfactants. Such differences could explain their variable efficiency and toxicity. 
However, a definitive conclusion may only be drawn upon the completion of the analysis of all 
four subcellular compartments, which will be conducted in the near future. 
 
Figure 2.4. Distribution of gemini surfactants: 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 in the 



























A simple and reliable FIA-MS/MS method was successfully developed and validated for the 
quantification of the gemini surfactants 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16 as gene 
delivery agents in PAM 212 cells. The sensitivity of the FIA-MS/MS method is superior to the 
reported HILIC-MS/MS method for the determination of these gemini surfactants at the subcellular 
level. The specificity, precision, accuracy, recovery, and stability are sufficient to quantify these 
gemini surfactants in the cellular matrix. Furthermore, the use of chromatographic separation, 
gradient elution, and an ion pairing reagent is eliminated in the reported approach, thus 
substantially simplifying the analytical method and reducing sample run time. The method was 
successfully applied to quantify the three gemini surfactants in the nuclear fraction of PAM 212 
cells treated with nanoparticles, which varied significantly and may explain differences in the 
observed efficiency and toxicity of these gemini surfactants in gene delivery. 
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Figure 2.S1. (A) Structures of 16-3-16-D66 and the monitored product ion, (B) structures of 16(Py)-S-2-S-
16(Py)-D10 and the monitored product ion, and (C) structures of 16-7N(GK)-16-D4 and the monitored 




Figure 2.S2. Illustration of no carry over. FIA-MS/MS chromatograms of the highest curve point of (a) 16-3-16, 
(c)16(Py)-S-2-S-16(Py), and (e) 16-7N(GK)-16, and the following blank samples of  (b) 16-3-16, (d)16(Py)-S-2-S-
16(Py), and (f) 16-7N(GK)-16.  
XIC of +MRM (4 pairs): 290.330/355.410 Da  from Sample 1 (CC_07) of CC_07.wiff (Turbo Spray) Max. 3.1e5 cps.
























XIC of +MRM (4 pairs): 349.280/203.090 Da  from Sample 1 (Blank-01) of Blank-01.wiff (Turbo Spray) Max. 360.0 cps.




































XIC of +MRM (4 pairs): 411.480/276.900 Da  from Sample 1 (Blank-1) of Blank-1.wiff (Turbo Spray) Max. 1493.3 cps.






























XIC of +MRM (4 pairs): 349.280/203.090 Da  from Sample 1 (16(Py)-s-2-s-16(Py)_C-7) of 16(Py)-s-2-s-16(Py)_C-7.wiff (Turbo Spray) Max. 9.7e4 cps.



























XIC of +MRM (4 pairs): 411.480/276.900 Da  from Sample 1 (CC_07) of CC_07.wiff (Turbo Spray) Max. 1.4e5 cps.






















XIC of +MRM (4 pairs): 290.330/86.110 Da  from Sample 1 (Blank) of Blank.wiff (Turbo Spray) Max. 210.0 cps.


































Figure 2.S3. The FIA-MS/MS chromatogram of blank cell matrix for MRM transitions: (a) 16-3-16, (b) 






Table 2.S1. Matrix effect of the gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py) and 16-7N(GK)-16  
Sample Replicates  
Matrix effect (Mean± SD) 
16-3-16 16(Py)-S-2-S-16(Py) 16-7N(GK)-16 
LQC  3 47.1%±1.5% 42.9%±4.9% 31.9%±1.5% 
MQC     3 33.4%±5.8% 35.4%±6.0% 40.5%±1.5% 
HQC     3 44.0%±5.2% 36.1%±2.4% 34.6%±2.5% 






Table 2.S2. Stability of the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) in cellular matrix 
Samples Stability 
Measured concentration 








LQC      
(30 nM) 
0 h 32.1±1.1 29.0±0.3 3.4% 1.1% 106.9% 96.8% 
6 freeze-thaw 32.7±0.9 29.5±1.5 2.8% 5.1% 109.1% 98.4% 
8 h (bench top) 33.2±0.3 32.2±0.9 0.8% 2.9% 110.8% 107.4% 
20 h (autosampler) 33.6±0.5 32.1±1.3 1.5% 4.1% 111.8% 107.1% 
90 days at -80℃ 28.0±0.9 28.2±1.3 3.2% 4.6% 93.4% 93.9% 
        
MQC 
(150 nM) 
0h 152.7±3.9 144.0±2.8 2.5% 2.0% 101.8% 96.0% 
6 freeze-thaw 162.7±3.8 139.2±5.5 2.3% 4.0% 108.4% 92.8% 
8 h (bench top) 155.3±2.7 153.7±2.3 1.7% 1.5% 103.6% 102.4% 
20 h (autosampler) 156.0±2.2 155.3±3.5 1.4% 2.3% 104.0% 103.6% 
90 days at -80℃ 138.8±3.4 138.2±2.8 2.5% 2.0% 92.6% 92.1% 
        
HQC    
(800 nM) 
0 h 823.7±8.0 804.5±16.3 1.0% 2.0% 103.0% 100.6% 
6 freeze-thaw 860.5±24.3 790.3±15.4 2.8% 1.9% 107.6% 98.8% 
8 h (bench top) 824.8±14.7 792.7±11.4 1.8% 1.4% 103.1% 99.1% 
20 h (autosampler) 821.8±10.3 818.7±17.6 1.2% 2.2% 102.7% 102.3% 





Table 2.S3. Stability of the gemini surfactant 16-7N(GK)-16 in cellular matrix 
Samples Stability Measured concentration  
(Mean± SD, nM) 
Precision Accuracy 
LQC       
(60 nM) 
0 h 56.9±2.5 4.5% 94.9% 
6 freeze-thaw 62.7±4.2 6.7% 104.4% 
8 h (bench top) 58.0±4.2 7.3% 96.7% 
20 h (autosampler) 58.2±2.5 4.4% 96.9% 
90 days at -80 ℃ 55.2±2.0 3.6% 91.9% 
     
MQC     
(400 nM) 
0 h 388.8±11.8 3.0% 97.2% 
6 freeze-thaw 394.2±23.9 6.1% 98.5% 
8 h (bench top) 399.8±10.5 2.6% 100.0% 
20 h (autosampler) 410.2±11.5 2.8% 102.5% 
90 days at -80 ℃ 386.7±27.1 7.0% 96.7% 
     
HQC     
(1600 nM) 
0 h 1600.0±87.2 5.4% 100.0% 
6 freeze-thaw 1515.0±53.6 3.5% 94.7% 
8 h (bench top) 1605.0±50.9 3.2% 100.3% 
20 h (autosampler) 1618.3±91.7 5.7% 101.1% 
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Transitioning Rationale:  
Once the FIA-MS/MS method was developed and validated in Chapter 2, it was applied for the 
quantification of three gemini surfactants 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16 in 
four subcellular fractions, namely nucleus, mitochrondria, plasma membrane, and cytosol, to 
determine their cellular uptake and subcellular distributions in PAM 212 cells, as described in this 
Chapter. In addition, DNA binding capability and the shape of aggregates were measured to explain 





Gemini surfactants are promising molecules utilized as non-viral gene delivery vectors. However, 
little is known about their cellular uptake and distribution after they release their therapeutic cargo. 
Therefore, we quantitatively evaluated the cellular uptake and distribution of three gemini 
surfactants, unsubstituted (16-3-16), with pyridinium head groups (16(Py)-S-2-S-16(Py)) and 
substituted with a glycyl-lysine di-peptide (16-7N(GK)-16). We also assessed the relationship 
between the cellular uptake and distribution of each gemini surfactant and its overall efficiency and 
toxicity. Epidermal keratinocytes PAM 212 cells were treated with gemini surfactant nanoparticles 
formulated with plasmid DNA and harvested at various time points to collect the enriched nuclear, 
mitochondrial, plasma membrane, and cytosolic fractions. Gemini surfactants were then extracted 
from each subcellular fraction and quantified using a validated flow injection analysis-tandem mass 
spectrometry (FIA-MS/MS) method. Mass spectrometry is superior to the use of fluorescent tags 
that alters the physicochemical properties and pharmacokinetics of the nanoparticles and can be 
cleaved from gemini surfactant molecules within biological systems. Overall, a significantly higher 
cellular uptake was observed for 16-7N(GK)-16 (17.0%) compared with 16-3-6 (3.6%) and 16(Py)-
S-2-S-16(Py) (1.4%), which explained the relatively higher transfection efficiency of 16-7N(GK)-
16. The gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) displayed similar subcellular 
distribution patterns, with major accumulation in the nucleus, followed by the mitochondrion, 
cytosol, and plasma membrane. In contrast, the gemini surfactant 16-7N(GK)-16 was relatively 
evenly distributed across all four subcellular fractions. However, accumulation within the nucleus 
after 5 h treatment was the highest for 16(Py)-S-2-S-16(Py) (50.3%), followed by 16-3-16 (41.8%) 
and then 16-7N(GK)-16 (33.4%), possibly leading to the relatively higher toxicity of 16(Py)-S-2-
S-16(Py). Ethidium bromide dye exclusion essay indicated that 16-7N(GK)-16 has a relatively 
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weaker DNA binding property, which has the ability to not only protect DNA but also facilitate its 
intracellular release, contributing to its high efficiency in gene transfection. In addition, Langmuir 
studies showed that 16-7N(GK)-16 has a flexible bilayer structure that tends to form the inverted 
hexagonal phase in combination with DOPE, promoting the cytoplasmic release of DNA from 
endosome and thus enhancing its gene delivery efficiency. 
Key words: Gemini surfactants; Gene delivery; Subcellular distribution; FIA-MS/MS; Toxicity; 
Transfection. 
3.2 Introduction 
Gemini surfactants are a versatile family of lipids that have a general structure of two surfactant 
monomers chemically linked by a spacer [1]. In particular, cationic gemini surfactants possess dual 
positively charged hydrophilic head groups, a spacer region, and two hydrophobic tails (Figure 4.1) 
[2]. They are promising vectors for non-viral gene delivery [3-5] as their structures enable them to 
bind and compact DNA, facilitating its cellular entry for gene transfection [6, 7]. Extensive 
research has been conducted to design and synthesize novel gemini surfactant compounds with the 
aim of enhancing transfection efficiency while reducing toxicity. For example, the positively 
charged head groups were altered using various cationic moieties, such as di-quaternary amines 
and di-pyridines, to attain effective compaction of DNA [2, 8]. Furthermore, amino acid moieties 
have been incorporated into the spacer region to enhance the biocompatibility of gemini surfactants 
and thus increase their transfection efficiency [9]. In addition, the formulation of gemini surfactant-
based lipoplexes and their cellular uptake mechanisms have been well studied [10, 11], and it has 
been found that endocytosis is the main pathway by which gemini surfactant nanoparticles are 
internalized by the cell [11]. 
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Despite their promise, gemini surfactants are still limited in their gene transfection efficiency [12, 
13], hindering their advancement from the experimental stage to clinical application. In addition, 
there are no clear explanations for the varying toxicities among different gemini surfactant 
structures. Therefore, a greater understanding of the mechanism of transfection and toxicity is 
required and will ultimately contribute to the development of more efficient and less toxic gemini 
surfactants. One factor that may be related to the overall efficiency and toxicity of gemini 
surfactants is their intracellular biological fate post transfection; that is, how they are distributed at 
the subcellular and tissue levels. However, as of yet, their biological fate is poorly understood, and 
little is known about their cellular uptake, distribution, and metabolite formation upon transfection. 
Garnering such knowledge will contribute to the design and development of more effective gemini 
surfactants. In addition, an understanding of the cellular distribution of the delivery agents is crucial 
to achieve targeted delivery at the subcellular level [14]. Our research hypothesis is that the 
structure of a gemini surfactant significantly influences its cellular uptake and subsequent 
partitioning which in turn has profound consequences with respect to efficiency and toxicity. In 
fact, we have recently demonstrated the role of the molecular structure of gemini surfactants in 
determining their skin penetration efficiency [15]. 
Gemini surfactants designated as 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16) have been 
studied as non-viral gene delivery agents [16-18]. Structurally, 16-3-16 is a conventional m-s-m 
type gemini surfactant bearing two quaternary amines, linked by a 3-carbon spacer region (m is the 
number of carbon atoms in the tail and s is the number of carbon atoms in the spacer); while 16(Py)-
S-2-S-(Py)16 is a pyrdinium-derived gemini surfactant containing two pyridines in the head groups, 
and 16-7N(GK)-16 bears a glycyl-lysine di-peptide within the spacer region (Figure 3.1), allowing 
for a better biocompatibility. In fact, these gemini surfactants have been successfully used for in 
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vitro and in vivo gene delivery [16-20]. For instance, the 16-3-16 nanoparticles have shown great 
promise in the treatment of localized scleroderma, as transgene expression in animal models was 
significantly increased with treatment of the nanoparticles compared with naked DNA, showing 









Figure 3.1 Schematic representation of the general structure of a gemini surfactant (A). The structures of 
gemini surfactants 16-3-16 (B), 16(Py)-S-2-S-16(Py) (C), and 16-7N(GK)-16 (D), showing their m/z values 
as well as the ions monitored during the FIA-MS/MS analysis. 
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The selection of the three gemini surfactants (Figure 3.1) was based on the variations in their 
molecular structures, transfection efficiency, and toxicity profiles [6, 8, 21]. Although these gemini 
surfactants belong to three different structural families that possess different head groups and 
spacer regions, they have the same number of carbon atoms in the tails (Figure 3.1). We are 
currently conducting a wide assessment of the gemini surfactants in various families with respect 
to the relationship between cellular uptake, subcellular distribution, efficiency, and toxicity. As 
such, we chose these three structures as model compounds. Previously, we determined that the 
trend of cellular uptake and clearance of 16-3-16 and 16(Py)-S-2-S-(Py)16 nanoparticles were 
similar in PAM 212 epidermal keratinocytes cells, which provides no explanation of the differential 
toxicities between the two compounds [22]. We, therefore, are testing the hypothesis that the 
relative efficiency and toxicity of these compounds is explained by a difference in their cellular 
uptake and subcellular distribution.  
To assess the cellular uptake and distribution of lipid-based nanoparticles, fluorescent tags have 
been incorporated into their structures [14, 23]. However, the use of fluorescent tags suffers from 
two main drawbacks. First, the addition of such structure-modified moieties alters the 
physicochemical properties and pharmacokinetics of the nanoparticles [24, 25]. Second, the 
fluorescent tags can be cleaved from the gemini surfactant molecules within biological systems, 
confounding subsequent data interpretation. Such limitations motivated us to develop mass 
spectrometry (MS)-based methods to monitor the fate of gemini surfactant nanoparticles in cells 
[22, 26]. The main advantage of MS is its capability to measure the original intact molecule with 
high selectivity and sensitivity [27]. Most recently, we developed and validated a simple flow 
injection analysis-tandem mass spectrometry (FIA-MS/MS) method that allows for the tracking of 
gemini surfactants at the subcellular level [28].  
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In the present study, the validated FIA-MS/MS method is applied to provide for the first time a 
quantitative assessment of the cellular uptake and subcellular distribution of three gemini 
surfactants gene delivery nanoparticles (Figure 3.1) within PAM 212 cells. We found that variable 
cellular uptake of the three gemini surfactants explained the differences in transfection efficiency, 
and that accumulation of gemini surfactant in the nucleus may provide insights into the observed 
increased toxicity. 
3.3 Materials and Methods 
3.3.1 Materials 
Gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 (Figure 3.1) and their 
deuterated internal standards 16-3-16-D66, 16(Py)-S-2-S-16(Py)-D10, and 16-7N(GK)-16-D4 
(Figure 3.S1 in supporting information) were synthesized according to established protocols [16, 
19, 29]. The neutral lipid 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Chloroform, methanol, acetonitrile, formic 
acid, tissue culture flasks (75 cm2, 150 cm2) and petri dishes (150 cm2) were purchased from Fisher 
Scientific (Ottawa, ON, Canada). 96-well tissue culture plates were obtained from Falcon (BD 
Mississauga, ON, Canada). PAM 212 keratinocyte cells were kindly provided by Dr. S. Yuspa, 
National Cancer Institute, Bethesda, MD, USA. Fetal bovine serum albumin (FBS), antibiotic-
antimycotic solution and minimum essential media (MEM) were obtained from Sigma-Aldrich 
(Oakville, ON, Canada). The protease inhibitor cocktail was purchased from Invitrogen 
(Burlington, ON, Canada). The plasmid DNA (pGTmCMV.IFN-GFP) was constructed in-house 
as previously described [6]. The motorized homogenizer was purchased from Fisher Scientific 




Gemini surfactants and internal standards were prepared at a concentration of 3 mM in aqueous 
solutions and stored at -80℃ under darkness. DOPE vesicles were prepared freshly at a 
concentration of 1 mM in isotonic sucrose solution (9.25% w/v, pH=9) based on an established 
protocol [5]. The plasmid DNA solution was prepared at 200 µg/mL in ultra-pure water and stored 
at -80 ℃.  
The nano-lipoplex formulation (P/G/L) was prepared with plasmid DNA, gemini surfactant, and 
lipid DOPE as previously described [6] with a nitrogen (cationic) to phosphate (anionic) charge 
ratio (N/P) at 10 for 16-3-16 and 16(Py)-S-2-S-16(Py) and at 2.5 for 16-7N(GK)-16. Briefly, to 
prepare 1 mL of the P/G/L for 16-3-16 and 16(Py)-S-2-S-16(Py), 38 µL of 3 mM gemini surfactants 
was added to 38 µL of 200 µg/mL plasmid DNA, gently mixed by pipetting up and down several 
times, and incubated for 15 min at room temperature. Subsequently, 924 µL of 1 mM DOPE 
solution was added to the binary mixture, gently mixed with a pipette and incubated for 15 min at 
room temperature to produce the ternary P/G/L system (nanoparticles). To prepare 1 mL of the 
P/G/L for 16-7N(GK)-16, 9.5 µL of 3 mM gemini surfactant was added to 38 µL of 200 µg/mL 
plasmid DNA, mixed and incubated for 15 min at room temperature, 952.5 µL of 1 mM DOPE 
solution was then added, mixed, and incubated to generate the nanoparticles. 
3.3.3 In vitro transfection 
PAM 212 cells were cultured in MEM media supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotic-antimycotic solution in 75 cm2 tissue culture flasks in a humidified incubator at 37 ℃ at 
an atmosphere of 5% CO2. Upon reaching 80% confluence, cells were washed with phosphate 
buffered saline (PBS, 8 mL), dissociated with a 5 min incubation in a versene (10x, 3 mL) and 
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trypsin (10x, 0.3 mL) mixture, and collected by centrifugation (250 x g, 5 min, 4 ℃). Twenty-four 
hours prior to transfection, three 96-well tissue culture plates were seeded with PAM 212 cells at 
a density of 2×104 cells/well. MEM was replaced with serum-free media 1 h prior to transfection. 
Cells were treated with 20 µL of the P/G/L nanoparticles per well and incubated for 5 h. The cells 
were then returned to the supplemented MEM for further incubation and the culture media was 
collected at 48 h for interferon-gamma (IFN-γ) measurement. 
An enzyme-linked immunosorbent assay (ELISA) was carried out to measure secreted IFN-γ using 
flat bottom 96-well plates (Immulon 2, Greiner Labortechnik, Germany) as per the BD Pharmingen 
protocol. An IFN-γ standard curve was established using recombinant mouse IFN-γ (BD 
Biosciences, Missisauga, ON, Canada) to allow for the concentration of secreted IFN-γ in the cell 
media to be quantified. The experiments were conducted in three plates of quadruplicate wells. 
3.3.4 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay 
A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was performed to 
determine the cytotoxicity of the gemini surfactants. PAM 212 cells were seeded in three 96-well 
cell culture plates at a density of 2×104 cells/well and treated with the P/G/L nanoparticles. Plates 
were incubated for 5 h at 37 °C with 5% CO2 in a humidified incubator and then the cell media 
was switched to supplemented MEM media. After 48 h of incubation, the cell media was removed, 
and cell toxicity was evaluated by the determination of cell viability. Briefly, 100 µL of 0.5 mg/mL 
sterile MTT (Invitrogen, USA) in the supplemented media was added to each well and the plates 
were incubated for 3 h at 37 °C. The media was then removed and 200 µL of dimethyl sulfoxide 
(DMSO) (spectroscopy grade, Sigma-Aldrich, ON, Canada) was added to each well to dissolve the 
formed purple formazan crystal. Subsequently, the plates were incubated at 37 °C for 10 min. 
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Absorbance was measured at 550 nm using a microplate reader (Bio-Tek® Microplate Synergy, 
HT, VT, USA). The experiments were conducted in three plates of quadruplicate wells, and the 
cytotoxicity of gemini surfactants reflects cell viability, expressed as a percentage of non-
transfected cells (control). 
3.3.5 Size and zeta-potential measurements 
Size and zeta-potential of the gemini surfactants-based nanoparticles were measured using a Zeta-
sizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK). The nanoparticles were 
prepared as described in section 3.3.2. Three measurements were conducted for each sample. The 
reported results are the mean of triplicate measurements ± standard deviation. 
3.3.6 Cell treatment and sample collection 
PAM 212 cells were cultured in 150 cm2 flasks until they reached 80% confluence. Cells were then 
washed with PBS (25 mL), dissociated with versene (10x, 5 mL) and trypsin (10x, 0.5 mL), and 
collected by centrifugation (250 x g, 5 min, 4 ℃). Twenty-four hours prior to treatment, 8×106 cells 
were seeded in each petri dish (150 cm2). Cells were switched to serum-free media 1 h prior to 
transfection. 500 µL of freshly prepared P/G/L nanoparticles were added to each dish in a drop-
wise manner. Following a 5 h of incubation, the cells were returned to supplemented MEM media 
for subsequent incubation steps. Triplicates of treated cell samples and one control (untreated cell) 
were trypsinized and collected at 2 h, 5 h and 8 h. As the treatment duration for PAM 212 cells is 
5 h, the collecting schedule was intended to include three time points, one prior to the completion 
of treatment (2 h), one at the completion of treatment (5 h) and one post the treatment (8 h). The 
collected cells were pelleted by centrifugation (250 x g, 5 min, 4 ℃), rinsed with PBS three times, 
re-suspended in 500 µL of ice-cold hypotonic homogenization buffer (10 mM NaCl, 1.5 mM 
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MgCl2, 10 mM Tris-HCl [PH 7.5], and cOmplete™ protease inhibitor), and incubated on ice for 
10 min. 
3.3.7 Subcellular fractionation using differential centrifugation 
Cells were gently homogenized using a motorized homogenizer on ice to break the plasma 
membrane and release subcellular organelles. The cell homogenates were then diluted with ice-
cold hypertonic buffer (420 mM mannitol, 140 mM sucrose, 10 mM Tris-HCl [pH 7.5], and 2 mM 
EDTA [pH 7.5]) to a final volume of 1 mL and enriched nuclear, mitochondrial, plasma membrane, 
and cytosolic fractions were isolated by differential centrifugation using an established protocol 
[30], with slight modifications (Figure 3.2). Briefly, homogenates were first centrifuged at 1,000 x 
g for 10 min at 4 ˚C, and the S1 supernatant was transferred to a clean ice-cooled microcentrifuge 
tube while the P1 pellet was collected as the nuclear fraction (nuclei, unbroken cells, and cell debris). 
The S1 supernatant was then subjected to further centrifugation at 15,000 x g for 15 min at 4 ˚C, 
yielding the S2 supernatant and the P2 pellet which contained the mitochondrial fraction. The S2 
supernatant was then centrifuged at 100,000 x g for 60 min at 4 ˚C. The resultant S3 supernatant 
contained the cytosol and the P3 pellet (the plasma membrane along with microsome, ER and 
Golgi). All collected fractions were kept on ice prior to being diluted to equal 950 µL volume with 
PBS and stored at -80 ℃. To verify the successful isolation and relative purity of enriched fractions, 
western blot analysis was performed. Relevant experimental details and results are shown in the 





Figure 3.2. Schematic illustration of the homogenization and subcellular fractionation protocol. Differential 
centrifugation was used to isolate several subcellular fractions, including those enriched for nuclei, 
mitochondria, plasma membrane and cytosolic fractions.  
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3.3.8 Sample preparation  
As we previously described [28], subcellular fractions (950 µL) were lysed and spiked with 50 µL 
of internal standard and sample extractions were conducted using the Bligh/Dyer method [31]. 
Briefly, 3.75 mL of methanol-chloroform (2:1, v/v) was added per 1 mL of sample, followed by 
the addition of 1.25 mL of chloroform and 1.25 mL of water. At each step, samples and the 
extraction solvent were vortexed thoroughly. The final mixture was centrifuged at 2,800 x g for 10 
min at room temperature to separate the aqueous and organic phases. The bottom organic phase 
(80% portion) was collected and dried under a nitrogen gas stream, followed by reconstitution in 
200 µL of methanol. Finally, 150 µL of methanol solution was transferred into an HPLC vial for 
analysis. 
3.3.9 FIA-MS/MS analysis 
The FIA-MS/MS analysis was performed on a quadrupole-linear ion trap (4000 QTRAP®) mass 
spectrometer with an electrospray ionization (ESI) source (AB Sciex, Concord, ON, Canada), 
coupled with an Agilent 1200 series HPLC (a quaternary pump, degasser, and auto sampler) 
(Agilent Technologies, Mississauga, ON, Canada). As recently described [28], 3 µL of sample was 
injected into the ESI source at a flow rate of 0.5 mL/min with an acetonitrile-water mixture (98:2, 
v/v) containing 0.1% formic acid as the mobile phase. The instrument source temperature was set 
at 600 ℃ and the ion spray voltage was at 5,500 V. Nitrogen gas was used for curtain gas at 30, 
nebulizer gas at 55, and heater gas at 50. Multiple reaction monitoring (MRM) in positive ion mode 
was used to monitor all analytes and internal standards. The monitored MRM transitions were as 
follows: 16-3-16 [M]2+ m/z 290.3→355.4, 86.1; 16-3-16-D66 [M]
2+ m/z 323.5→388.6; 16(Py)-S-
2-S-(Py)16 [M]2+ m/z 349.3→396.3, 203.1; 16(Py)-S-2-S-(Py)16-D10 [M]
2+ m/z 354.3→401.3; and 
16-7N(GK)-16 [M]2+ m/z 411.4→276.8, 268.3; 16-7N(GK)-16-D4 [M]
2+ m/z 413.4→278.8 
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(Figures 3.1 and 3.S1). The compound-dependent parameters for analytes and internal standards 
were optimized as previously described [28]. A stable isotope dilution standard curve and three 
quality control samples (low, medium, and high) were run along with the samples in each batch. 
The data acquisition time per sample was 2 min. Data acquisition and analysis was performed using 
AB Sciex Analyst software (version 1.6.0). 
3.3.10 Ethidium bromide dye exclusion assay 
The plasmid DNA (200 µg/mL) was complexed with the three gemini surfactants at various charge 
ratios in the presence or absence of DOPE on 96-well plates. Ethidium bromide was added to all 
samples at a final concentration of 1 µg/mL. The samples were then incubated for 10 min at room 
temperature. After that, fluorescence excitation was carried out at 530 nm and emission was 
measured at 590 nm using a microplate reader (Biotek Microplate Synergy HT, VT, USA). The 
relative fluorescence of the P/G/L and P/G complexes was expressed as a percentage of 
fluorescence of the pure plasmid DNA solution. Measurements were conducted in triplicate. 
3.3.11 Langmuir studies  
Langmuir trough was used to measure the monolayer surface area of the gemini surfactant head 
group. Surface pressure-mean molecular area isotherms were obtained using a KSV 2,000 
Langmuir trough instrument (KSV Instruments Ltd, Helsinki, Finland). A stock solution of each 
gemini surfactant was prepared at 1 mM in chloroform and 40 µL of each stock solution was added 
dropwise on the sub-phase using a Hamilton syringe. The monolayer was left for a minimum of 10 
min to allow chloroform to evaporate, a constant rate compression of 20 mm/min was then applied 
on the monolayer molecules until collapse of the monolayer lipid. The ultra-pure water (Millipore, 
resistivity 18 MΩ· cm) was used as a sub-phase in the trough and the sub-phase temperature was 
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set at 22 °C. Triplicate measurements were collected for each gemini surfactant and data collection 
was performed using the KSV software (KSV Instruments Ltd, Helsinki, Finland). 
3.3.12 Statistical analysis 
Statistical analyses were performed by one-way analysis of variance (ANOVA) and Tukey’s 
multiple comparison tests using SPSS 25 software. Significant difference was established at the p 
< 0.05 level of significance. Results are expressed as the mean of triplicates ± standard deviation. 
3.4 Results and Discussion 
3.4.1 In vitro transfection activity 
Since these gemini surfactant nanoparticles have shown great promise in treating the localized 
scleroderma, a rare skin disease [6, 20], we are currently tuning the gemini surfactant nanoparticles 
to develop an effective, non-invasive topical gene delivery system for the treatment of the fibrotic 
skin conditions. As such, the epidermal keratinocyte cells, PAM 212, was used as the cell model 
in this study. To evaluate the efficiency of the gemini surfactants to mediate transfection in PAM 
212 cells, the amount of secreted IFN-γ was quantified 48 h post-transfection. As determined in 
previous work [6, 16], the optimal N/P to obtain the best transfection efficiency for 16-3-16 is 10 
and for 16-7N(GK)-16 is 2.5. We also determined that the optimal N/P for 16(Py)-S-2-S-16(Py) is 
10 based on the assessment of various N/P ratios at 0.5, 1, 2.5, 5, 10, and 20 for transfection (data 
not shown). For the best comparison of transfection capability as well as for proper toxicity 
assessment, the in vitro transfection study was conducted at the optimal N/P of each gemini 
surfactant, as it reflects the real conditions in which these compounds are used for in vitro gene 
delivery. At the optimal N/P of 10, the P/G/L of 16(Py)-S-2-S-(Py)16 resulted in a significantly 
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lower level of IFN-γ (1.19 ± 0.08 ng/2x104 cells) compared with that of 16-3-16 (2.77 ± 0.13 
ng/2x104 cells) (p <0.05) (Figure 3.3). In comparison, the P/G/L of 16-7N(GK)-16 at its optimal 
N/P of 2.5 yielded a IFN-γ level (3.76 ± 0.27 ng/2x104 cells) [21] that is significantly higher than 
that of 16-3-16 (p<0.05). In summary, the relative transfection efficiency of the three gemini 
surfactant nanoparticles was determined, with 16-7N(GK)-16 being the most effective and 16(Py)-
S-2-S-(Py)16 the least effective. 
 
Figure 3.3. Transfection efficiencies of the P/G/Ls of 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16 in 
PAM 212 cells. *16-7N(GK)-16 transfection was recently reported by our group, extracted from ref. [21]. 
 
3.4.2 Cytotoxicity  
In the present study, the cytotoxicity of the gemini surfactants 16-3-16 and 16(Py)-S-2-S-(Py)16 
was evaluated in PAM 212 cells. It was observed that cell viability was significantly higher upon 
treatment with the P/G/L of 16-3-16 (76%) compared with that of 16(Py)-S-2-S-(Py)16 (61%, p 
<0.05) (Figure 3.4), indicating that the former has significantly lower cytotoxicity than the latter 
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lower toxicity (89% cell viability) than 16-3-16 [21]. Hence, 16-7N(GK)-16 possesses the lowest 
cytotoxicity and 16(Py)-S-2-S-(Py)16 has the highest cytotoxicity among the three gemini 
surfactants. 
 
Figure 3.4. Cytotoxicity of the P/G/L of 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16 in PAM 212 
cells. *16-7N(GK)-16 cytotoxicity was recently reported by our group, extracted from ref. [16, 21]. 
 
3.4.3 Determination of size and zeta-potential 
Size and zeta potential of the P/G/L nanoparticles were measured as they are important 
characteristics of the delivery systems, which can have an influence on their stability, cellular 
uptake, and cytotoxicity [32, 33]. At the optimal N/P of 10, the P/G/L of 16-3-16 displayed a size 
of 131.9 ± 1.48 nm and positive zeta potential at 17.3 ± 1.38 mV, and the P/G/L of 16(Py)-S-2-S-
16 (Py)) showed a comparable size of 123.1 ± 0.76 nm and zeta potential at 23.3 ± 0.32 mV. 
Compared with the P/G/Ls of 16-3-16 and 16(Py)-S-2-S-16(Py), the P/G/L of 16-7N(GK)-16 at its 
optimal N/P of 2.5 showed a similar zeta potential at 24 ± 2.00 mV but a bit smaller size of 80 ± 
1.00 nm as reported in previous work [21]. Endocytosis has shown to be the main mechanism for 




















caeolae-mediated endocytosis are most common pathways for the cellular uptake of gemini 
surfactant nanoparticles. In fact, the internalization of amino acid-substituted gemini surfactant 
nanoparticles involves equally both clathrin and caeolae-mediated endocytosis [11]. While 
particles with smaller sizes of 60-80 nm typically undergo caveolae-mediated endocytosis for their 
internalization, particles with relatively larger size in the range of 120-200 nm often enter the cells 
via clathrin-mediated endocytosis [36, 37]. As such, all three gemini surfactant nanoparticles have 
the particle sizes that are appropriate for their cellular uptake. However, the smaller size of the 
P/G/L of 16-7N(GK)-16 could be a contributing factor for its high efficiency in gene transfection, 
as nanoparticles with small size at 70 nm have been reported to display significantly higher 
transfection efficiency than large-sized nanoparticles at 200 nm [32]. 
3.4.4 Cellular uptake and distribution of gemini surfactants 
To determine the cellular uptake and distribution of the gemini surfactants in PAM 212 cells, 
fractions enriched for nuclei, mitochondria, plasma membrane, and cytosol were isolated by 
differential centrifugation, extracted, and analyzed by the validated FIA-MS/MS method [28]. 
Differential centrifugation is an isolation technique that uses stepwise increases in centrifugal force 
to precipitate subcellular components based on their distinct density, size, and shape [38]. During 
the FIA-MS/MS analysis, the standard curve achieved a less than 15% deviation of the nominal 
value for each standard point other than the lower limit of quantification (LLOQ), which was 20%, 
and the quality control (QC) samples were accepted with a less than 15% deviation of the nominal 
values, as per FDA guidelines [39]. 
Cellular uptake of the three gemini surfactants, expressed as percentage of dose, was observed to 
increase rapidly over the course of a 5 h treatment in PAM 212 cells, reaching a maximum of 17.0% 
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for 16-7N(GK)-16, 1.4% for 16-3-6, and 3.6% for 16(Py)-S-2-S-16(Py), followed by a gradual 
depletion after the removal of the nanoparticles from the media (Figure 3.5a). A significantly higher 
cellular uptake was observed for 16-7N(GK)-16 compared with 16-3-16 and 16(Py)-S-2-S-16(Py) 
(Figure 3.5a) (p <0.05). It should be noted that the optimal N/P for 16-3-16 and 16(Py)-S-2-S-
16(Py) is 10, whereas for the 16-7N(GK)-16 is 2.5 as previously determined in our lab [6, 16], and 
all transfections were conducted with equal amounts of plasmid DNA in the P/G/L nanoparticles. 
Therefore, the higher cellular uptake of 16-7N(GK)-16 implies that there is a higher transfection 
efficiency with this gemini surfactant relative to 16-3-16 and 16(Py)-S-2-S-16(Py) and offers a 
mechanistic explanation as to why PAM 212 cells exposed to 16-7N(GK)-16 secrete greater 
amounts of IFN-γ (Figure 3.3).  
While the gemini surfactant 16(Py)-S-2-S-16(Py) accumulated more significantly than 16-3-16 in 
PAM 212 after a 5 h treatment (p <0.05), less IFN-γ was produced, arguing that transfection 
efficiency is lower with 16(Py)-S-2-S-16(Py) than 16-3-16. The relatively higher toxicity of 16 
(Py)-S-2-S-16(Py) (Figure 3.4) might have contributed to its reduced gene transfection efficiency 
as it caused greater cell death, resulting in a smaller number of live cells available for gene 
transfection. 
In terms of subcellular distribution, normalized for each surfactant to total cellular uptake, the 
gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) exhibited comparable partitioning with 
significant accumulation in the nucleus, followed by mitochondria, cytosol, and plasma membrane 
(Figures 3.5b and c) (p <0.05). In contrast, the distribution of 16-7N(GK)-16 was relatively even 
across the four subcellular compartments (Figure 3.5d). No significant difference was observed 
among the three gemini surfactants with respect to their relative distribution in the mitochondrial 
and cytosolic fractions. However, accumulation in the nucleus was the highest for 16(Py)-S-2-S-
126 
 
16(Py) (50.3%), followed by 16-3-16 (41.8%) and then 16-7N(GK)-16 (33.4%) (p<0.05) at the 5 
h duration of treatment (Figure 3.5e), which correlates with the relative toxicity observed for the 
three gemini surfactants (Pearson’s correlation r = 0.9993). Even at the 2 h and 8 h time points post 
treatment, 16-7N(GK)-16 still displayed significantly lower accumulation in the nucleus relative 
to 16(Py)-S-2-S-16(Py) and 16-3-16 (p <0.05). Although there is a difference in the accumulation 
among the three gemini surfactants at 2 h time point, this accumulation might not be informative 
as the cellular uptake are still in rapid progress at this stage. Surprisingly, 16(Py)-S-2-S-16(Py) 
showed a similar distribution percentage in the nucleus as 16-3-16 at the 8 h time point; however, 
the distribution quantity (in terms of absolute amount) of 16-3-16 is significantly less compared 
with that of 16(Py)-S-2-S-16(Py) (Table 3.S1 in supporting information) as 16-3-16 has much 
lower cellular uptake in comparison with 16(Py)-S-2-S-16(Py) (Figure 3.5a), resulting in less 
toxicity of 16-3-16.   
Nuclear accumulation may result from either the entry of the gemini surfactants into the 
compartment or their association with the nuclear envelope, as it has been reported that lipoplexes 
can fuse with the membrane and release their DNA cargo into the nucleus [40]. However, it is 
currently not known that the entry of gemini surfactants into the nucleus is in the form of lipid 
molecules or lipoplexes. Although the entry of lipoplexes is unlikely due to the small pore size of 
nuclear membrane, it can take place during cell mitosis. As such, it could be in either form or both.  
The nucleus has crucial functions within a cell, ensuring the faithful storage and expression of 
genetic material essential to regulating cellular metabolism and growth [41]. Therefore, nuclear 
association or accumulation of gemini surfactants could impact outer membrane integrity and 
normal organelle function. As such, the higher cellular uptake and preferential accumulation of 
16(Py)-S-2-S-16(Py) within the nucleus could provide a basis for its higher toxicity relative to 16-
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3-16 and 16-7N(GK)-16. Thus, to date, our findings provide the only quantitative distinction in the 
subcellular profiles of these three gemini surfactants, without the use of a florescent tag. The results 
may offer the first mechanistic insight into the various efficiencies and toxicities observed for the 
three promising gene delivery agents. 
   
a                                                          b                                      c                    
  
     d                       e                
Figure 3.5. The cellular uptake and distribution of gemini surfactants in PAM 212 cells. a) Cellular uptake, 
normalized based on the dose, of three gemini surfactants; b-d) Subcellular distribution, normalized based 
on the total cellular uptake, of 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-16; and e) Distribution 
percentage in nucleus. (Cyto-cytosol, Mito-mitochondria, Nuc-nucleus and PM-plasma membrane).               
* indicates p <0.05 
In addition, it was observed that 16-7N(GK)-16 has a significantly higher distribution within the 



















































However, this did not result in higher toxicity, as evidenced by the viability of PAM 212 cells 
treated with the 16-7N(GK)-16 nanoparticles (Figure 3.4). In fact, 16-7N(GK)-16 displayed the 
lowest cytotoxicity among the three gemini surfactants in gene transfection. Stefanutti et al. [42] 
reported that the internalization of lipoplexes of DMPC and a cationic gemini surfactant traversing 
cell membrane did not cause a significant biological damage to the cells. In addition, Marjan et al. 
[43] reported that although nanoparticle treatment disturbed membrane integrity, the cells were still 
alive and metabolically active during the transfection process. Therefore, accumulation in the 
plasma membrane does not appear to cause toxicity. 
3.4.5 Ethidium bromide dye exclusion assay 
To explore why unique gemini surfactants differentially accumulate within distinct subcellular 
compartments, an ethidium bromide dye exclusion assay was conducted to investigate their DNA 
binding and compaction capabilities. Gemini surfactants bind and compact plasmid DNA via 
electrostatic interactions to form nanosized particles, which hinder the penetration of ethidium 
bromide into the complexes. As a result, fluorescence is quenched due to the lack of intercalation 
between ethidium bromide and the base-pairs of DNA. The stronger the compaction of DNA by 
gemini surfactants, the more intense the fluorescence quenching in the complex. As shown in 
Figure 3.6, the lowest fluorescence emission was observed at the N/P of 5, with 13.0% for 16-
7N(GK)-16, 8.1% for 16-3-16, and 8.9% for 16(Py)-S-2-S-16(Py) in the absence of the helper lipid 
DOPE. The data indicate that 16-7N(GK)-16 has a significantly lower DNA compaction capability 
compared with the other two compounds (p <0.05). In the presence of a helper lipid, the 
fluorescence values were increased to 45.7% for 16-7N(GK)-16, 23.6% for 16-3-16, and 28.3% 
for 16(Py)-S-2-S-16(Py), again showing 16-7N(GK)-16 is significantly less efficient at binding 




Figure 3.6. Ethidium bromide dye exclusion assay to evaluate the DNA binding and compaction capability 
of the gemini surfactants. A lower fluorescence indicates stronger DNA binding and compaction. 
 
However, the relatively lower DNA binding capability of 16-7N(GK)-16 does not undermine its 
gene transfection capability, as evidenced in the transfection study, since gene transfection requires 
not only effective compaction of DNA for their protection and cellular entry, but also efficient 
release from the complex into the nucleus for transgene expression . It is believed that the presence 
of glycyl-lysine moiety in the spacer offers conformational flexibility of the structure, which 
bestows 16-7N(GK)-16 with softened DNA binding properties [9, 44]. Although 16-7N(GK)-16 
has a relatively weaker DNA binding ability than the other two compounds as indicated by its 
higher fluorescence emission of 13% compared with 8.1% for 16-3-16 and 8.9% for 16(Py)-S-2-
S-16(Py), such binding provides the DNA with much needed protection against enzymatic 
degradation while also facilitating its intracellular release, thereby enhancing overall transfection 
efficiency [9, 44]. This special binding capability may be caused by the overall interaction of 
multiple bonding forces, including hydrogen bonding and electrostatic interactions [45]. In addition, 
the various amine groups in the amino acids can allow for additional buffering capacity, which 
helps in the disruption of the endosomal membrane for the intracellular release of DNA and their 












































































Due to the weaker DNA binding of 16-7N(GK)-16, the encapsulated DNA could be released more 
efficiently from the lipoplexes into the cytoplasm to translocate into the nucleus for gene expression. 
As such, this led to a lesser accumulation of 16-7N(GK)-16 in the nucleus. Conversely, the 
lipoplexes formed with 16-3-16 and 16(Py)-S-2-S-16(Py) release the DNA less efficiently and 
potentially at a later stage due to their stronger association with DNA (Figure 3.6), which could be 
one of the reasons for their lower transfection efficiency relative to 16-7N(GK)-16, as it has been 
reported that slow vector unpacking is linked to a decreased transfection efficiency [46, 47]. In this 
case, the lipoplexes rather than free DNAs are more likely to be translocated into the nucleus. 
Consistent with this idea, we observed elevated accumulation of both 16-3-16 and 16(Py)-S-2-S-
16(Py) in the nucleus (Figures 3.5b and c).  
3.4.6 Molecular packing parameter                                                                
In addition to their DNA compaction and binding property, the molecular shape of gemini 
surfactants also has a great impact on the performance of the gene delivery system [16, 48]. 
Therefore, to further understand the behavioral differences among the three gemini surfactants, the 
structural differences in the formed aggregates were evaluated using the molecular packing 
parameter (P) [48]. The P was estimated based on the structures of gemini surfactants and the 
behavior of gemini surfactants at the air-water interface [49], and is defined as:  
P = v/aol 
Where v is the volume of the hydrophobic tails, l is the length of the hydrocarbon tails, and ao is 
the head group area per molecule in aqueous solution. The v and l are the geometrical properties of 
gemini surfactants, which can be calculated from their chemical structures [50, 51]. The ao is an 
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equilibrium parameter dependent upon both the attractive forces of the hydrophobic chains and the 
repulsive forces of the head groups, which can be determined by the Langmuir studies. A specific 
P value can be linked to a particular geometrical shape [49]. Spherical micelles typically have a P 
value of less than 0.33, cylindrical micelles possess a P value between 0.33 and 0.50, and flexible 
bilayers (vesicles) usually have a P value between 0.5 and 1.0 [49].  
As the three gemini surfactants have the same l and v of hydrophobic tails, the ao is the main 
determinant of the P value. The l was calculated to be 21.74 Å using the Avogadro software [52], 
and the v was calculated to be 918 Å3 with the Gaussian 09 software (revision B. 01) [53] (Table 
3.1). Based on the Langmuir studies, the gemini surfactant 16-7N(GK)-16 showed the smallest a0 
of 84 Å2 and thus the largest P of 0.51, indicating the aggregates formed by 16-7N(GK)-16 are 
typically flexible bilayers. The gemini surfactant 16-3-16 displayed an a0 of 116 Å2 and a P value 
of 0.36, which suggested the formation of aggregates shaped as cylindrical micelles (Table 3.1). 
This is in agreement with the literature [51, 54] reporting that aggregates formed by m-3-m gemini 
surfactants tend to form cylindrical micelles. Similarly, the gemini surfactant 16(Py)-S-2-S-16(Py) 
had an a0 of 110 Å2 and a P value of 0.38, which argues it too forms cylindrical micelles in aqueous 
solution.  
Table 3.1. The molecular packing parameter (p) and the shapes of aggregates of the gemini surfactants. 
Gemini surfactant a0(Å2) 𝑙(Å) 𝑣(Å3) P Shape of aggregate 
16-3-16 116 21.74 918 0.36 Cylindrical micelle 
16(Py)-S-2-S-16(Py) 110 21.74 918 0.38 Cylindrical micelle 
16-7N(GK)-16 84 21.74 918 0.51 Flexible bilayer, vesicle 
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Although 16-3-16 and 16(Py)-S-2-S-16(Py) have unique structural head groups, their areas are 
comparable and enable them to have similar packing parameters and a preference towards forming 
cylindrical micelle aggregates (Table 3.1). The same aggregates would allow for a similar 
internalization process of the two gemini surfactant nanoparticles for gene delivery, which 
explained the similar trends observed for their uptake and subcellular distribution (Figures 3.5b 
and c). Conversely, the substitution of a di-peptide in the spacer region provides 16-7N(GK)-16 
with conformational flexibility [9]. It has a much smaller head group area and thus a flexible bilayer 
structure (Table 3.1), which allows for the formation of the inverted hexagonal phase of the 
lipoplex [48]. Such a conformation facilitates not only the destabilization of endosomal membrane 
to promote the cytoplasmic release of DNA but also the dissociation of DNA from the lipoplexes, 
thus resulting in enhanced efficiency in gene transfection [55].  
3.5 Conclusions 
The cellular uptake and distribution of the gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 
16-7N(GK)-16 as gene delivery agents in PAM 212 cells were evaluated by analyzing subcellular 
fractions using a validated FIA-MS/MS method. The three gemini surfactants varied with respect 
to their uptake and subcellular distribution profiles, with 16-7N(GK)-16 exhibiting a greater uptake 
and a higher transfection efficiency. Preferential nuclear accumulation of 16(Py)-S-2-S-16(Py) 
may explain its relatively higher toxicity. DNA binding properties and molecular packing 
parameters provided explanations to the different cellular behaviors of the gemini surfactants. 
Overall, the results presented herein demonstrate the general applicability of the combined 
differential centrifugation and MS approach for assessing the uptake and subcellular distribution 
of gemini surfactants and emphasize that it is superior to a fluorescence-labelling method as it does 
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not require any structural modifications. We are currently investigating the metabolite formation 
of the three structures, which may provide additional insight into their relative efficiencies and 
toxicities. In the future, it may be worthwhile isolating more cellular organelles, such as the 
endosomes and lysosomes to better understand the cellular trafficking of lipid-based gene delivery 
agents.  
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Figure 3.S1. Structures of (A) 16-3-16-D66 and the monitored product ion, (B) 16(Py)-S-2-S-16(Py)-D10 
and the monitored product ion, and (C) 16-7N(GK)-16-D4 and the monitored product ion.  
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Table 3.S1. Cellular uptake and distribution of the three gemini surfactants in PAM 212 cells, expressed as 
an absolute amount. 
Subcellular 
fraction 



















Cyto (nmoL) 0.15 0.20 0.20 0.13 0.26 0.42 0.10 0.25 0.40 
Mito (nmoL) 0.23 0.18 0.29 0.29 0.62 0.63 0.16 0.49 0.56 
Nuc (nmoL) 0.30 0.27 0.32 0.34 1.04 0.81 0.33 0.92 0.47 
PM (nmoL) 0.03 0.02 0.22 0.06 0.15 0.57 0.03 0.12 0.42 
Total uptake 
(nmoL) 
0.72 0.67 1.04 0.82 2.06 2.42 0.63 1.77 1.86 
Uptake (%) 1.3% 1.2% 7.3% 1.4% 3.6% 17.0% 1.1% 3.1% 13.0% 
(Dose amount: 57 nmoL for 16-3-16 and 16(Py)-S-2-S-16(Py), and 14.25 nmoL for 16-7N(GK)-16. Cyto-cytosol, 




3.9 Appendix B - Supplementary Methods and Results 
3.9.1 Western blotting procedure 
To solubilize membrane proteins, the freshly collected nuclear, mitochondrial, and plasma 
membrane fractions were re-suspended in 150 μL of ice-cold RIPA buffer (10 mM Tris-HCl [pH 
8], 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and 1x 
protease inhibitor cocktail) for 30 min on ice. The clarified extracts were collected after 
centrifugation (15,000 x g, 20 min, 4 ̊ C). No protein recovery was needed for the cytosolic fraction. 
An appropriate volume of 4x Laemmli sample buffer containing 600 mM dithiothreitol was added 
to each fraction, which was then incubated for 10 min in a 37 ˚C water bath. Approximately 20 μg 
of proteins from each fraction was loaded on 4-15% SDS-PAGE gradient gel and electrophoresed 
for 1.5 h at 120 V. Proteins were then transferred to nitrocellulose membrane at 400 mA for 1.75 
h. After a 2 h room temperature incubation in TBST buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 
and 0.05% Tween-20) containing 5% non-fat dried milk, the membrane was incubated overnight 
at 4 ˚C with a primary antibody specific to each subcellular fraction. The following day, the 
membrane was washed 6 times with TBST and incubated in secondary antibody for 2 h at room 
temperature. Finally, the membrane was washed 6 times with TBST and developed with an 
enhanced chemiluminescence assay kit (Bio-Rad, Canada). Immunoreactive bands were visualized 
using a VersaDocTM Image System (Bio-Rad Laboratory, Hercules, CA, USA). 
3.9.2 Western blotting analysis of subcellular fractions 
Western blotting was conducted with organelle or compartment-specific markers to verify the 
relative purify of each subcellular fraction. As showed in Figure 3.S2, each marker was most 
abundant in the expected fraction. The modest amount of SDH70 shown in the nuclear fraction 
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likely reflects a small number of residuals and unbroken cells in the preparation. The results 
indicated that differential centrifugation of homogenates allowed for the successful isolation of 
enriched nuclear, mitochondrial, plasma membrane and cytosolic fractions from PAM 212 cells.  
 
 
Figure 3.S2. Western blot analysis of the subcellular fractions. Samples were probed with antibodies for 
organelle-specific markers. The bands correspond to their relevant molecular weights, showing the identities 
of the proteins and thus the isolation of subcellular fractions. The protein band sizes are Na+/K+ ATPase 
(110 kDa) for plasma membrane (PM), Lamin A/C (70 kDa) for nucleus (Nuc). SDH70 (70 kDa) for 
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In addition to the assessment of cellular uptake and subcellular distribution conducted in Chapters 
2 and 3, the metabolism of the gemini surfactants 16-3-16, 16(Py)-S-2-S-(Py)16, and 16-7N(GK)-
16  was investigated in this Chapter using high-resolution mass spectrometry, which contributes to 




Gemini surfactants are a class of lipid molecules that have been successfully used in vitro and in 
vivo as non-viral gene delivery vectors. However, the biological fate of gemini surfactants has not 
been well investigated. In particular, the metabolism of gemini surfactants after they enter cells as 
gene delivery vehicles is unknown. In this work, we used a high-resolution quadrupole-Orbitrap 
mass spectrometry (Q-Exactive®) instrument to detect the metabolites of three model gemini 
surfactants, namely a) unsubstituted (16-3-16), b) with pyridinium head groups (16(Py)-S-2-S-
16(Py)), and c) substituted with a glycyl-lysine di-peptide (16-7N(GK)-16). The metabolites were 
also characterized, and structures proposed, based on accurate masses and characteristic product 
ions. Metabolic behaviors of the three gemini surfactants were very different as 16-3-16 was not 
metabolized in PAM 212 cells, whereas 16(Py)-S-2-S-16(Py) was metabolized primarily via phase 
I reactions, including oxidation and de-alkylation, producing metabolites that could be linked to its 
observed high toxicity. The third gemini surfactant 16-7N(GK)-16 was metabolized mainly via 
phase II reactions, including methylation, acetylation, glucose conjugation, palmityl conjugation, 
and stearyl conjugation. The metabolism of gemini surfactants provides insight for future directions 
in the design and development of more effective gemini surfactants with lower toxicity. The 
reported approach can also be applied to study the metabolism of other structurally related gemini 
surfactants. 
Key words: Gemini surfactants; Gene delivery; Metabolites; High-resolution mass spectrometry; 




Gemini surfactants are a class of self-assembled lipid molecules that have a general structure of 
two hydrophilic head groups, a spacer region, and two hydrophobic tails (Figure 4.1a) [1]. Gemini 
surfactants have been extensively studied as non-viral gene delivery vectors [2-4], as they have the 
ability to compact DNA to form nanosized particles, facilitating their cellular entry [5, 6]. 
Numerous studies evaluated gemini surfactants to increase their transfection efficiency and reduce 
toxicity. First, a wide range of gemini surfactants were designed and synthesized by varying the 
head groups, the spacer region, and the length and saturation of the hydrophobic tails [7, 8]. Second, 
the formulation strategy for gemini surfactant-based lipoplexes has been studied, such as the 
application of lyophilization [9]. Lastly, the internalization mechanism of gemini surfactants was 
determined to be endocytosis, with the aim in increasing cellular uptake and thereby enhancing 
transfection efficiency [10]. These efforts have greatly contributed to the development of novel 
gemini surfactants used as gene delivery agents. 
Despite the substantial improvements, gemini surfactants as non-viral vectors are still limited in 
gene transfection abilities, particularly for in vivo applications [11, 12]. In addition, the differences 
in cellular toxicities among different structures are not fully understood. Currently, studies are 
primarily focused on the development of efficient delivery systems by modifications of the 
structures of gemini surfactants, optimization of the formulation methods, and facilitation of 
endosomal escape [9, 10, 13]. However, the biological fate of gemini surfactants has not been fully 
explored and little is known about their cellular uptake, distribution, and metabolite formation upon 
entry into biological systems, which can be an important contributing factor for their observed 
efficiencies and toxicities. High-resolution mass spectrometry (MS) instruments, such as a 
quadrupole-time of flight (Q-TOF) and a quadrupole-Orbitrap (Q-Exactive®), have been 
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extensively used for the identification and characterization of a wide range of molecules as they 
can provide high sensitivity, accurate mass measurement, and a wide dynamic range [14, 15]. 
Typically, these instruments can achieve a mass accuracy of less than 5 ppm, allowing for the 
determination of molecular formula to assist in the identification of unknown compounds [16, 17]. 
In addition, tandem mass spectrometric (MS/MS) analysis can aid in the characterization of the 
target metabolites. For example, the gemini surfactants G12-s and G18:1-s have been characterized 
with mass accuracy less than 5 ppm for their structural elucidation using a Q-TOF instrument with 
internal calibration [18]. Similarly, a Q-Exactive instrument was used for the identification and 
characterization of phase II pharmaceutical metabolites in reclaimed water [19].   
To assess the biological fate of gemini surfactants, we have evaluated three gemini surfactants, 
designated as 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16) (Figures 4.1b-d) to understand 
their biological fate and explore the relationship between the cellular uptake, distribution, and 
metabolism in relation to their overall efficiencies and toxicities. The three gemini surfactants 
belong to different structural families; 16-3-16 is a conventional gemini surfactant with two 
quaternary amines in the head groups, whereas 16(Py)-S-2-S-(Py)16 contains two pyridine 
moieties in the head groups and 16-7N(GK)-16 is a glycyl-lysine di-peptide substituted gemini 
surfactant (Figures 4.1b-d). These gemini surfactants have been successfully used in vitro and in 
vivo as non-viral gene delivery agents [20-22]; however, they vary among each other in terms of 
gene transfer efficiencies and toxicities [23, 24].  
As our main therapeutic use for gemini surfactants is topical application, particularly for the 
treatment of localized scleroderma, a connective tissue disease, the epidermal keratinocytes PAM 
212 cells were selected for the evaluation of the biological fate of these three gemini surfactants. 
In fact, we have shown recently in an ex-vivo experiment that gemini surfactants localized mainly 
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in the skin with minimal penetration of skin tissues to enter the compartment representing the 
circulation [25]. As such, it is of great importance to evaluate their metabolism within a cell line 
that represents the target organ, i.e., the skin. Our group previously evaluated the cellular uptake 
and distribution of these three gemini surfactants within murine keratinocytes PAM 212 cells using 
mass spectrometric (MS) methods [26]. Typically, high cellular uptake of the gemini surfactants 
resulted in high gene transfection, whereas unfavorable accumulation in the nucleus was likely a 
major contributing factor to their toxicity [26]. However, the metabolism of the gemini surfactants 
remains unclear and there is no report describing the metabolite profiles of the gemini surfactants 
when used as gene delivery agents. An investigation of metabolite formation will help determine 
how the gemini surfactants interact within biological systems to generate different metabolic 
products, such as phase I and phase II metabolites. Such information will ultimately contribute to 
the design and development of novel gemini surfactants with better therapeutic profiles. Therefore, 
we utilized a high-resolution mass spectrometry instrument to detect and characterize the 
metabolites of the three lead gemini surfactants within PAM 212 cell line. 
                                                           
              
Figure 4.1. The structures of gemini surfactants. a) The general structure of gemini surfactants, b) 16-3-16, 
c) 16(Py)-S-2-S-16(Py), and d) 16-7N(GK)-16. 
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4.3 Materials and Methods 
4.3.1 Materials 
All gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 (Figures 4.1b-d) and 
their deuterium-labelled counterparts 16-3-16-D66, 16(Py)-S-2-S-16(Py)-D10, and 16-7N(GK)-16-
D4 (Figure 4.S1 in supporting information) were synthesized based on established protocols [21, 
22, 23]. The neutral lipid, 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), was obtained 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Chloroform, methanol, formic acid, cell 
culture flasks (75 cm2), and petri dishes (60 cm2) were purchased from Fisher Scientific (Ottawa, 
ON, Canada). Murine keratinocyte PAM 212 cells were obtained from Dr. S. Yuspa, National 
Cancer Institute, Bethesda, MD, USA. Minimum essential media (MEM), fetal bovine serum (FBS) 
albumin, and antibiotic-antimycotic solution were purchased from Sigma-Aldrich (Oakville, ON, 
Canada).  
4.3.2 Formulation 
All gemini surfactants were prepared as 3 mM aqueous solution and stored at -80 ℃ under darkness. 
The DOPE vesicles were prepared freshly in isotonic sucrose solution (9.25%, w/v, pH=9) at a 
concentration of 1 mM as per an established protocol [22]. The plasmid DNA solution was prepared 
in ultra-pure water at 200 µg/mL and stored at -80 ℃, and was allowed to thaw at room temperature 
prior to use.  
Lipoplexes were prepared with plasmid DNA, gemini surfactant (labeled or non-labeled), and 
helper lipid DOPE (P/G/L) as previously described [22], with a nitrogen (cationic) to phosphate 
(anionic) charge ratio (N/P) of 10 for 16-3-16, 16-3-16-D66, 16(Py)-S-2-S-16(Py), 16(Py)-S-2-S-
16(Py)-D10, and N/P of 2.5 for 16-7N(GK)-16 and 16-7N(GK)-16-D4. Briefly, an appropriate 
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amount of 3 mM aqueous solution of labeled or non-labeled gemini surfactants was added to the 
200 µg/mL plasmid DNA and gently mixed with a pipette, followed by a 15 min incubation at 
room temperature. A 1 mM DOPE solution was then added to the binary mixture, gently mixed, 
and subsequently incubated at room temperature for 15 min to produce the ternary P/G/L system 
(i.e., nanoparticles).  
4.3.3 Cell treatment and sample collection 
PAM 212 cells were cultured in 75 cm2 cell culture flasks inside a humidified incubator at 37 ℃ in 
an atmosphere of 5% CO2. When the cells reached 80% confluence, they were washed with 
phosphate buffered saline (PBS, 6 mL), dissociated with a 5 min incubation in a mixture of versene 
(10x, 3 mL) and trypsin (10x, 0.3 mL) and collected by centrifugation (250 x g, 5 min, 4 ℃). At 24 
h prior to treatment, the cells were seeded at 2×106 cells per petri dish (60 cm2), and at 1 h prior to 
transfection the cell media was switched to a serum-free media. Freshly prepared nanoparticle 
formulations (100 µL) were added to each dish drop by drop, followed by an incubation for 5 h 
based on previously established protocol [22]; upon completion, the cells were returned to the 
supplemented media for all subsequent incubation steps. During the incubation period, duplicates 
of treated cell samples and one control (untreated cells) were trypsinized and collected at 5 h. At 
10 h, two additional treated cell samples and one control were also collected. The collected cells 
were pelleted (250 x g, 5 min, 4 ℃), rinsed with PBS twice, reconstituted in 250 µL of PBS solution, 
and stored at -80 ℃ for subsequent sample preparation. In addition, each gemini surfactant was 
incubated in the media for 10 h as a control experiment 
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4.3.4 Sample preparation 
The 250 µL collected cell samples were thawed and lysed by undergoing six 
freeze/thaw cycles plus 1 h sonication at 25 kHz in a water bath at room temperature. Liquid-liquid 
extraction of the gemini surfactants from cellular matrix was carried out using the Bligh/Dyer 
method [27]. Briefly, each 250 µL of sample was mixed with 937.5 µL of methanol-chloroform 
(2:1, v/v), followed by mixing with 312.5 µL of chloroform and finally 312.5 µL of water. At each 
step, samples were vortexed thoroughly. The final combined mixture was then centrifuged at 2,800 
x g for 10 min at room temperature to separate the aqueous and organic phases. The bottom organic 
phase was retrieved and dried under a nitrogen gas stream, followed by reconstitution in 250 µL of 
methanol. Methanol solution (200 µL) was transferred into an HPLC vial for analysis. 
4.3.5 Flow-injection mass spectrometric analysis 
Flow injection was performed using a Thermo UltiMate 3000 HPLC system equipped with a well 
plate autosampler. Twenty microlitres of sample at 6 ℃ was directly injected (i.e., no column) into 
the source with an isocratic mobile phase consisting of methanol-water containing 0.000625% 
formic acid (90:10, v/v) at a flow rate of 0.2 mL/min. The data acquisition time was 2 min. 
All samples were analyzed using a quadrupole-Orbitrap mass spectrometer (Q-Exactive®, Thermo 
Scientific, Waltham, MA, USA) equipped with a heated electrospray ionization (HESI) source 
operated in positive ion mode. The HESI source voltage was optimized at 3 kV. The vaporizer and 
capillary temperatures were set to 350 °C and 300 °C, respectively. Ultra-high purity nitrogen was 
used as the ion source and collision gas. Mass spectrometric parameters were set as follows: Sheath 
gas, 40; Aux gas, 20; and Sweep gas, 5. MS full scans with a range of m/z 80-1200 at a resolving 
power of 140,000 (at m/z 200) and data dependent MS/MS scans with a product ion resolving 
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power of 17,500 (at m/z 200) were employed. A mass accuracy was obtained with less than 2 ppm 
for metabolite ions and less than 10 ppm for their product ions. The m/z values for ions of interest 
were entered in an inclusion list to trigger MS/MS scans. The isolation window for MS/MS scans 
was set at m/z 0.7 and dynamic exclusion was 15 s. For MS/MS analysis, normalized collision 
energy (NCE) was stepped between 20, 30, and 40. Data acquisition and analysis was performed 
with XcaliburTM software (Thermo Scientific, Waltham, MA, USA). 
4.4 Results and Discussion 
4.4.1 Detection of gemini surfactant metabolites  
The metabolic profiles of gemini surfactants were established by comparing control cells (i.e., no 
treatment) to cells treated with gemini surfactant nanoparticles (deuterium labeled or non-labeled). 
Possible metabolites were initially detected based on high-resolution full scan mass spectra as their 
molecular formulae were determined according to accurate mass measurements. Since gemini 
surfactants contain two positive charges in their structures, positive ion mode was used to identify 
potential metabolites. In fact, a preliminary analysis of treated cell extracts with a Q-TOF 
instrument (QSTAR® Elite, Concord, ON, Canada) indicated the absence of potential metabolites 
of the gemini surfactants in the negative ion mode. In addition to non-labeled gemini surfactants, 
deuterium-labeled gemini surfactants were also used to formulate nanoparticles and treat cells to 
confirm the presence of potential metabolites. 
No difference was observed in the full scan MS analysis between controls and cells treated with 
16-3-16 nanoparticles at 5 h and 10 h, indicating that the gemini surfactant 16-3-16 was not 
metabolized in PAM 212 cells. This result was confirmed by the metabolic profile of cells treated 
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with 16-3-16-D66 nanoparticles in which no metabolites were observed. Therefore, the gemini 
surfactant 16-3-16 is a non-biodegradable compound within PAM 212 cells. 
Conversely, cells treated with 16(Py)-S-2-S-16(Py) nanoparticles revealed the presence of three 
possible metabolites observed as doubly charged ions at m/z 357.2770 (M-1), 365.2748 (M-2), and 
373.2720 (M-3),  and two metabolites as singly charged ions observed at m/z 396.2756 (M-4) and 
412.2703 (M-5), which were not present in the control (Table 4.1 and Figure 4.S2 in supporting 
information). The accurate masses of these metabolites are all within 1.0 ppm mass error compared 
with the proposed molecular formula (Table 4.1). The doubly charged ion at m/z 357.2770 suggests 
that metabolite M-1 is an oxidization product of 16(Py)-S-2-S-16(Py), with one oxygen atom 
(15.9949 Da) added to the original structure (Table 4.1). The presence of a doubly charged ion at 
m/z 362.3084 (M-1’) in cells treated with the deuterium version of this compound (i.e., 16(Py)-S-
2-S-16(Py)-D10; the m/z shift of 5.0314 corresponds to the addition of 10 deuteriums) supports the 
existence of such a metabolite (Figure 4.S2 and Table 4.S1 in supporting information). Similarly, 
metabolites M-2 (m/z 365.2748) and M-3 (m/z 373.2720) were also determined based on their 
accurate mass measurements, showing two and three oxygen atoms added to the structures of 
16(Py)-S-2-S-16(Py) (Table 4.1). The deuterium-labeled compound gave corresponding 
metabolites M-2’ and M-3’ (Table 4.S1 in supporting information). 
The metabolites of 16(Py)-S-2-S-16(Py) observed at m/z 396.2756 (M-4) and 412.2703 (M-5) are 
singly charged ions, which are consistent with a dealkylation product and its oxidized form, 
respectively (Table 4.1). As expected, the deuterated gemini surfactant 16(Py)-S-2-S-16(Py)-D10 
metabolites at m/z 401.3070 (M-4’) and 417.3017 (M-5’) were also observed (Figure 4.S2 and 
Table 4.S1 in supporting information), which confirmed the presence of the two metabolites of 
16(Py)-S-2-S-16(Py). It should be noted that 16(Py)-S-2-S-16(Py) was also oxidized by incubation 
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in the media alone, generating the products of M-1 and M-2. However, the ion intensity of M-1 
and M-2 is significantly lower compared with those obtained in the media with PAM 212 cells and 
the production of M-3 was not observed in the media as shown in Figure 4.S3 in supporting 
information). In addition, the production of the oxidation metabolite M-3 was not observed in the 
media, confirming that oxidation was a process mediated by cellular enzyme and not merely due 
to natural oxidation within the aqueous media. As indicated in Table 4.1, the gemini surfactant 
16(Py)-S-2-S-16(Py) was mainly metabolized via phase I reactions, including oxidation and 
dealkylation. Although authentic reference standards are needed for the unambiguous 
authentication of the proposed structures, additional MS/MS analyses were performed to confirm 
the proposed metabolic reactions and the analysis is discussed in section 4.4.2. 
Likewise, possible metabolites of gemini surfactant 16-7N(GK)-16 were also initially detected 
based on the comparison of the metabolic profiles of treated cells versus controls. Unlike 16(Py)-
S-2-S-16(Py), the gemini surfactant 16-7N(GK)-16 was metabolized primarily via phase II 
reactions, including methylation, acetylation, glucose conjugation, palmitoyl conjugation, and 
stearyl conjugation (Table 4.1). This is probably due to the presence of a reactive functional group 
of an amino acid within its structure, prone to phase II reactions [27]. 
Six metabolites showing doubly charged ions at m/z 432.4238, 439.4317, 447.4291, 492.4448, 
530.5334, and 544.5491 were observed (Figure 4.S4 in supporting information) and their chemical 
formulae were determined according to their accurate masses (mass accuracy <1.0 ppm, Table 4.1). 
Metabolite M-a at m/z 432.4238 is a possible phase II product from an acetylation reaction, whereas 
metabolites M-b and M-c at m/z at 439.4317 and 447.4291 are the result of acetylation with 
methylation, and acetylation with methylation and hydroxylation, respectively (Table 4.1). In 
addition, metabolites M-d, M-e, and M-f observed at m/z 492.4448, 530.5334, and 544.5491 were 
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also determined as possible phase II reaction products corresponding to the addition of glucose, 
palmitoyl, and stearyl groups to the original structure, respectively (Table 4.1). The presence of 
these metabolites is confirmed by the metabolism of 16-7N(GK)-16-D4, showing six similar 
metabolites with the expected mass shift of 2.0136 Da at m/z 434.4362, 441.4438, 449.4413, 
494.4569, 532.5454, and 546.5611 (Figure 4.S4 and Table 4.S1 in supporting information). 
MS/MS analyses discussed below (section 4.4.3) are used to confirm the proposed metabolic 
reactions.  
Table 4.1 Potential metabolites based on accurate mass measurements for the gemini surfactants 16(Py)-













16(Py)-S-2-S-16(Py) C44H78N2S22+ 349.2798 349.2805 2.0  
M-1 C44H78N2OS22+ 357.2772 357.2770 0.6 Oxidation 
M-2 C44H78N2O2S22+ 365.2747 365.2748 0.3 Oxidation 
M-3 C44H78N2O3S22+ 373.2722 373.2720 0.5 Oxidation 
M-4 C23H42NS2+ 396.2753 396.2756 0.8 Dealkylation 
M-5 C23H42NOS2+ 412.2702 412.2703 0.2 Dealkylation, Oxidation 
      
16-7N(GK)-16 C50H106N6O22+ 411.4183 411.4186 0.7  
M-a C52H108N6O32+ 432.4236 432.4238 0.5 Acetylation 
M-b C53H110N6O32+ 439.4314 439.4317 0.7 Acetylation, Methylation 
M-c C53H110N6O42+ 447.4289 447.4291 0.4 Acetylation, Methylation, 
Hydroxylation 
 M-d C56H116N6O72+ 492.4447 492.4448 0.2 Glucose conjugation 
M-e C66H136N6O32+ 530.5331 530.5334 0.6 Palmitoyl conjugation 




4.4.2 MS/MS analysis of 16(Py)-S-2-S-16(Py) and its metabolites  
An MS/MS analysis was performed in an effort to determine the proposed metabolic pathways of 
each gemini surfactant and thereby support the structural assignments of the proposed metabolites. 
Specifically, the metabolites detected based on accurate mass measurements were subjected to 
MS/MS analysis. The observed product ions were then compared with those of their respective 
parent compounds to explore structural similarities and determine structural changes within the 
metabolites. Thus, the combination of high-resolution accurate mass measurements and MS/MS 
data resulted in high confidence in the proposed metabolite assignments. 
Figure 4.2 shows the MS/MS spectra of 16(Py)-S-2-S-16(Py) and its metabolites. The gemini 
surfactant 16(Py)-S-2-S-16(Py) displayed four major characteristic product ions at m/z 396.2749, 
317.2326, 309.7588, and 257.2294, along with other product ions (Figure 4.2a). These observed 
product ions are the same as those obtained on a triple quadrupole linear ion trap (Q-LIT) 
instrument in our previous work in which the structures of all product ions were determined [28]. 
The product ion at m/z 309.7588 was formed through the loss of one pyridine moiety from the 
parent molecule that further underwent S-dealkylation to generate the product ion at m/z 257.2294. 
The product ion at m/z 396.2749 was produced via loss of the pyrdinium group along with the alkyl 
chain through S-dealkylation. The ion further lost one pyridine moiety to generate the product ion 
at m/z 317.2326, followed by S-dealkylation to also yield the product ion at m/z 257.2294 (Figure 
4.3a). As expected, the deuterated gemini surfactant 16(Py)-S-2-S-16(Py)-D10 displayed similar 
characteristic product ions observed at m/z 401.3065, 317.2332, 312.2740, and 257.2295 (Figure 
4.S5a in supporting information). 
The metabolite M-1 was determined as an oxidized species of 16(Py)-S-2-S-16(Py) with an m/z 
value of 357.2770. MS/MS analysis of M-1 yielded characteristic product ions at m/z 412.2701, 
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352.2671, 333.2279, 302.2841, and 257.2296 (Figure 4.2b). Similar to the formation of the product 
ions at m/z 396.2749, 317.2326, and 257.2294 of 16(Py)-S-2-S-16(Py), the product ions at m/z 
412.2701, 333.2279, and 257.2296 of M-1 were formed via S-dealkylation, N-dealkylation 
resulting in loss of one pyridine moiety, and subsequent S-dealkylation (Figure 4.3b). By 
comparing with the product ions at m/z 396.2749 and 317.2326 of 16(Py)-S-2-S-16(Py), the 
product ions at m/z 412.2701 and 333.2279 of M-1 suggested that an oxygen atom was added to 
one of the two sulfur atoms in the original structure (Figure 4.3b). The product ion at m/z 352.2671 
was formed through S-dealkylation, which further yielded the product ion at m/z 302.2841, also 
confirming the oxidation reaction (Figure 4.3b). This conclusion is supported by the corresponding 
metabolite M-1’ at m/z 362.3084 of 16(Py)-S-2-S-16(Py)-D10 (Figure 4.S2 in supporting 
information), which displayed characteristic product ions at m/z 417.3004, 357.2973, 333.2277, 
307.3152, and 257.2296 (Figure 4.S5b in supporting information).  
Similarly, metabolites M-2 and M-3 were also determined to be oxidation products of 16(Py)-S-2-
S-16(Py) with accurate masses at m/z 365.2748 and 373.2720, respectively. Like the metabolite M-
1, the metabolite M-2 was characterized with its unique product ions at m/z 428.2627, 352.2639, 
349.2233, 302.2830, and 273.2266, indicating two oxygens were added to the sulfur atoms (Figures 
4.2c and 4.3c). In particular, the product ion at m/z 352.2639 indicated the presence of one oxygen 
on each sulfur atom, as it was formed through S-dealkylation with the loss of one oxygen-
containing alkyl group (Figure 4.3c). The product ions at m/z 428.2627, 349.2233, and 273.2266 
also support the attachment of an oxygen to each of the two sulfur atoms (Figure 4.3c). In addition, 
the deuterated gemini surfactant 16(Py)-S-2-S-16(Py)-D10 displayed a similar metabolite M-2’ 
with an accurate mass at m/z 370.3064 (Figure 4.S2 in supporting information), which showed 
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corresponding product ions at m/z 433.2959, 357.2975, 307.3151, and 273.2238 (Figure 4.S5c in 
supporting information).  
Due to low ion abundance, the MS/MS spectra of metabolite M-3 was not obtained; its structure 
was proposed to contain three oxygen atoms based on accurate mass measurement (Table 4.1 and 
Figure 4.S2 in supporting information). On the contrary, the MS/MS spectra of metabolite M-3’ of 
16(Py)-S-2-S-16(Py)-D10 was obtained and showed characteristic product ions at m/z 449.2918, 
399.3087, 357.2977, 307.3153, and 273.2244 (Figure 4.S5d in supporting information), suggesting 
three oxygens were added to the sulfur atoms in the original structure. This dissociation behavior 
mimics what was observed for metabolite M-2, supporting the proposed structure (Figure 4.S6 in 
supporting information). 
The metabolite M-4, a singly charged ion at m/z 396.2756, is an S-dealkylation product of 16(Py)-
S-2-S-16(Py) (Figure 4.3d), whereas the metabolite M-5, with an accurate mass at m/z 412.2703, 
is proposed to be an oxidized form of M-4 (Figure 4.3e). An MS/MS analysis of metabolite M-4 
showed two major product ions at m/z 317.2336 and 257.2297 (Figure 4.2d); whereas metabolite 
M-5 displayed two major product ions at m/z 333.2272 and 257.2294 (Figure 4.2e), indicating it is 
an oxidized version of M-4. Likewise, the deuterated gemini surfactant 16(Py)-S-2-S-16(Py)-D10 
also showed two singly charged metabolites M-4’ and M-5’ with accurate masses at m/z 401.3070 
and 417.3017, which displayed similar fragmentation patterns as metabolites M-4 and M-5, 
supporting the proposed structures of the two metabolites (Figures 4.S5e and f in supporting 
information).  
Based on the proposed structures of the metabolites, a suggested metabolic pathway for the gemini 
surfactant 16(Py)-S-2-S-16(Py) is presented in Figure 4.4, indicating that this compound is mainly 
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metabolized via phase I metabolic reactions. In particular, it can either go through a series of 
oxidations to generate S-oxidized products, or a second pathway involving S-dealkylation and 
subsequent S-oxidation to produce dealkylation and sulfoxide oxidation metabolites. Metabolites 
of the deuterated gemini surfactant 16(Py)-S-2-S-16(Py)-D10 (Figure 4.S7 in supporting 




Figure 4.2. The MS/MS spectra of 16(Py)-S-2-S-16(Py) and its metabolites: a) 16(Py)-S-2-S-16(Py), b) M-
1, c) M-2, d) M-4, and e) M-5. (# denotes the parent ion and * denotes the diagnostic product ion). The 














Figure 4.3.  The proposed structures of major product ions of 16(Py)-S-2-S-16(Py) and its metabolites. a) 
16(Py)-S-2-S-16(Py), b) M-1, c) M-2, d) M-4, and e) M-5. 
 
 
Figure 4.4. The metabolites of 16(Py)-S-2-S-16(Py) and its proposed metabolic pathway. 
4.4.3 MS/MS analysis of 16-7N(GK)-16 and its metabolites 
MS/MS analysis of 16-7N(GK)-16 showed characteristic product ions at m/z 283.2132, 276.7643, 
270.3153, and 268.2510 (Figure 4.5a). The doubly charged product ion at m/z 276.7643 was formed 
via deamination of the tail region and subsequent deamination of the second tail region resulted in 
the singly charged product ion at m/z 283.2132. Conversely, the product ion at m/z 276.7643 could 
instead lose an ammonia moiety to form a doubly charged ion containing a 6-membered ring 
observed at m/z 268.2510. Subsequent dealkylation of this ion, by losing the spacer group with its 
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attached amino acid, results in the formation of the product ion at m/z 270.3153 (Figure 4.6a). This 
fragmentation pattern is consistent with what was previously obtained via collision induced 
dissociation (CID) on a Q-LIT instrument [29]. In a similar manner, the deuterated gemini 
surfactant 16-7N(GK)-16-D4 produced characteristic product ions with the expected mass shift of 
2.0136 Da at m/z 287.2389, 278.7767, 270.3151, and 270.2637 (Figure 4.S8a in supporting 
information). 
The metabolite M-a was proposed to be an acetylation product of 16-7N(GK)-16, with an accurate 
mass at m/z 432.4238, corresponding to N-acetylation (42.0106 Da) of the original structure. 
However, the precise location of substitution on the lysine could not be determined (shown for 
illustration on the lysine side chain), as the acetylation products with both primary amines generate 
the same characteristic product ions. MS/MS analysis showed that M-a has the expected 
characteristic product ions at m/z 297.7698, 276.7638, 270.3154, and 268.2511 (Figure 4.5b). The 
product ion at m/z 297.7698 is a deamination product containing an acetyl moiety (Figure 4.6b); 
whereas the product ions at m/z 276.7638, 268.2511, and 270.3154 were formed through sequential 
deacetylation, loss of ammonia, and eventual N-dealkylation (Figure 4.6b), similar to the formation 
of the same product ions observed for 16-7N(GK)-16 (Figure 4.6a). As expected, the deuterated 
gemini surfactant 16-7N(GK)-16-D4 also showed corresponding metabolite, M-a’, with an accurate 
mass at m/z 434.4362 (Figure 4.S3 in supporting information), which displayed characteristic 
product ions at m/z 299.7821, 278.7776, and 270.3162 (Figure 4.S8b in supporting information), 
supporting the proposed acetylation reaction. 
Similar to metabolite M-a, metabolites M-b and M-c were also determined to be the acetylation-
related products of 16-7N(GK)-16, with accurate masses at m/z 439.4317 and 447.4291, 
respectively. These two metabolites were formed via acetylation, followed by methylation in case 
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of M-b and methylation along with hydroxylation for M-c. Acetylation is shown on the terminal 
amine on the lysine side chain, and methylation on the backbone amine for illustrative purposes as 
the precise location of N-acetylation and N-methylation on lysine could not be determined. M-b 
has characteristic product ions at m/z 304.7587, 276.7651, 270.3150, and 268.2498 (Figure 4.5c), 
which were formed via deamination, loss of acetyl and methyl groups, loss of an ammonia, and N-
dealkylation, respectively (Figure 4.6c); whereas M-c showed characteristic product ions at m/z 
312.7746, 296.7601, 289.7542, and 270.3150 (Figure 4.5d), which were generated through 
deamination, loss of a methanol, loss of an ammonia, loss of a methyl group, and N-dealklyation 
(Figure 4.6d). The formation of these product ions is similar to that of the product ions observed 
for metabolite M-a (Figure 4.5a). The deuterated gemini surfactant 16-7N(GK)-16-D4 also 
exhibited corresponding metabolites M-b’ (m/z 441.4438) and M-c’ (m/z 449.4413), which 
displayed similar fragmentation patterns (Figures 4.S8c and d in supporting information) as those 
of metabolites M-b and M-c, supporting the proposed metabolite pathway . 
In addition, metabolites M-d, M-e and M-f were observed with accurate masses at m/z 492.4448, 
530.5334, and 544.5491, which were determined to be phase II metabolites of 16-7N(GK)-16 with 
the addition of glucose, palmitoyl, and stearyl groups, respectively (Figures 4.6e and f, substitution 
shown on the terminal amine of lysine). Due to low ion abundance, the MS/MS spectra of 
metabolite M-d was not obtained; the structure of M-d was proposed based on accurate mass 
measurement (Table 4.1 and Figure 4.S4 in supporting information). In contrast, the MS/MS 
spectrum for metabolite M-d’ of 16-7N(GK)-16-D4 was obtained (Figure 4.S8e in supporting 
information), which displayed characteristic product ions at m/z 359.8058, 287.2389, 278.7776, 




Similarly, metabolite M-e showed characteristic product ions at m/z 395.8799, 283.2132, 276.7643, 
270.3158, and 268.2517 (Figure 4.5e). The doubly charged product ion at m/z 395.8799 was formed 
via deamination, which further underwent the loss of one palmitoyl group to produce the ion at m/z 
276.7643. Subsequent loss of ammonia, deamination of the tail region, and dealkylation of the 
spacer resulted in the formation of the ions at m/z 268.2517, 283.2132, and 270.3158 (Figure 4.6e), 
similar to the formation of the same product ions of 16-7N(GK)-16 (Figure 4.6a). The metabolite 
M-f displayed characteristic product ions at m/z 409.8953, 283.2123, 276.7648, 270.3166, and 
268.2505 (Figure 4.5f); these ions were formed in a manner similar to the generation of the 
characteristic product ions of M-e (Figure 4.6f). As anticipated, the deuterated gemini surfactant 
16-7N(GK)-16-D4 showed corresponding metabolites  M-e’ and M-f’, with the expected mass shift 
of 2.0136 Da at m/z 532.5454 and 546.5611 (Figure 4.S3 and table 4.S1 in supporting information), 
which displayed similar product ions as those of metabolites M-e and M-f (Figures 4.S8f and g in 
supporting information), suggesting the accuracy of the proposed metabolic reactions. 
According to the suggested structures of the metabolites, a metabolic pathway of the gemini 
surfactant 16-7N(GK)-16 is described (Figure 4.7), showing that phase II metabolic reactions 
mainly occur for this compound. Specifically, the gemini surfactant 16-7N(GK)-16 can be 
metabolized via acetylation, acetylation with methylation, and acetylation with methylation and 
hydroxylation to generate a variety of acetylation-related products. In addition, it also can be 
metabolized through various conjugation processes, such as glucose conjugation, palmitoyl 
conjugation, and stearyl conjugation, to produce conjugated metabolites. Such a metabolic pathway 
is supported by the metabolites of the deuterated gemini surfactant 16-7N(GK)-16-D4 (Figure 




Figure 4.5.  The MS/MS spectra of 16-7N(GK)-16 and its metabolites: a) 16-7N(GK)-16, b) M-a, c) M-b, 
d) M-c, e) M-e, and f) M-f. (# denotes the parent ion and * denotes the diagnostic product ion). The MS/MS 















Figure 4.6. The proposed structures of major product ions of 16-7N(GK)-16 and its metabolites: a) 16-






Figure 4.7. The metabolites of 16-7N(GK)-16 and its proposed metabolic pathway. 
 
 
4.4.4 Significance of gemini surfactant cellular metabolism 
Ideally, lipid-based nanoparticles should deliver their therapeutic materials to the desired site(s), 
followed by degradation and excretion, to achieve optimal efficiency and minimal toxicity. 
However, the release of therapeutic agents and degradation of nanoparticles may take place at any 
time during the delivery process, which can result in reduced efficiency and increased toxicity. 
Furthermore, the longer the nanoparticles remain inside the biological systems, the higher toxicity 
they may cause [30]. In addition, the cellular metabolism of the building blocks of the nanoparticles 
might be harmful to host cells, contributing to the overall toxicity of the delivery systems [7].  
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Phase I and II biotransformations are common pathways for drugs and other foreign substances to 
be detoxified and eliminated [31, 32]. Although liver is the principal organ of drug metabolism, 
other tissues, such as the gastrointestinal tract, the lungs, the skin, the kidneys, and the brain, also 
display considerable enzymatic activities [33-35]. In particular, both phase I and phase II drug 
metabolizing enzymes, such as cytochrome P450 and UDP-glucuronosyltransferase, have been 
reported in the mammalian skin [36, 37]. The gemini surfactant 16-3-16 was found to be a non-
biodegradable in PAM 212 cells as there was not metabolite determined for this compound. This 
suggests that 16-3-16 will likely remain intact during detoxification and cellular elimination. It is 
also possible that metabolism was minimum and the current instrument was not sufficiently 
sensitive to detect minor metabolite formation for 16-3-16.  
Although the gemini surfactants 16(Py)-S-2-S-16(Py) and 16-7N(GK)-16 were metabolized in 
PAM 212 cells, they underwent different biotransformation pathways. Phase I reactions, including 
oxidation and dealkylation, mainly occurred for 16(Py)-S-2-S-16(Py), resulting in oxidized and 
dealkylated products. In contrast, 16-7N(GK)-16 was primarily metabolized via phase II reactions, 
such as methylation, acetylation, glucose conjugation, palmityl conjugation, and stearyl 
conjugation, which generated a variety of metabolized products. However, the roles of these 
metabolites regarding gene delivery efficiency and cellular toxicity remain unclear and more 
research needs to be conducted to better understand their metabolic pathways. In general, 
hydrophilic phase II metabolites are more rapidly excreted and less toxic compared to phase I 
metabolites in biological systems [38]. As the gemini surfactant 16-7N(GK)-16 has been shown to 
be less toxic than 16(Py)-S-2-S-16(Py) [24, 26], this could be the result of the formation of phase 
II metabolites of 16-7N(GK)-16, leading to more rapid clearance than the phase I metabolites of 
16(Py)-S-2-S-16(Py). In addition, phase I metabolites, such as M-4, could be involved in reactions 
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with thiol groups in proteins, potentially contributing to toxicity. During the data analysis, we 
observed additional peaks associated with chloride and formic acid adducts, as well as possible 
amino acid and peptide adducts/conjugates, which will be further confirmed to evaluate their 
biological impact. Furthermore, the Bligh-Dyer extraction method might not be efficient in 
extracting relatively polar metabolites of gemini surfactants, possibly resulting in not identifying 
them. Future studies will be conducted using various sample extraction methods to improve the 
coverage of possible gemini surfactant metabolites. For example, Al-Dulaymi et al [25] has 
reported a modified Folch method that provides high extraction recovery for gemini surfactants 
with more hydrophilic nature. In addition, the amount of the metabolites of tested gemini 
surfactants have not been determined in this study, future studies should also include the 
quantification of these metabolites using LC-MS/MS to further investigate their roles in biological 
systems. 
The current work provides a foundation study describing the various metabolic pathways. To 
further understand the role of these metabolites, we will confirm their structures with synthesized 
standards and assess the rate of metabolite formation, which will allow their roles with respect to 
efficiency and toxicity to be determined. 
4.5 Conclusions 
The metabolism of the three gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 
were investigated using a high-resolution quadrupole-Orbitrap mass spectrometer instrument, and 
the structures of their metabolites were characterized based on accurate mass measurements and 
their corresponding MS/MS analysis. The gemini surfactant 16-3-16 was found not to be 
metabolized in PAM 212 cells. The gemini surfactant 16(Py)-S-2-S-16(Py) was metabolized 
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primarily via phase I reactions, generating metabolized products that could contribute to its high 
toxicity; while 16-7N(GK)-16 was metabolized mainly via phase II reactions, resulting in 
metabolites that could lead to its low toxicity in gene transfection. The metabolism of 16-7N(GK)-
16 indicates that a phase II reaction-prone moiety, such as an amino acid, in the structure could 
play an important role for degradation and elimination of gemini surfactants, thus reducing its 
potential toxicity. In the future, we will be identifying the structures of the metabolites and 
evaluating the rate of metabolism. Finally, the reported approach can be applied to study metabolite 
formation of other gemini surfactants in various families for better understanding of their toxicities.  
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4.8 Supporting information 
 




Figure 4.S1. The structures of deuterated gemini surfactants, a) 16-3-16-D66, b) 16(Py)-S-2-S-16(Py)-D10, 




      
   
      
   
Figure 4.S2. MS spectra of the metabolites of 16(Py)-S-2-S-16(Py) and 16(Py)-S-2-S-16(Py)-D10 based on 
accurate mass measurement at 5 h of treatment. (* denotes the peak of the metabolite. panel A-control, panel 
B-cells treated with 16(Py)-S-2-S-16(Py) nanoparticles, and panel C-cells treated with 16(Py)-S-2-S-
16(Py)-D10 nanoparticles. Zoomed in all three panels to show the peaks of the metabolites). 
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Figure 4.S3. MS spectra of metabolite M-1 and M-2 of 16(Py)-S-2-S-16(Py) produced in PAM 212 cells 
and media at 10 h of treatment. The ion intensity of M-1 and M-2 generated by natural oxidation of 16(Py)-
S-2-S-16(Py) in media is significantly lower compared with that in cells, indicating the oxidation 
metabolism in cells   
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Figure 4.S4. MS spectra of the metabolites of 16-7N(GK)-16 and 16-7N(GK)-16-D4 based on accurate 
mass measurement at 5 h treatment. (* denotes the peaks of the identified metabolites. panel A-control, 
panel B-cells treated with 16-7N(GK)-16 nanoparticles, and panel C-cells treated with 16-7N(GK)-16-D4 




Figure 4.S5.  The MS/MS spectra of 16(Py)-S-2-S-16(Py)-D10 and its metabolites: a) 16(Py)-S-2-S-16(Py)-
















Figure 4.S8.  The MS/MS spectra of 16-7N(GK)-16-D4 and its metabolites: a) 16-7N(GK)-16-D4, b)  M-















Table 4.S1. Potential metabolites based on accurate mass measurements for the gemini surfactants 16(Py)-













16(Py)-S-2-S-16(Py)-D10 C44H68D10N2S22+ 354.3112 354.3115 0.8  
M-1’ C44H68D10N2OS22+ 362.3086 362.3084 0.6 Oxidation 
M-2’ C44H68D10N2O2S22+ 370.3061 370.3063 0.5 Oxidation 
M-3’ C44H68D10N2O3S22+ 378.3035 378.3038 0.8 Oxidation 
M-4’ C23H37D5NS2+ 401.3067 401.3070 0.7 Dealkylation 
M-5’ C23H37D5NOS2+ 417.3016 417.3016 0.0 Dealkylation, Oxidation 
      
16-7N(GK)-16-D4 C50H102D4N6O22+ 413.4309 413.4307 0.5  
M-a’ C52H104D4N6O32+ 434.4362 434.4362 0.0 Acetylation 
M-b’ C53H106D4N6O32+ 441.4440 441.4438 0.5 Acetylation, Methylation 
M-c’ C53H106D4N6O42+ 449.4414 449.4413 0.2 Acetylation, Methylation, 
Hydroxylation 
M-d’ C56H112D4N6O72+ 494.4573 494.4569 0.8 Glucoside conjugation 
M-e’ C66H132D4N6O32+ 532.5457 532.5454 0.6 Palmitoyl conjugation 






5 Chapter 5 - Discussion, Future Perspectives, and Conclusions 
5.1 Discussion 
Cationic lipids have been increasingly used as non-viral vectors for gene delivery in recent years 
[1-3]. In particular, cationic gemini surfactants are promising gene delivery agents as they have the 
ability to compact nucleic acids into nanoparticles, facilitate their cellular entry, and prevent them 
from cytoplasmic enzymatic degradation [4-6]. In addition, gemini surfactants displayed 
significantly better transfection activity and biocompatibility than other cationic lipids in gene 
delivery [7, 8]. To date, a large number of gemini surfactants have been successfully used in vitro 
and in vivo for gene delivery, showing their great potential for clinical applications [9-12]. Towards 
this goal, extensive investigations and development have been performed to increase efficiency 
and decrease toxicity of gemini surfactants, which include the development of novel gemini 
surfactant compounds [13-16], optimization of the formulation strategy of gemini surfactant-based 
lipoplexes [17], and investigation of the mechanism of their cellular uptake [18]. As a result, 
significant progress has been achieved in improving the efficiency and toxicity profiles of gemini 
surfactants used as non-viral gene delivery agents. 
While gemini surfactant nanoparticle-based gene delivery are taking strides towards clinical 
applications, their biological fate has not been investigated. In particular, the cellular uptake, 
distribution, and metabolite formation of gemini surfactant nanoparticles upon entering a biological 
system are not well understood, which could be linked to their efficiencies and toxicities. An 
understanding of the relationship between cellular uptake, subcellular distribution, metabolite 
formation, efficiency, and toxicity will aid in the development of less toxic and more effective 
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gemini surfactant compounds. Therefore, the focus of my Ph.D. research is the assessment of the 
biological behavior of gemini surfactant nanoparticles using mass spectrometry, with an emphasis 
on the qualitative and quantitative analysis of gemini surfactant nanoparticles in the cellular matrix. 
5.1.1 Determination of gemini surfactants in cellular matrix using a validated FIA-MS/MS 
method 
To investigate the cellular uptake and distribution of gemini surfactants, an effective analytical 
method is needed. In light of the complexity of the cellular matrix, an analytical method with high 
sensitivity and specificity is preferred for the analysis of gemini surfactant nanoparticles in treated 
cells. As gemini surfactants lack a chromophore or fluorophore and contain permanent positive 
charges in their structures [19], MS is ideal for their detection and quantification. In particular, 
MRM scan provides high sensitivity and specificity [20], allowing for the determination of gemini 
surfactants in complex biological matrices. Therefore, an FIA-MS/MS method that is simple and 
sensitive was developed for the quantification of three gemini surfactants 16-3-16, 16(Py)-S-2-S-
(Py)16, and 16-7N(GK)-16 in my Ph.D. research. 
The FIA-MS/MS method was developed and validated as per the USFDA guidelines [21]. It is the 
first FIA-MS/MS method that was developed for the quantification of gemini surfactants within 
different structural families. Compared with previous analytical methods employing cyano and 
HILIC columns for the quantification of 16-3-16 and 16(Py)-S-2-S-16(Py) in treated cells [22, 23], 
the FIA-MS/MS method eliminated the use of chromatographic separation, gradient elution, and 
an ion pairing reagent, which substantially simplified the method, shortened the time needed for 
method development, and reduced sample analysis time [24]. Furthermore, the sensitivity of the 
method is superior to the previous methods [22, 23], which could be attributable to the narrower 
and more symmetrical analyte peaks obtained with the optimized solvent mobile phases. In fact, 
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Buse et al. [25] conducted a comparison of various MS-based methods for the quantification of 16-
3-16, and a 10 fold higher sensitivity was achieved in the FC-Qtrap-MS/MS method compared 
with the LC-Qtrap-MS/MS method. To avoid potential matrix effect, deuterium-labelled gemini 
surfactants were used as internal standards that were added into samples prior to sample extraction 
and analysis. In addition, an efficient liquid-liquid extraction was achieved for 16-3-16 (104.2 ± 
9.5%) and 16(Py)-S-2-S-16(Py) (100.6 ± 4.3%) with the use of the Bligh/Dyer lipid extraction 
method [26], contributing to their determination in the cellular matrix. However, the extraction 
recovery of 16-7N(GK)-16 (36.2 ± 5.1%) is relatively low due to its highly hydrophilic nature, 
which is a limitation to this method. Although the use of internal standards allows for the correction 
for different extraction recoveries, various extraction methods including different extraction 
solvents and techniques should be explored to increase the recovery of 16-7N(GK)-16 as 
articulated in the future directions. 
Overall, the FIA-MS/MS method is effective for the determination of the three studied gemini 
surfactants at the subcellular level. As demonstrated in the application, the determined 
concentrations of the three gemini surfactants showed that there are significant variations in their 
accumulation in the nuclear fraction of treated PAM 212 cells (Figure 2.4), which may explain the 
observed differences in their toxicity.  
5.1.2 Cellular uptake and distribution of gemini surfactant nanoparticles 
The cellular uptake and distribution of gemini surfactants nanoparticles provides information on 
how they behave in biological systems, thus offering a better understanding of their observed 
efficiency and toxicity. To determine the cellular uptake and subcellular distribution of the three 
gemini surfactant nanoparticles in treated PAM 212 cells, four subcellular fractions (namely nuclei, 
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mitochondria, plasma membrane, and cytosol) were collected by differential centrifugation and 
subsequently extracted and analyzed by the FIA-MS/MS method (Chapter 2). The determination 
of gemini surfactants in subcellular fractions allowed for evaluating the relationship between 
cellular uptake, subcellular distribution, efficiency, and toxicity. 
The cellular uptake data revealed that the three gemini surfactants were rapidly taken up by PAM 
212 cells during a course of 5 h treatment, followed by subsequent depletion after removal of the 
nanoparticles from the media (Figure 3.5a). These observations are consistent with previously 
obtained results for 16-3-16 and 16(Py)-S-2-S-16(Py), which showed a maximal uptake prior to a 
decrease in their cellular concentrations [22]. The rapid cellular uptake of gemini surfactants 
corresponds to the quick internalization of the gemini surfactants-based DNA nanoparticles for 
gene transfection, whereas subsequent depletion reflects their cellular degradation and elimination. 
In fact, it was observed that 16(Py)-S-2-S-16(Py) and 16-7N(GK)-16 were metabolized in PAM 
212 cells post treatment (Chapter 4), which could contribute to their depletion. Overall, a 
significantly higher cellular uptake was observed for 16-7N(GK)-16 relative to the other two 
compounds (Figure 3.5a), which explained its relatively high efficiency in gene transfection 
(Figure 3.3). 
In addition to cellular uptake, the subcellular distribution of the three gemini surfactants was also 
determined in an effort to explain their varying efficiencies and toxicities. The subcellular data 
showed different distribution profiles among the three gemini surfactants in PAM 212 cells. In 
general, the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) displayed a similar subcellular 
distribution pattern that showed significant variations in different subcellular compartments 
(Figures 3.5b and c), whereas 16-7N(GK)-16 showed a relatively even distribution within the four 
compartments (Figure 3.5d). The difference in subcellular distribution might be due to their distinct 
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physicochemical properties, as 16-7N(GK)-16 possesses a di-peptide in its structure, providing 
greater biocompatibility and flexibility compared to the other two compounds [13]. While there is 
no significant difference among the three compounds in terms of their distributions in the 
mitochondria, plasma membrane and cytosol, the distribution in the nucleus is the highest for 
16(Py)-S-2-S-16(Py), followed by 16-3-16 and then 16-7N(GK)-16 (Figure 3.5e), which is in 
agreement with the observed toxicity of the three gemini surfactant nanoparticles (Figure 3.4). This 
differential nuclear distribution may provide an explanation for the toxicity of the three gemini 
surfactants, as non-preferable accumulation in the nucleus may pose harmful effects to the 
biological integrity and function of the cells. 
To further explain the difference of the three gemini surfactant nanoparticles in terms of their 
cellular uptake and subcellular distribution, ethidium bromide dye exclusion assays were carried 
out to determine their DNA binding capabilities. The results indicated that 16-7N(GK)-16 has a 
relatively weaker DNA binding property compared with the other two compounds (Figure 3.6). As 
gene transfection involves not only proper compaction and cellular delivery of DNA but also 
efficient endosomal escape and dissociation of DNA from lipoplexes [13, 18], neither a weak 
binding nor a strong binding will allow for an efficient gene transfection. A weak binding cannot 
provide sufficient compaction and protection of DNA for efficient delivery, whereas a strong 
binding will not enable efficient release of DNA for transgene expression [27]. Due to the presence 
of amino acid moieties in the structure, providing structural flexibility [27], the gemini surfactant 
16-7N(GK)-16 has the ability to provide sufficient protection for DNA while at the same time 
facilitate its intracellular release, thereby resulting in enhanced transfection efficiency. The similar 
results have also been previously obtained with other amino acid-substituted gemini surfactants 
due to their improved biocompatibility and structural flexibility [13]. 
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Additionally, Langmuir studies were conducted to measure the molecular packing parameters of 
the three gemini surfactants for determining their aggregate shapes. Similar to the  previous results 
determined for peptide-modified gemini surfactants [28], we observed that the shape of aggregates 
of gemini surfactants has a great impact on their performance as gene delivery agents. Specifically, 
the gemini surfactant 16-7N(GK)-16 forms a flexible bilayer structure in aqueous solution (Table 
3.1), which tends to generate an inverted hexagonal phase with DOPE to facilitate the cytoplasmic 
release of DNA from the endosomes [29], thus resulting in enhanced gene transfection and less 
accumulation in the nucleus. In contrast, the gemini surfactants 16-3-16 and 16(Py)-S-2-S-16(Py) 
are prone to form cylindrical micelle structures that restricted their endosomal scape (Table 3.1), 
leading to reduced efficiency in transfection. Together, the DNA binding capability and the shape 
of the aggregates of the gemini surfactants explained the different behaviors of the three gemini 
surfactant nanoparticles in biological systems. 
In this study, the isolation of subcellular fractions, namely nuclei, mitochondria, plasma membrane, 
and cytosol, was confirmed by western blotting assay, showing the identity of each cellular 
compartment. However, coomassie reagent was not used to stain the gel to thoroughly visualize all 
protein bands, which is a limitation in this study. The coomassie staining can provide a further 
evaluation of the relative purity of each fraction. As such, future studies should consider this as a 
complementary approach to confirm the isolated subcellular fractions. 
5.1.3 Detection and characterization of gemini surfactant metabolites using high-resolution 
mass spectrometry 
Despite the substantial advancement with gemini surfactants as gene delivery agents, their 
metabolism is still not well understood. Investigation of the metabolite formation is of great 
importance as it provides information to understand how gemini surfactants interact with biological 
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components. Such information will aid in the design and development of novel gemini surfactants 
that are more efficient and less toxic. Therefore, we studied the metabolism of the three gemini 
surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 in PAM 212 cells, as they belong to 
three structural families with different functional groups. We attempted to assess the impact of 
various functional groups on the metabolism of gemini surfactants in relation to their efficiencies 
and toxicities. 
 As we are developing gemini surfactant-based gene delivery systems mainly for topical 
applications, particularly for the treatment of localized scleroderma, the keratinocyte PAM 212 
cells were used in this study. In light of the relatively low quantity of the metabolites in the cellular 
matrix, MS is an ideal technique for their detection and analysis, especially high-resolution mass 
spectrometry that provides accurate mass measurement, high sensitivity, and high selectivity for 
the analysis of chemical compounds [30, 31]. Furthermore, MS/MS analysis offers characteristic 
product ions that can aid in the characterization and structural elucidation of a compound [32]. As 
such, we employed a high-resolution quadrupole-Orbitrap (Q-Exactive®) mass spectrometer to 
detect and characterize the metabolites of the three gemini surfactants in biological systems. 
While there is no metabolite found for 16-3-16 in PAM212 cells, suggesting it most likely remained 
as an intact molecule during the elimination process in biological systems; the gemini surfactant 
16(Py)-S-2-S-16(Py) was metabolized primarily via phase I reactions, including oxidation and 
dealkylation. Oxidation is mainly due to the presence of sulfur atoms in the structure, which enables 
the formation of a series of oxidation products [33]. In addition, the covalent carbon-sulfur bond 
tends to break in biological systems to form the dealkylation metabolic products. Conversely, the 
gemini surfactant 16-7N(GK)-16 was metabolized mainly via phase II reactions, including 
methylation, acetylation, and various conjugations as shown in Figure 4.7. This is largely due to 
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the existence of reactive amino acid moieties in the structure [33], which are prone to conjugations 
with various endogenous compounds, such as glucose, palmitic acid, and stearic acid. Although 
conjugations with fatty acids are not common phase II reactions for drug metabolites, a number of 
such conjugation reactions, particularly with palmitic acid and stearic acid, have been reported [34, 
35]. For example, it has been reported that 11-hydroxy-Δ9-tetrahydrocannabinol was metabolized 
via a conjugation reaction with palmitic acid to form the product 11-palmitoyloxy-Δ9-
tetrahydrocannabinol in rat tissue and the metabolite 11-palmitoyloxy-Δ9-tetrahydrocannabinol 
showed a less pronounced pharmacological activity compared to the original compound [36]. As 
phase II metabolites are generally less toxic compared to phase I metabolites in biological systems 
[37], phase II reactions of 16-7N(GK)-16 might have contributed to reducing its toxicity. Thus, the 
metabolic pathways of gemini surfactants provide an insight for future directions in the design and 
development of more effective and less toxic compounds. 
In light of the complexity of cellular matrix and the variability of the abundance of metabolites, the 
dynamic exclusion was used in the MS method in order to detect the metabolites with low ion 
intensity [38]. This technique enables the detection of ions with low intensity by excluding high 
intense ions in previous scans [39], thus resulting in the discovery of more metabolites. However, 
although a number of metabolites have been determined for tested gemini surfactants, the detection 
of their metabolites may have not been complete. This is in part due to the Bligh/Dye method used 
in this study that probably does not effectively extract relatively polar compounds. This is 
particularly concerning for the metabolites of relatively hydrophilic 16-7N(GK)-16. To increase 
the metabolite coverage, future studies should seek more efficient extraction methods to increase 
the extraction recovery of polar compounds. A modified Folch method has been reported with 
relatively high recovery for hydrophilic gemini surfactants [40], which might be suitable for the 
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extraction of polar metabolites. Another limitation is the use of FIA-MS that could possibly reduce 
the number of determined metabolites in the sample as the metabolites in low abundance may not 
be properly detected and characterized due to matrix effects and potential interferences. As such, 
it will be important to employ LC-MS to investigate the metabolism of gemini surfactants, which 
can provide additional insights into metabolite formation for gemini surfactants within biological 
systems. In addition, it will also be worthwhile to investigate the metabolite formation of these 
gemini surfactants in other cell lines as described in the future directions to confirm the detected 
metabolites by ruling out any degradation products and possibly discovery new metabolites, 
providing a better understanding of their metabolic pathways.  
While the metabolites of 16(Py)-S-2-S-16(Py) and 16-7N(GK)-16 were determined and 
characterized based on accurate mass measurements and characteristic product ions, their 
structures have not been unambiguously identified. To identify the structures of these metabolites, 
two approaches can be applied. One approach is to compare the accurate masses and characteristic 
product ions of potential metabolites with those of authentic reference standards [41]. In addition, 
the retention time of metabolites and reference standards can be compared for authentication if LC 
separation is used [41]. Such an approach provides a high confidence for the identification of the 
metabolites. For example, phase II pharmaceutical metabolites in reclaimed water have been 
identified and characterized based on accurate mass measurements, characteristic product ions, and 
retention time in comparison with reference standards [42]. However, this approach requires the 
use of reference standards for all metabolites, which are typically difficult to obtain if they are 
unknown compounds and not commercially available. Alternatively, the metabolites of gemini 
surfactants can be isolated and purified, and then subjected to nuclear magnetic resonance (NMR) 
analysis for structural elucidation [41]. For instance, nine phase I metabolites of phillyrin, a 
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bioactive component of the fruit of Frosythia suspensa, have been isolated in rats and structurally 
identified using MS and NMR analyses [43]. Similarly, eight phase II metabolites of echinacoside, 
an antioxidant, have been isolated from rat’s bile after intravenous administration and their 
structures were elucidated using 1H and 13C-NMR spectroscopies [44]. However, NMR analysis 
typically requires a relatively large quantity of purified compounds, which is often not achievable 
in in vitro studies due to the limited capacity of cells.  
In summary, this work provided an example for investigating the metabolism of gemini surfactants 
in biological systems. We demonstrated the feasibility of using a high-resolution mass 
spectrometry instrument to detect and characterize the metabolites of gemini surfactants based on 
accurate mass measurements and characteristic product ions. This approach can also be applied to 
study the metabolite formation of other gemini surfactants in various families for better 
understanding of their toxicities. 
5.2 Future Perspectives 
The work in my Ph.D. research lays the foundation to investigate the behavior of gemini surfactant 
nanoparticles in biological systems. As a powerful analytical technique, mass spectrometric 
platform can still play a key role in future studies of gemini surfactants as non-viral gene delivery 
vectors in two main directions, as outlined below. 
5.2.1 Evaluation of the in vivo fate of gemini surfactants in animals 
The determination of the cellular uptake and distribution of the three gemini surfactants 16-3-16, 
16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 using an FIA-MS/MS analysis sets the foundation to 
study their in vivo fate in biological systems. Such an investigation will help gain information about 
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the absorption, distribution, and excretion of the gemini surfactants within the host body in relation 
to their efficiency and toxicity. The three gemini surfactant nanoparticles have demonstrated in 
vitro transfection capabilities within PAM 212 cells, suggesting their potentials for an in vivo 
application. In fact, the gemini surfactant 16-3-16 nanoparticles have demonstrated great promise 
as topical gene delivery system in treating localized scleroderma [10, 45], as they were able to 
deliver a significantly higher level of transgenic materials than naked DNA in animal models of 
scleroderma [45]. As such, future studies should be conducted to evaluate the efficiency and 
toxicity of these three gemini surfactants in delivering therapeutic genes to animals. In particular, 
the gemini surfactant 16-7N(GK)-16 should be thoroughly investigated in vivo as it displayed the 
highest in vitro gene transfection efficiency with lowest toxicity among the three compounds, 
showing the greatest potential for topical applications. As such, an evaluation of the in vivo fate, 
including the absorption, distribution, and excretion, of these gemini surfactants in skin tissue upon 
application would be of great importance to understand their efficiency and toxicity profiles for in 
vivo gene delivery.  
To quantify gemini surfactants in skin tissue and systemic circulation, an FIA-MS/MS method can 
be developed in the tissue matrix for simple and fast analysis. Alternatively, an LC-MS/MS can 
also be developed to minimize potential matrix effect and interferences for quantitative analysis. 
Our group has recently developed an FIA-MS/MS relative quanitification method for the ex-vivo 
cutaneous determination of peptide-modified gemini surfactants and found that the relative amount 
of gemini surfactants accumulated in skin tissue correlated with their transfection efficiencies [40]. 
In addition, a minimal escape of gemini surfactants into the circulation compartment was observed, 
showing their potential low toxicity for topical applications [40]. As the Bligh/Dyer extraction 
method used in this study has a low extraction efficiency for polar compounds, it is important to 
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explore various extraction methods and develop a method that can effectively extract relatively 
polar compounds, especially for hydrophilic gemini surfactant 16-7N(GK)-16 and its metabolites, 
from the skin tissue. The modified Folch method in combination with solid phase extraction was 
previously used for the extraction of peptide-substituted gemini surfactants and relatively high 
extraction recovery was achieved in the ex vivo cutaneous experiment [35]. As such, it will be 
valuable to employ these methods to extract gemini surfactants and their metabolites in the skin 
tissue for MS analysis. Together, these studies on in vitro and in vivo fate of gemini surfactants 
will assist in the comprehensive understanding of the relationship between their structures, 
biological fate, efficiency, and toxicity. 
5.2.2 Investigation of the metabolite formation of other gemini surfactants  
The investigation on the metabolism of the three gemini surfactants conducted in my Ph.D. research 
offered effective approaches to study the metabolite formation of gemini surfactants in general. 
Future research can be conducted using similar approaches to evaluate the metabolite formation of 
other gemini surfactants from various structural families, as their metabolic pathways remain 
unclear. The metabolite formation of gemini surfactants provides information on their metabolic 
pathways, which will aid in understanding their efficiency and toxicity in relation to their structures.  
In addition to the epidermal keratinocyte cell, PAM 212, used in this work, other epithelial cell 
lines, such as cottontail rabbit epithelial cell, Sf 1Ep, and African green monkey kidney fibroblast 
cell, COS-7, can also be used. Sf 1Ep and COS-7 cells have been widely used in vitro to evaluate 
the transfection efficiency and toxicity of gemini surfactants for the treatment of atopic dermatitis 
and for wound healing as these cells represent the intended organ, eg., skin, for applications [27, 
46]. They may contain different enzymes than PAM 212 cells that can metabolize gemini 
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surfactants in various ways, contributing to the extensive understanding of their metabolite profiles. 
Thus, it is crucial to investigate the metabolism of gemini surfactants within various cell lines. In 
the long term, knowledges on the metabolism will benefit the development of novel gemini 
surfactants that are more efficient and less toxic. 
5.3 Conclusions 
The biological fate, including cellular uptake, distribution, and metabolite formation, of three 
gemini surfactants 16-3-16, 16(Py)-S-2-S-16(Py), and 16-7N(GK)-16 was investigated for the first 
time to explain their various efficiencies and toxicities in gene transfection. Specifically, high 
cellular uptake of gemini surfactants corresponds to high efficiency in gene transfection and high 
accumulation in the nucleus may contribute to the observed high toxicity. In addition, different 
metabolic pathways were determined for the three gemini surfactants, suggesting that phase II 
metabolites could contribute to reduced toxicity. Among the three gemini surfactants, 16-7N(GK)-
16 has been shown to be most promising gene delivery agent with high efficiency and low toxicity, 
which should be further studied as the next generation of gemini surfactants in the future. 
Overall, my work on assessing the biological behavior of gemini surfactants will feed into the 
rationale for designing novel and better gene delivery systems, which also provides a new paradigm 
for future investigation and development of gemini surfactants. Ultimately, the results will 
contribute to the development of novel gene delivery systems with increased efficiency and 
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6 Appendix - Metabolic Profiles of Treated Cells and Control 
 
Figure 6.1. The metabolic profile of control (untreated PAM 212 cells) established in positive ESI mode on 
a Q-TOF instrument.  
 
 
Figure 6.2. The metabolic profile of PAM 212 cells treated with 16-3-16 nanoparticles established in 





Figure 6.3. The metabolic profile of PAM 212 cells treated with 16(Py)-S-2-S-16(Py) nanoparticles 
established in positive ESI mode on a Q-TOF instrument. Several peaks were detected as potential 
metabolites of 16(Py)-S-2-S-16(Py). 
 
 
Figure 6.4. The metabolic profile of PAM 212 cells treated with 16-7N(GK)-16 nanoparticles established 







Figure 6.5 The metabolic profile of control (untreated PAM 212 cells) established in negative ESI mode on 




Figure 6.6. The metabolic profile of PAM 212 cells treated with 16-3-16 nanoparticles established in 
negative ESI mode on a Q-TOF instrument. The gemini surfactant 16-3-16 and its potential metabolites 




Figure 6.7. The metabolic profile of PAM 12 cells treated with 16(Py)-S-2-S-16(Py) nanoparticles 
established in negative ESI mode on a Q-TOF instrument. The gemini surfactant 16(Py)-S-2-S-16(Py) and 





Figure 6.8. The metabolic profile of PAM212 cells treated with 16-7N(GK)-16 nanoparticles established 
in negative ESI mode on a Q-TOF instrument. The gemini surfactant 16-7N(GK)-16 and its potential 




Figure 6.9. The metabolic profile of control (untreated PAM 212 cells) established in positive ESI mode on 




Figure 6.10. The metabolic profile of PAM 212 cells treated with 16-3-16 nanoparticles established in 





Figure 6.11. The metabolic profile of PAM 212 cells treated with 16(Py)-S-2-S-16(Py) nanoparticles 
established in positive ESI mode on a Q-exactive instrument. The metabolites M-1, M-2, M-3, M-4, and M-
5 were determined for 16(Py)-S-2-S-16(Py). 
 
 
Figure 6.12. The metabolic profile of PAM 212 cells treated with 16-7N(GK)-16 nanoparticles established 
in positive ESI mode on a Q-exactive instrument. The metabolites M-a, M-b, M-c, M-d, M-e, and M-f were 






Figure 6.13. The metabolic profile of PAM 212 cells treated with 16-3-16-D66 nanoparticles established in 
positive ESI mode on a Q-exactive instrument. No metabolite was determined for 16-3-16-D66. 
 
 
Figure 6.14.The metabolic profile of PAM 212 cells treated with 16(Py)-S-2-S-16(Py)-D10 nanoparticles 
established in positive ESI mode on a Q-exactive instrument. The metabolites M-1’, M-2’, M-3’, M-4’, and 






Figure 6.15. The metabolic profile of PAM 212 cells treated with 16-7N(GK)-16-D4 nanoparticles 
established in positive ESI mode on a Q-exactive instrument. The metabolites M-a’, M-b’, M-c’, M-d’, M-
e’, and M-f’ were determined for 16-7N(GK)-16-D4. 
 
16-7N(GK)-16-D4 
